

PATENT APPLICATION

Mammalian Sweet Taste Receptors

Inventor(s): Charles S. Zuker

Nicholas J. P. Ryba

Greg Nelson

Mark A. Hoon

Jayaram Chandrashekar

Yifeng Zhang

Assignee(s): The Regents of the University of California

The Government of the United States of America as represented by the Secretary
of the Department of Health and Human Services

Entity: Large

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200

Mammalian Sweet Taste Receptors

CROSS-REFERENCES TO RELATED APPLICATIONS

5 The present application claims priority to USSN 60/302,898, filed July 3, 2001, herein incorporated by reference in its entirety.

The present application is related to USSN 60/095,464, filed July 28, 1998; USSN 60/112,747, filed December 17, 1998; USSN 09/361,631, filed July 27, 1999; USSN 60/094,465, and filed July 28, 1998; USSN 09/361,652, filed July 27, 1000, herein each incorporated by reference in its entirety.

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

Not applicable.

REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK

Not applicable.

FIELD OF THE INVENTION

20 The sense of taste provides animals with valuable information about the quality and nutritional value of food. Previously, we identified a large family of mammalian taste receptors involved in bitter taste perception (the T2Rs). We now report the characterization of mammalian sweet taste receptors. First, transgenic rescue experiments prove that the *Sac* locus encodes T1R3, a member of the T1R family of candidate taste
25 receptors. Second, using a heterologous expression system, we demonstrate that T1R2 and T1R3, when expressed in the same cell, function as a sweet receptor, recognizing sweet tasting molecules as diverse as sucrose, saccharin, dulcin and acesulfame-K. The T1R family therefore forms sweet receptors comprising polypeptides such as T1R2 and T1R3, and T1R1 and T1R3. Finally, we present a detailed analysis of the patterns of expression of T1Rs and
30 T2Rs, thus providing a view of the representation of sweet and bitter taste at the periphery.

BACKGROUND OF THE INVENTION

Our sense of taste is capable of detecting and responding to sweet, bitter, sour, salty and umami stimuli (reviewed by Lindemann, 1996). It is also responsible for distinguishing between these various taste modalities, for instance, the sweetness of honey from the bitterness of tonic water; the sourness of unripe fruit from the saltiness of the ocean. This discriminatory power provides valuable sensory input: bitter receptors elicit aversive behavioral reactions to noxious substances, while sweet receptors allow recognition of high caloric food sources.

We have been interested in basic questions of taste signal detection and information coding, and have focused on the isolation and characterization of genes encoding sweet and bitter taste receptors. The identification of taste receptors generates powerful molecular tools to investigate not only the function of taste receptor cells, but also the logic of taste coding. For example, defining the size and diversity of the receptor repertoire provide evidence for how a large number of chemosensory ligands may be recognized (i.e., molecular diversity), while analysis of the patterns of receptor expression contributes important insight to our understanding of chemosensory discrimination and coding. Recently, we described the isolation of two novel families of G-protein coupled receptors (GPCRs) expressed in subsets of taste receptor cells of the tongue and palate (T1Rs and T2Rs; Hoon *et al.*, 1999; Adler *et al.*, 2000). One of these, the T2Rs, is a family of ~30 different genes that include several functionally validated mammalian bitter taste receptors (Adler *et al.*, 2000; Chandrashekar *et al.*, 2000; Matsunami *et al.*, 2000). Nearly all of the T2R-genes are clustered in regions of the genome that have been genetically implicated in controlling responses to diverse bitter tastants in humans and mice, consistent with their proposed role as bitter taste receptors (Adler *et al.*, 2000).

Notably, most T2Rs are co-expressed in the same subset of taste receptor cells (Adler *et al.*, 2000), suggesting that these cells are capable of responding to a broad array of bitter compounds, but not discriminating between them. This is logical for a sensory modality like bitter, in which the animal needs to recognize and react to many noxious tastants, but not necessarily discriminate between them (i.e., we need to know that a tastant is bad news, but not necessarily what makes it bad). This interpretation is consistent with behavioral and psychophysical findings in rodents and humans demonstrating limited discrimination between various bitter tastants (McBurney and Gent, 1979).

How is sweet taste specified? There is considerable evidence that G-protein coupled receptors are also involved in this taste modality (Lindemann, 1996). In contrast to

bitter taste, the number of biologically relevant sweet tastants is modest. Thus, we might expect the sweet receptor family to be quite small. Interestingly, psychophysical, behavioral and electrophysiological studies suggest that animals distinguish between various sweet tastants (Schiffman *et al.*, 1981; Ninomiya *et al.*, 1984; Ninomiya *et al.*, 1997), perhaps reflecting (and predicting) the organization of the sweet taste system into distinct types of sweet receptor cells and pathways.

Genetic studies of sweet tasting have identified a single principal locus in mice influencing responses to several sweet substances (Fuller, 1974; Lush, 1989). This locus, named *Sac*, determines threshold differences in the ability of some strains to distinguish saccharin-containing solutions from water (Fuller, 1974). *Sac* tasters respond to ~5-fold lower concentrations of saccharin than "sweet-insensitive" *Sac* non-taster mice (Fuller, 1974; Capeless and Whitney, 1995); additionally, *Sac* influences preferences to sucrose, acesulfame-K and dulcin (Lush, 1989). Recently, several groups reported that a T1R-related gene, *T1R3*, might encode *Sac* (Kitagawa *et al.*, 2001; Max *et al.*, 2001; Montmayeur *et al.*, 2001; Sainz *et al.*, 2001).

We now demonstrate that transgenic expression of T1R3 from a taster strain transforms sweet-insensitive animals to tasters, affirming *T1R3* as the *Sac* gene. We then developed a cell-based reporter system to prove that T1Rs encode functional sweet taste receptors. Lastly, we show that the patterns of T1R expression define at least three distinct cell types, and that sweet and bitter receptors are tightly segregated at the periphery.

BRIEF SUMMARY OF THE INVENTION

The present invention thus provides for the first time a sweet taste receptor comprising a T1R3 polypeptide. The present invention provides sweet taste receptor comprising a T1R3 polypeptide and a heterologous member of the T1R family, e.g., T1R1 or T1R2, that transduces a signal in response to sweet taste ligands when T1R3 and either T1R1 or T1R2 are co-expressed in the same cell. In one embodiment, the T1R3 polypeptide and the heterologous T1R polypeptide form a heterodimer. In another embodiment, the T1R3 polypeptide and the heterologous T1R polypeptide are non-covalently linked. In another embodiment, the T1R3 polypeptide and the heterologous T1R polypeptide are covalently linked.

In one aspect, the present invention provides an sweet taste receptor comprising a T1R3 polypeptide, the T1R3 polypeptide comprising greater than about 70% amino acid sequence identity to an amino acid sequence of SEQ ID NO:15, SEQ ID NO:20,

SEQ ID NO:23, or SEQ ID NO:25, or encoded by a nucleotide sequence hybridizing under moderately or highly stringent hybridization conditions to a nucleotide sequence encoding an amino acid sequence of SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25.

5 In one embodiment, the receptor specifically binds to polyclonal antibodies generated against SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25. In another embodiment, the receptor has G-protein coupled receptor activity. In another embodiment, the T1R3 polypeptide has an amino acid sequence of SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25. In another embodiment, the receptor is from a human, a rat, or a mouse.

10 In one aspect, the present invention provides a sweet taste receptor, the receptor comprising a T1R3 polypeptide and a heterologous polypeptide, the T1R3 polypeptide comprising greater than about 70% amino acid sequence identity to an amino acid sequence of SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25, or encoded by a nucleotide sequence hybridizing under moderately or highly stringent
15 hybridization conditions to a nucleotide sequence encoding an amino acid sequence of SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25.

In one embodiment, the heterologous polypeptide is a T1R family member. In another embodiment, the heterologous polypeptide is T1R1 or T1R2. In one embodiment, the T1R1 polypeptide is encoded by a nucleotide sequence that hybridizes under moderately
20 or highly stringent conditions to a nucleotide sequence encoding SEQ ID NO:1, 2., or 3. In one embodiment, the T1R2 polypeptide is encoded by a nucleotide sequence that hybridizes under moderately or highly stringent conditions to a nucleotide sequence encoding SEQ ID NO:7, 8., or 9. In one embodiment, the receptor specifically binds to polyclonal antibodies generated against SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25. In
25 another embodiment, the receptor has G-protein coupled receptor activity. In another embodiment, the T1R3 polypeptide has an amino acid sequence of SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25. In another embodiment, the receptor is from a human, a rat, or a mouse.

In one embodiment, the T1R3 polypeptide and the T1R polypeptide form a
30 heterodimer. In one embodiment, the T1R3 polypeptide and the T1R heterologous polypeptide are non-covalently linked. In another embodiment, the T1R3 polypeptide and the T1R heterologous polypeptide are covalently linked.

In one aspect, the present invention provides an isolated polypeptide comprising an extracellular, a transmembrane domain, or a cytoplasmic domain of a sweet

taste receptor, the extracellular, a transmembrane domain, or a cytoplasmic domain comprising greater than about 70% amino acid sequence identity to the extracellular, a transmembrane domain, or a cytoplasmic domain of SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25. In another embodiment, the extracellular, transmembrane, or cytoplasmic domain hybridize under moderately or highly stringent conditions to an extracellular, transmembrane, or cytoplasmic domain of SEQ ID NO:15, 20, 23, or 25.

In one embodiment, the polypeptide encodes the extracellular, a transmembrane domain, or a cytoplasmic domain of SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25. In another embodiment, the extracellular, a transmembrane domain, or a cytoplasmic domain is covalently linked to a heterologous polypeptide, forming a chimeric polypeptide. In another embodiment, the chimeric polypeptide has G-protein coupled receptor activity.

In one aspect, the present invention provides an antibody that selectively binds to a sweet taste receptor, the receptor comprising a T1R3 polypeptide and a heterologous polypeptide, the antibody raised against a receptor comprising a T1R3 polypeptide comprising greater than about 70% amino acid sequence identity to an amino acid sequence of SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25, or encoded by a nucleotide sequence hybridizing under highly or moderately stringent hybridization conditions to a nucleotide sequence encoding an amino acid sequence of SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25. In one embodiment, the T1R3 polypeptide forms a heterodimeric receptor, either by covalent or non-covalent linkage, with a T1R polypeptide, to which the antibody specifically binds.

In another aspect, the present invention provides a method for identifying a compound that modulates sweet taste signaling in taste cells, the method comprising the steps of: (i) contacting the compound with a sweet receptor comprising a T1R3 polypeptide, the polypeptide comprising greater than about 70% amino acid sequence identity to the extracellular domain of SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25; or encoded by a nucleotide sequence hybridizing under moderately or highly stringent hybridization conditions to a nucleotide sequence encoding an amino acid sequence of SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25; and (ii) determining the functional effect of the compound upon the receptor.

In one embodiment, the receptor comprises T1R3, is heterodimeric receptor, and is linked to a heterologous polypeptide either covalently or non-covalently. In another embodiment, the receptor comprises T1R1 and T1R3. In another embodiment, the receptor

comprises T1R2 and T1R3. In another embodiment, the polypeptide has G-protein coupled receptor activity. In another embodiment, the functional effect is determined *in vitro*. In another embodiment, the receptor is linked to a solid phase, either covalently or non-covalently. In another embodiment, the functional effect is determined by measuring changes
5 in intracellular cAMP, IP3, or Ca²⁺. In another embodiment, the functional effect is a chemical or phenotypic effect. In another embodiment, the functional effect is a physical effect. In another embodiment, the functional effect is determined by measuring binding of the compound to the extracellular domain of the receptor. In another embodiment, the polypeptide is recombinant. In another embodiment, the polypeptide is expressed in a cell or
10 cell membrane. In another embodiment, the cell is a eukaryotic cell, e.g., a mammalian cell, e.g., a human cell.

In one aspect, the present invention provides an isolated nucleic acid encoding a T1R3 polypeptide, the polypeptide comprising greater than about 70% amino acid identity to an amino acid sequence of SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID
15 NO:25.

In one embodiment, the nucleic acid comprises a nucleotide sequence of SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:22, or SEQ ID NO:24. In another embodiment, the nucleic acid is amplified by primers that selectively hybridize under stringent hybridization conditions to SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:22, or SEQ ID NO:24.

20 In another aspect, the present invention provides an isolated nucleic acid encoding a T1R3 polypeptide, wherein the nucleic acid specifically hybridizes under moderately or highly stringent conditions to a nucleic acid encoding SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25 or having the sequence of SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:22, or SEQ ID NO:24.

25 In another aspect, the present invention provides an isolated nucleic acid encoding a T1R3 polypeptide, the polypeptide comprising greater than about 70% amino acid identity to a polypeptide having a sequence of SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25, wherein the nucleic acid selectively hybridizes under moderately stringent hybridization conditions to a nucleotide sequence of SEQ ID NO:14, SEQ ID
30 NO:19, SEQ ID NO:22, or SEQ ID NO:24.

In another aspect, the present invention provides an isolated nucleic acid encoding an extracellular domain, a transmembrane domain, or a cytoplasmic domain of a T1R3 polypeptide, the extracellular domain, a transmembrane domain, or a cytoplasmic domain having greater than about 70% amino acid sequence identity to the extracellular

domain, a transmembrane domain, or a cytoplasmic domain of SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25.

In another aspect, the present invention provides an expression vector comprising a nucleic acid encoding a polypeptide comprising greater than about 70% amino acid sequence identity to an amino acid sequence of SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:25. In another aspect, the present invention provides a host cell transfected with the expression vector.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. *T1R3* maps to the *Sac* locus

(a) Radiation hybrid and STS mapping localized all three T1R genes to the distal end of chromosome 4. The *T1R3* gene is closely linked to *D18346*, an STS marker within the *Sac* genetic interval (Kitagawa *et al.*, 2001; Li *et al.*, 2001; Max *et al.*, 2001; Montmayeur *et al.*, 2001; Sainz *et al.*, 2001). (b) Cladogram showing sequence similarity between human (h) and mouse (m) T1Rs and related receptors (Nakanishi, 1992; Brown *et al.*, 1993; Herrada and Dulac, 1997; Matsunami and Buck, 1997; Ryba and Tirindelli, 1997; Kaupmann *et al.*, 1997; Hoon *et al.*, 1999); mouse V2Rs do not have human counterparts.

Figure 2. *T1R3* encodes *Sac*

(a) Schematic diagram indicating structure of the *T1R3* gene and transgenic construct. The alternate 3'-UTRs used for genotyping and *in situ* hybridization are highlighted in green and red. (b) *In situ* hybridization demonstrated perfect concordance in the expression pattern of the T1R3 transgene (red) and the endogenous gene (green). The dotted lines illustrate the outline of selected taste buds; sections were cut perpendicular to the planes shown in figure 3. (c-h) Taste preferences of control and transgenic animals (solid red circles) were measured using standard two bottle preference tests. The behavioral responses of mice expressing the T1R3 transgene to saccharin and sucrose (panels c and d) were indistinguishable from those of the control taster mice (C57BL/6; open red circles). Siblings without the transgene (solid black circles) behaved like 129/Sv non-taster control mice (open black circles). Responses to bitter, salty, sour and umami stimuli (panels e-h) were not affected by presence of the transgene.

Figure 3. Expression of T1Rs in subsets of taste receptor cells

In situ hybridizations with digoxigenin-labeled antisense RNA probes

demonstrated that T1R3 is expressed in subsets of mouse taste receptor cells (upper panels).

Approx. 30% of cells in fungiform, circumvallate, foliate and palate taste buds express T1R3.

- 5 Shown for comparison are similar, but not serial, sections labeled with T1R1 and T1R2 (middle and lower panels; see also Hoon *et al.*, 1999 and figure 4). The dotted lines illustrate the outline of a sample taste bud. Note that the selectivity of T1R3 expression closely resembles that of T1R1 plus T1R2.

10 Figure 4. T1R expression patterns define three cell types

Double-label fluorescent *in situ* hybridization was used to directly examine the

overlap in cellular expression of T1Rs. Two-channel fluorescent images (1-2 μ m optical

sections) are overlaid on difference interference contrast images. (a) Fungiform papillae

illustrating co-expression of T1R1 (red) and T1R3 (green). At least 90% of the cells

- 15 expressing T1R1 also express T1R3; similar results were observed in the palate. Note the presence of some T1R3 positive but T1R1 negative cells. (b) Circumvallate papillae illustrating co-expression of T1R2 (green) and T1R3 (red). Every T1R2 positive cell expresses T1R3.

20 Figure 5. T1R2+3 responds to sweet tastants

HEK-293 cells co-expressing promiscuous G proteins and rat T1R2 and T1R3

were stimulated with various sweet compounds. Robust increases in $[Ca^{2+}]_i$ were observed upon addition of 250 mM sucrose (d, g), 180 μ M GA-2 (e, h) and 10 mM acesulfame-K (f, i).

Panels a-c show cells prior to stimulation. No responses were detected without receptors

- 25 (panel j) or promiscuous G proteins (panel k). Glucose and several other sweet tastants (see next figure) did not activate this receptor combination (panel l); scales indicate $[Ca^{2+}]_i$ (nM) determined from FURA-2 F_{340}/F_{380} ratios. Line traces (g-i) show the kinetics of the $[Ca^{2+}]_i$ changes for representative cells from panels (d-f). The bar indicates the time and duration of the stimulus.

30

Figure 6. T1R2+3 selectively responds to a broad range of sweet compounds

(a) The responses of the T1R2+3 receptor combination were specific to sucrose, fructose and five artificial sweeteners. Concentrations used are: GA-1 (500 μ M); GA-2 (500 μ M); sucrose (250 mM); fructose (250 mM), acesulfame-K (10 mM); dulcin (2 mM), sodium saccharin (5 mM); N-methyl saccharin (5 mM), glucose (250 mM); maltose (250 mM); lactose (250 mM); galactose (250 mM); palatinose (250 mM); thaumatin (0.1%); sodium cyclamate (15 mM); aspartame (2mM). Columns represent the mean \pm SEM of a minimum of 16 independent determinations. (b) Dose response of T1R2+3 to sucrose, saccharin, acesulfame-K and GA-2. The relative changes in $[Ca^{2+}]_i$ are shown as FURA-2 (F_{340}/F_{380}) ratios normalized to the responses obtained for the highest concentration of each compound. Each point represents the mean \pm SEM of a minimum of 20 assays. (c) Kinetics and desensitization of T1R2+3 sweet responses. Cells expressing T1R2+3 were stimulated with multiple pulses of sweet tastants; GA-2 (360 μ M), sucrose, (suc: 250 mM), acesulfame-K (ace: 10 mM), cyclamate (sic: 15 mM), glucose (glu: 250 mM) and aspartame (asp: 2 mM). Dots and horizontal bars indicate the time and duration of the stimulus. Sucrose, GA-2 and acesulfame-K elicit robust responses; repeated or prolonged stimulation with any one of these tastants (e.g., GA-2) results in a decreased response indicative of desensitization. Stimulation with sucrose or acesulfame-K immediately after GA-2 results in an attenuated response suggesting cross-desensitization. The trace was derived from 80 responding cells in the field of view.

Figure 7. T1Rs and T2Rs are segregated in distinct populations of taste receptor cells

Double-label fluorescent *in situ* hybridization was used to examine the degree of overlap between the T1R and T2R families of sweet and bitter taste receptors. (a) T1R3 (green) and T2Rs (a mixture of 20 receptors, red) are never co-expressed. (b) A section through a circumvallate papilla is shown (b) as in panel (a), but with a mixture of all three T1Rs (green) versus twenty T2Rs in a foliate papilla.

DETAILED DESCRIPTION

INTRODUCTION

The present invention provides sweet taste receptors comprising members of the T1R family of G-protein coupled receptors. In a preferred embodiment, the present invention provides sweet taste receptor comprising a T1R3 polypeptide and a second, heterologous T1R polypeptide, e.g., T1R1 or T1R2. These sweet taste receptors are GPCR components of the taste transduction pathway, and when co-expressed in the same cell, the polypeptides transduce signal in response to sweet taste ligand.

These nucleic acids and proteins encoding the receptors provide valuable probes for the identification of taste cells, as the nucleic acids are specifically expressed in taste cells. For example, probes for GPCR polypeptides and proteins can be used to identify subsets of taste cells such as foliate cells, palate cells, and circumvallate cells, or specific taste receptor cells, e.g., sweet taste receptor cells. As described below, T1R1 and T1R3, and T1R2 and T1R3 are co-expressed in specific taste receptor cell subsets. They also serve as tools for the generation of taste topographic maps that elucidate the relationship between the taste cells of the tongue and taste sensory neurons leading to taste centers in the brain. Furthermore, the nucleic acids and the proteins they encode can be used as probes to dissect taste-induced behaviors.

The invention also provides methods of screening for modulators, e.g., activators, inhibitors, stimulators, enhancers, agonists, and antagonists, of these novel sweet taste receptors comprising T1R3 and another member of the T1R family such as T1R1 or T1R2. Such modulators of sweet taste transduction are useful for pharmacological and genetic modulation of sweet taste signaling pathways, and for the discovery of novel sweet taste ligands. These methods of screening can be used to identify high affinity agonists and antagonists of sweet taste cell activity. These modulatory compounds can then be used in the food and pharmaceutical industries to customize taste. Thus, the invention provides assays for taste modulation, where the T1R3-comprising receptor acts as an direct or indirect reporter molecule for the effect of modulators on sweet taste transduction. GPCRs can be used in assays, e.g., to measure changes in ligand binding, G-protein binding, regulatory molecule binding, ion concentration, membrane potential, current flow, ion flux, transcription, signal transduction, receptor-ligand interactions, neurotransmitter and hormone release; and second messenger concentrations, *in vitro*, *in vivo*, and *ex vivo*. In one embodiment, a receptor comprising T1R3 can be used as an indirect reporter via attachment to a second reporter molecule such as green fluorescent protein (*see, e.g.,* Mistili & Spector,

Nature Biotechnology 15:961-964 (1997)). In another embodiment, a receptor comprising T1R3 is recombinantly expressed in cells, and modulation of taste transduction via GPCR activity is assayed by measuring changes in Ca²⁺ levels.

Methods of assaying for modulators of taste transduction include *in vitro* ligand binding assays using receptors comprising T1R3, portions thereof such as the extracellular domain, or chimeric proteins comprising one or more domains of T1R3, and in *in vivo* (cell-based and animal) assays such as oocyte T1R3 receptor expression; tissue culture cell T1R3 receptor expression; transcriptional activation of T1R3; phosphorylation and dephosphorylation of GPCRs; G-protein binding to GPCRs; ligand binding assays; voltage, membrane potential and conductance changes; ion flux assays; changes in intracellular second messengers such as cAMP and inositol triphosphate; changes in intracellular calcium levels; and neurotransmitter release.

DEFINITIONS

A “T1R family taste receptor” refers to a receptor comprising a member of the T1R family of G-protein coupled receptors, e.g., T1R1, T1R2, and T1R3, or any combination thereof. In one embodiment, the T1R family receptor comprises T1R3 (a “T1R3-comprising taste receptor” or a “T1R3-comprising sweet taste receptor”) and a heterologous polypeptide of the T1R family. In one embodiment, the receptor comprises T1R1 and T1R3. In another embodiment, the receptor comprises T1R2 and T1R3. In one embodiment the T1R3-comprising receptor is active when the two members of the receptor are co-expressed in the same cell, e.g., T1R1 and T1R3 or T1R2 and T1R3. In another embodiment, the T1R polypeptides are co-expressed in the same cell and form a heterodimeric receptor, in which the T1R polypeptides of the receptor are non-covalently linked or covalently linked. The receptor has the ability to recognize a sweet tasting molecule such as sucrose, saccharin, dulcin, acesulfame-K, as well as other molecules, sweet and non-sweet, as described herein. These molecules are examples of compounds that “modulate sweet taste signal transduction” by acting as ligands for the sweet G protein coupled receptor comprising T1R3.

The terms “GPCR-B3 or T1R1,” “GPCR-B4 or T1R2,” and “T1R3” or a nucleic acid encoding “GPCR-B3 or T1R1,” “GPCR-B4 or T1R2,” and “T1R3” refer to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and interspecies homologs that are members of the T1R family of G protein coupled receptors and: (1) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%

or greater amino acid sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acids, to an amino acid sequence encoded by SEQ ID NO:1, 2, 3, 7, 8, 9, 15, 18, 20, 23, or 25; (2) bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence encoded by
5 SEQ ID NO:1, 2, 3, 7, 8, 9, 15, 18, 20, 23, or 25, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to an anti-sense strand corresponding to a nucleic acid sequence encoding a T1R protein, e.g., SEQ ID NO:4, 5, 6, 10, 11, 12, 13, 14, 16, 17, 19, 21, 22, or 24, and conservatively modified variants thereof; (4) have a nucleic acid sequence that has greater than about 60% sequence identity,
10 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%, or higher nucleotide sequence identity, preferably over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to SEQ ID NO:4, 5, 6, 10, 11, 12, 13, 14, 16, 17, 19, 21, 22, or 24. The T1R family polypeptide of the invention (e.g., T1R1, T1R2, or T1R3) or T1R3-comprising receptor further has G protein coupled receptor activity, either alone or
15 when co-expressed in the same cell, or when co-expressed as a heterodimer with another T1R family member. Accession numbers for amino acid sequences and nucleotide sequences of T1R1, T1R2, and T1R3 can be found in GenBank.

T1R proteins have "G-protein coupled receptor activity," e.g., they bind to G-proteins in response to extracellular stimuli, such as ligand binding, and promote production
20 of second messengers such as IP3, cAMP, and Ca²⁺ via stimulation of enzymes such as phospholipase C and adenylate cyclase. Such activity can be measured in a heterologous cell, by coupling a GPCR (or a chimeric GPCR) to either a G-protein or promiscuous G-protein such as Gα15, and an enzyme such as PLC, and measuring increases in intracellular calcium using (Offermans & Simon, *J. Biol. Chem.* 270:15175-15180 (1995)). Receptor activity can
25 be effectively measured, e.g., by recording ligand-induced changes in [Ca²⁺], using fluorescent Ca²⁺-indicator dyes and fluorometric imaging.

Such GPCRs have transmembrane, extracellular and cytoplasmic domains that can be structurally identified using methods known to those of skill in the art, such as sequence analysis programs that identify hydrophobic and hydrophilic domains (*see, e.g.,*
30 Kyte & Doolittle, *J. Mol. Biol.* 157:105-132 (1982)). Such domains are useful for making chimeric proteins and for *in vitro* assays of the invention (*see, e.g.,* WO 94/05695 and US Patent 5,508,384).

The phrase “functional effects” in the context of assays for testing compounds that modulate activity (e.g., signal transduction) of a sweet taste receptor or protein of the invention includes the determination of a parameter that is indirectly or directly under the influence of a GPCR or sweet taste receptor, e.g., a physical, phenotypic, or chemical effect, such as the ability to transduce a cellular signal in response to external stimuli such as ligand binding, or the ability to bind a ligand. It includes binding activity and signal transduction. “Functional effects” include *in vitro*, *in vivo*, and *ex vivo* activities.

By “determining the functional effect” is meant assaying for a compound that increases or decreases a parameter that is indirectly or directly under the influence of a T1R GPCR protein or a sweet taste receptor comprising one or more T1R GPCR proteins, e.g., physical (direct) and chemical or phenotypic (indirect) effects. Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index); hydrodynamic (e.g., shape); chromatographic; or solubility properties for the protein; measuring inducible markers or transcriptional activation of the protein; measuring binding activity or binding assays, e.g., binding to antibodies; measuring changes in ligand binding activity or analogs thereof, either naturally occurring or synthetic; measuring cellular proliferation; measuring cell surface marker expression, measurement of changes in protein levels for T1R-associated sequences; measurement of RNA stability; G-protein binding; GPCR phosphorylation or dephosphorylation; signal transduction, e.g., receptor-ligand interactions, second messenger concentrations (e.g., cAMP, cGMP, IP3, PI, or intracellular Ca^{2+}); neurotransmitter release; hormone release; voltage, membrane potential and conductance changes; ion flux; regulatory molecule binding; identification of downstream or reporter gene expression (CAT, luciferase, β -gal, GFP and the like), e.g., via chemiluminescence, fluorescence, colorimetric reactions, antibody binding, and inducible markers.

“Inhibitors,” “activators,” and “modulators” of T1R family polynucleotide and polypeptide sequences and T1R family sweet receptors are used to refer to activating, inhibitory, or modulating molecules identified using *in vitro* and *in vivo* assays of T1R polynucleotide and polypeptide sequences and T1R family sweet receptors, including heterodimeric receptors. Inhibitors are compounds that, e.g., bind to, partially or totally block activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of T1R family sweet receptors such as a receptor comprising a T1R3 polypeptide, e.g., antagonists. “Activators” are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate a T1R family sweet

receptor, such as a receptor comprising a T1R3 polypeptide, e.g., agonists. Inhibitors, activators, or modulators also include genetically modified versions of T1R family sweet receptors, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, antisense molecules, ribozymes, small chemical molecules and the like. Such assays for inhibitors and activators include, e.g., expressing T1R family sweet receptors *in vitro*, in cells, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above. The sweet taste receptor comprising a T1R3 polypeptide has the ability to recognize a sweet tasting molecule such as sucrose, saccharin, dulcin, acesulfame-K, and other molecules, as described herein. These molecules are examples of compounds that modulate sweet taste signal transduction by acting as extracellular ligands for the sweet G protein coupled receptor and activating the receptor. In other embodiments, compounds that modulate sweet taste signal transduction are molecules that act as intracellular ligands of the receptor, or inhibit or activate binding of an extracellular ligand, or inhibit or activate binding of intracellular ligands of the receptor.

Samples or assays comprising T1R family sweet receptors that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of a T1R family sweet receptor is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25-0%. Activation of a T1R family sweet receptor is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%, more preferably 200-500% (i.e., two to five fold higher relative to the control), more preferably 1000-3000% higher.

The term "test compound" or "drug candidate" or "modulator" or grammatical equivalents as used herein describes any molecule, either naturally occurring or synthetic, e.g., protein, oligopeptide (e.g., from about 5 to about 25 amino acids in length, preferably from about 10 to 20 or 12 to 18 amino acids in length, preferably 12, 15, or 18 amino acids in length), small organic molecule, polysaccharide, lipid (e.g., a sphingolipid), fatty acid, polynucleotide, oligonucleotide, etc., to be tested for the capacity to directly or indirectly modulation taste. The test compound can be in the form of a library of test compounds, such as a combinatorial or randomized library that provides a sufficient range of diversity. Test compounds are optionally linked to a fusion partner, e.g., targeting compounds, rescue compounds, dimerization compounds, stabilizing compounds, addressable compounds, and

other functional moieties. Conventionally, new chemical entities with useful properties are generated by identifying a test compound (called a “lead compound”) with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.

A “small organic molecule” refers to an organic molecule, either naturally occurring or synthetic, that has a molecular weight of more than about 50 daltons and less than about 2500 daltons, preferably less than about 2000 daltons, preferably between about 100 to about 1000 daltons, more preferably between about 200 to about 500 daltons.

“Biological sample” include sections of tissues such as biopsy and autopsy samples, and frozen sections taken for histologic purposes. Such samples include blood, sputum, tissue, cultured cells, e.g., primary cultures, explants, and transformed cells, stool, urine, etc. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.

A “heterodimer” is a dimer comprising two different molecules, e.g., two different polypeptides, where the molecules are associated via either covalent, e.g., through a linker or a chemical bond, or non-covalent, e.g., ionic, van der Waals, electrostatic, or hydrogen bonds linkages. The T1R2-comprising receptors of the invention function when co-expressed in the same cell, or optionally when co-expressed so that they form a heterodimer, either covalently or non-covalently linked.

The terms “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region (e.g., nucleotide sequences SEQ ID NO:1-25), when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (*see, e.g.,* NCBI web site or the like). Such sequences are then said to be “substantially identical.” This definition also refers to, or may be applied to, the complement of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is

at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (*see, e.g., Current Protocols in Molecular Biology* (Ausubel *et al.*, eds. 1995 supplement)).

A preferred example of algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.*, *Nuc. Acids Res.* 25:3389-3402 (1997) and Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990), respectively. BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*).

These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching
5 residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of
10 either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix
15 (see Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding
20 naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by
25 the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ -carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified
30 R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

5 “Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large
10 number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified
15 variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a
20 polypeptide is implicit in each described sequence with respect to the expression product, but not with respect to actual probe sequences.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino
25 acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.

30 The following eight groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan

(W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (*see, e.g., Creighton, Proteins* (1984)).

Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, *see, e.g., Alberts et al., Molecular Biology of the Cell* (3rd ed., 1994) and Cantor and Schimmel, *Biophysical Chemistry Part I: The Conformation of Biological Macromolecules* (1980).

“Primary structure” refers to the amino acid sequence of a particular peptide. “Secondary structure” refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains, e.g., extracellular domains, transmembrane domains, and cytoplasmic domains. Domains are portions of a polypeptide that form a compact unit of the polypeptide and are typically 15 to 350 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of β -sheet and α -helices. “Tertiary structure” refers to the complete three dimensional structure of a polypeptide monomer. “Quaternary structure” refers to the three dimensional structure formed by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.

A particular nucleic acid sequence also implicitly encompasses “splice variants.” Similarly, a particular protein encoded by a nucleic acid implicitly encompasses any protein encoded by a splice variant of that nucleic acid. “Splice variants,” as the name suggests, are products of alternative splicing of a gene. After transcription, an initial nucleic acid transcript may be spliced such that different (alternate) nucleic acid splice products encode different polypeptides. Mechanisms for the production of splice variants vary, but include alternate splicing of exons. Alternate polypeptides derived from the same nucleic acid by read-through transcription are also encompassed by this definition. Any products of a splicing reaction, including recombinant forms of the splice products, are included in this definition.

A “label” or a “detectable moiety” is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include ^{32}P , fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide.

The term “recombinant” when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been

modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, *Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes*, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T_m , 50% of the probes are occupied at equilibrium). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C.

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon

degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary “moderately stringent hybridization conditions” include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and *Current Protocols in Molecular Biology*, ed. Ausubel, *et al.*

For PCR, a temperature of about 36°C is typical for low stringency amplification, although annealing temperatures may vary between about 32°C and 48°C depending on primer length. For high stringency PCR amplification, a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50°C to about 65°C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90°C - 95°C for 30 sec - 2 min., an annealing phase lasting 30 sec. - 2 min., and an extension phase of about 72°C for 1 - 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis *et al.*, *PCR Protocols, A Guide to Methods and Applications* (1990).

“Antibody” refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. Typically, the antigen-binding region of an antibody will be most critical in specificity and affinity of binding.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kD) and one “heavy” chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (V_L) and variable heavy chain (V_H) refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce $F(ab)'_2$, a dimer of Fab which itself is a light chain joined to V_H-C_{H1} by a disulfide bond. The $F(ab)'_2$ may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the $F(ab)'_2$ dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (see *Fundamental Immunology* (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized *de novo* either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized *de novo* using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty *et al.*, *Nature* 348:552-554 (1990))

For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many technique known in the art can be used (see, e.g., Kohler & Milstein, *Nature* 256:495-497 (1975); Kozbor *et al.*, *Immunology Today* 4: 72 (1983); Cole *et al.*, pp. 77-96 in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc. (1985); Coligan, *Current Protocols in Immunology* (1991); Harlow & Lane, *Antibodies, A Laboratory Manual* (1988); and Goding, *Monoclonal Antibodies: Principles and Practice* (2d ed. 1986)). Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (see, e.g., McCafferty *et al.*, *Nature* 348:552-554 (1990); Marks *et al.*, *Biotechnology* 10:779-783 (1992)).

A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.

In one embodiment, the antibody is conjugated to an “effector” moiety. The effector moiety can be any number of molecules, including labeling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the antibody modulates the activity of the protein.

5 The phrase “specifically (or selectively) binds” to an antibody or “specifically (or selectively) immunoreactive with,” when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein, often in a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein at least two times the background and
10 more typically more than 10 to 100 times background. Specific binding to an antibody under such conditions requires an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies raised to a T1R protein or a heterodimeric T1R3-comprising sweet taste receptor comprising a sequence of or encoded by SEQ ID NO:1-25, polymorphic variants, alleles, orthologs, and conservatively modified variants, or splice
15 variants, or portions thereof, can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with T1R proteins and/or heterodimeric T1R3-comprising sweet taste receptors and not with other proteins. In one embodiment, the antibodies react with a heterodimeric T1R3-comprising taste receptor, but not with individual protein members of the T1R family. This selection may be achieved by subtracting out antibodies
20 that cross-react with other molecules. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (*see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual* (1988) for a description of immunoassay formats and conditions that can be used to
25 determine specific immunoreactivity).

ISOLATION OF NUCLEIC ACIDS ENCODING T1R FAMILY MEMBERS

This invention relies on routine techniques in the field of recombinant genetics. Basic texts disclosing the general methods of use in this invention include
30 Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (2nd ed. 1989); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); and *Current Protocols in Molecular Biology* (Ausubel *et al.*, eds., 1994)).

T1R nucleic acids, polymorphic variants, orthologs, and alleles that are substantially identical to an amino acid sequences disclosed herein can be isolated using T1R

nucleic acid probes and oligonucleotides under stringent hybridization conditions, by screening libraries. Alternatively, expression libraries can be used to clone T1R protein, polymorphic variants, orthologs, and alleles by detecting expressed homologs immunologically with antisera or purified antibodies made against human T1R or portions thereof.

To make a cDNA library, one should choose a source that is rich in T1R RNA, e.g., taste buds such as circumvallate, foliate, fungiform, and palate. The mRNA is then made into cDNA using reverse transcriptase, ligated into a recombinant vector, and transfected into a recombinant host for propagation, screening and cloning. Methods for making and screening cDNA libraries are well known (*see, e.g., Gubler & Hoffman, Gene* 25:263-269 (1983); Sambrook *et al., supra*; Ausubel *et al., supra*).

For a genomic library, the DNA is extracted from the tissue and either mechanically sheared or enzymatically digested to yield fragments of about 12-20 kb. The fragments are then separated by gradient centrifugation from undesired sizes and are constructed in bacteriophage lambda vectors. These vectors and phage are packaged *in vitro*. Recombinant phage are analyzed by plaque hybridization as described in Benton & Davis, *Science* 196:180-182 (1977). Colony hybridization is carried out as generally described in Grunstein *et al., Proc. Natl. Acad. Sci. USA.,* 72:3961-3965 (1975).

An alternative method of isolating T1R nucleic acid and its orthologs, alleles, mutants, polymorphic variants, and conservatively modified variants combines the use of synthetic oligonucleotide primers and amplification of an RNA or DNA template (*see U.S. Patents 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications* (Innis *et al., eds*, 1990)). Methods such as polymerase chain reaction (PCR) and ligase chain reaction (LCR) can be used to amplify nucleic acid sequences of human T1R directly from mRNA, from cDNA, from genomic libraries or cDNA libraries. Degenerate oligonucleotides can be designed to amplify T1R homologs using the sequences provided herein. Restriction endonuclease sites can be incorporated into the primers. Polymerase chain reaction or other *in vitro* amplification methods may also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of T1R encoding mRNA in physiological samples, for nucleic acid sequencing, or for other purposes. Genes amplified by the PCR reaction can be purified from agarose gels and cloned into an appropriate vector.

Gene expression of T1R can also be analyzed by techniques known in the art, e.g., reverse transcription and amplification of mRNA, isolation of total RNA or poly A⁺

RNA, northern blotting, dot blotting, *in situ* hybridization, RNase protection, high density polynucleotide array technology, e.g., and the like.

Nucleic acids encoding T1R protein can be used with high density oligonucleotide array technology (e.g., GeneChipTM) to identify T1R protein, orthologs, alleles, conservatively modified variants, and polymorphic variants in this invention (*see, e.g.,* Gunthand *et al.*, *AIDS Res. Hum. Retroviruses* 14: 869-876 (1998); Kozal *et al.*, *Nat. Med.* 2:753-759 (1996); Matson *et al.*, *Anal. Biochem.* 224:110-106 (1995); Lockhart *et al.*, *Nat. Biotechnol.* 14:1675-1680 (1996); Gingeras *et al.*, *Genome Res.* 8:435-448 (1998); Hacia *et al.*, *Nucleic Acids Res.* 26:3865-3866 (1998)).

The gene for T1R is typically cloned into intermediate vectors before transformation into prokaryotic or eukaryotic cells for replication and/or expression. These intermediate vectors are typically prokaryote vectors, e.g., plasmids, or shuttle vectors.

EXPRESSION IN PROKARYOTES AND EUKARYOTES

To obtain high level expression of a cloned gene, such as those cDNAs encoding a T1R protein, one typically subclones T1R into an expression vector that contains a strong promoter to direct transcription, a transcription/translation terminator, and if for a nucleic acid encoding a protein, a ribosome binding site for translational initiation. The T1R nucleic acids can be co-expressed or separately expressed, preferably co-expressed on the same or a different vector. Suitable bacterial promoters are well known in the art and described, e.g., in Sambrook *et al.*, and Ausubel *et al. supra*. Bacterial expression systems for expressing the T1R protein are available in, e.g., *E. coli*, *Bacillus sp.*, and *Salmonella* (Palva *et al.*, *Gene* 22:229-235 (1983); Mosbach *et al.*, *Nature* 302:543-545 (1983). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available. In one preferred embodiment, retroviral expression systems are used in the present invention.

Selection of the promoter used to direct expression of a heterologous nucleic acid depends on the particular application. The promoter is preferably positioned about the same distance from the heterologous transcription start site as it is from the transcription start site in its natural setting. As is known in the art, however, some variation in this distance can be accommodated without loss of promoter function.

In addition to the promoter, the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required for

the expression of the T1R encoding nucleic acid in host cells. A typical expression cassette thus contains a promoter operably linked to the nucleic acid sequence encoding T1R and signals required for efficient polyadenylation of the transcript, ribosome binding sites, and translation termination. Additional elements of the cassette may include enhancers and, if genomic DNA is used as the structural gene, introns with functional splice donor and acceptor sites.

In addition to a promoter sequence, the expression cassette should also contain a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region may be obtained from the same gene as the promoter sequence or may be obtained from different genes.

The particular expression vector used to transport the genetic information into the cell is not particularly critical. Any of the conventional vectors used for expression in eukaryotic or prokaryotic cells may be used. Standard bacterial expression vectors include plasmids such as pBR322 based plasmids, pSKF, pET23D, and fusion expression systems such as MBP, GST, and LacZ. Epitope tags can also be added to recombinant proteins to provide convenient methods of isolation, e.g., c-myc. Sequence tags may be included in an expression cassette for nucleic acid rescue. Markers such as fluorescent proteins, green or red fluorescent protein, β -gal, CAT, and the like can be included in the vectors as markers for vector transduction.

Expression vectors containing regulatory elements from eukaryotic viruses are typically used in eukaryotic expression vectors, e.g., SV40 vectors, papilloma virus vectors, retroviral vectors, and vectors derived from Epstein-Barr virus. Other exemplary eukaryotic vectors include pMSG, pAV009/A⁺, pMTO10/A⁺, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the CMV promoter, SV40 early promoter, SV40 later promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.

Expression of proteins from eukaryotic vectors can be also be regulated using inducible promoters. With inducible promoters, expression levels are tied to the concentration of inducing agents, such as tetracycline or ecdysone, by the incorporation of response elements for these agents into the promoter. Generally, high level expression is obtained from inducible promoters only in the presence of the inducing agent; basal expression levels are minimal.

In one embodiment, the vectors of the invention have a regulatable promoter, e.g., tet-regulated systems and the RU-486 system (*see, e.g., Gossen & Bujard, Proc. Nat'l Acad. Sci. USA* 89:5547 (1992); Oligino *et al., Gene Ther.* 5:491-496 (1998); Wang *et al., Gene Ther.* 4:432-441 (1997); Neering *et al., Blood* 88:1147-1155 (1996); and Rendahl *et al., Nat. Biotechnol.* 16:757-761 (1998)). These impart small molecule control on the expression of the candidate target nucleic acids. This beneficial feature can be used to determine that a desired phenotype is caused by a transfected cDNA rather than a somatic mutation.

Some expression systems have markers that provide gene amplification such as thymidine kinase and dihydrofolate reductase. Alternatively, high yield expression systems not involving gene amplification are also suitable, such as using a baculovirus vector in insect cells, with a T1R encoding sequence under the direction of the polyhedrin promoter or other strong baculovirus promoters.

The elements that are typically included in expression vectors also include a replicon that functions in *E. coli*, a gene encoding antibiotic resistance to permit selection of bacteria that harbor recombinant plasmids, and unique restriction sites in nonessential regions of the plasmid to allow insertion of eukaryotic sequences. The particular antibiotic resistance gene chosen is not critical, any of the many resistance genes known in the art are suitable. The prokaryotic sequences are preferably chosen such that they do not interfere with the replication of the DNA in eukaryotic cells, if necessary.

Standard transfection methods are used to produce bacterial, mammalian, yeast or insect cell lines that express large quantities of T1R protein, which are then purified using standard techniques (*see, e.g., Colley et al., J. Biol. Chem.* 264:17619-17622 (1989); *Guide to Protein Purification, in Methods in Enzymology*, vol. 182 (Deutscher, ed., 1990)). Transformation of eukaryotic and prokaryotic cells are performed according to standard techniques (*see, e.g., Morrison, J. Bact.* 132:349-351 (1977); Clark-Curtiss & Curtiss, *Methods in Enzymology* 101:347-362 (Wu *et al., eds*, 1983)).

Any of the well-known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, biolistics, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (*see, e.g., Sambrook et al., supra*). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing T1R.

After the expression vector is introduced into the cells, the transfected cells are cultured under conditions favoring expression of T1R , which is recovered from the culture using standard techniques identified below.

5 PURIFICATION OF T1R POLYPEPTIDES

Either naturally occurring or recombinant T1R polypeptides or T1R3-comprising receptors can be purified for use in functional assays. Naturally occurring T1R proteins or T1R3-comprising receptors can be purified, e.g., from human tissue. Recombinant T1R proteins or T1R3-comprising receptors can be purified from any suitable
10 expression system. T1R polypeptides are typically co-expressed in the same cell to form T1R3-comprising receptors.

The T1R protein or T1R3-comprising receptor may be purified to substantial purity by standard techniques, including selective precipitation with such substances as ammonium sulfate; column chromatography, immunopurification methods, and others (*see*,
15 *e.g.*, Scopes, *Protein Purification: Principles and Practice* (1982); U.S. Patent No. 4,673,641; Ausubel *et al.*, *supra*; and Sambrook *et al.*, *supra*).

A number of procedures can be employed when recombinant T1R protein or T1R3-comprising receptor is being purified. For example, proteins having established molecular adhesion properties can be reversibly fused to the T1R protein or T1R3-comprising
20 receptor. With the appropriate ligand, T1R protein or T1R3-comprising receptor can be selectively adsorbed to a purification column and then freed from the column in a relatively pure form. The fused protein is then removed by enzymatic activity. Finally, T1R protein or T1R3-comprising receptor could be purified using immunoaffinity columns.

25 A. Purification of T1R from recombinant bacteria

Recombinant proteins are expressed by transformed bacteria in large amounts, typically after promoter induction; but expression can be constitutive. Promoter induction with IPTG is one example of an inducible promoter system. Bacteria are grown according to standard procedures in the art. Fresh or frozen bacteria cells are used for isolation of protein.

30 Proteins expressed in bacteria may form insoluble aggregates ("inclusion bodies"). Several protocols are suitable for purification of T1R protein or T1R3-comprising receptor inclusion bodies. For example, purification of inclusion bodies typically involves the extraction, separation and/or purification of inclusion bodies by disruption of bacterial cells, e.g., by incubation in a buffer of 50 mM TRIS/HCL pH 7.5, 50 mM NaCl, 5 mM

MgCl₂, 1 mM DTT, 0.1 mM ATP, and 1 mM PMSF. The cell suspension can be lysed using 2-3 passages through a French Press, homogenized using a Polytron (Brinkman Instruments) or sonicated on ice. Alternate methods of lysing bacteria are apparent to those of skill in the art (*see, e.g., Sambrook et al., supra; Ausubel et al., supra*).

5 If necessary, the inclusion bodies are solubilized, and the lysed cell suspension is typically centrifuged to remove unwanted insoluble matter. Proteins that formed the inclusion bodies may be renatured by dilution or dialysis with a compatible buffer. Suitable solvents include, but are not limited to urea (from about 4 M to about 8 M), formamide (at least about 80%, volume/volume basis), and guanidine hydrochloride (from about 4 M to
10 about 8 M). Some solvents which are capable of solubilizing aggregate-forming proteins, for example SDS (sodium dodecyl sulfate), 70% formic acid, are inappropriate for use in this procedure due to the possibility of irreversible denaturation of the proteins, accompanied by a lack of immunogenicity and/or activity. Although guanidine hydrochloride and similar agents are denaturants, this denaturation is not irreversible and renaturation may occur upon
15 removal (by dialysis, for example) or dilution of the denaturant, allowing re-formation of immunologically and/or biologically active protein. Other suitable buffers are known to those skilled in the art. Human T1R proteins or T1R3-comprising receptors are separated from other bacterial proteins by standard separation techniques, e.g., with Ni-NTA agarose resin.

20 Alternatively, it is possible to purify T1R protein or T1R3-comprising receptor from bacteria periplasm. After lysis of the bacteria, when the T1R protein or T1R3-comprising receptor is exported into the periplasm of the bacteria, the periplasmic fraction of the bacteria can be isolated by cold osmotic shock in addition to other methods known to skill in the art. To isolate recombinant proteins from the periplasm, the bacterial cells are
25 centrifuged to form a pellet. The pellet is resuspended in a buffer containing 20% sucrose. To lyse the cells, the bacteria are centrifuged and the pellet is resuspended in ice-cold 5 mM MgSO₄ and kept in an ice bath for approximately 10 minutes. The cell suspension is centrifuged and the supernatant decanted and saved. The recombinant proteins present in the supernatant can be separated from the host proteins by standard separation techniques well
30 known to those of skill in the art.

B. Standard protein separation techniques for purifying T1R proteins

Solubility fractionation

Often as an initial step, particularly if the protein mixture is complex, an initial salt fractionation can separate many of the unwanted host cell proteins (or proteins derived from the cell culture media) from the recombinant protein of interest. The preferred salt is ammonium sulfate. Ammonium sulfate precipitates proteins by effectively reducing the amount of water in the protein mixture. Proteins then precipitate on the basis of their solubility. The more hydrophobic a protein is, the more likely it is to precipitate at lower ammonium sulfate concentrations. A typical protocol includes adding saturated ammonium sulfate to a protein solution so that the resultant ammonium sulfate concentration is between 20-30%. This concentration will precipitate the most hydrophobic of proteins. The precipitate is then discarded (unless the protein of interest is hydrophobic) and ammonium sulfate is added to the supernatant to a concentration known to precipitate the protein of interest. The precipitate is then solubilized in buffer and the excess salt removed if necessary, either through dialysis or diafiltration. Other methods that rely on solubility of proteins, such as cold ethanol precipitation, are well known to those of skill in the art and can be used to fractionate complex protein mixtures.

Size differential filtration

The molecular weight of the T1R proteins or T1R3-comprising receptors can be used to isolate it from proteins of greater and lesser size using ultrafiltration through membranes of different pore size (for example, Amicon or Millipore membranes). As a first step, the protein mixture is ultrafiltered through a membrane with a pore size that has a lower molecular weight cut-off than the molecular weight of the protein of interest. The retentate of the ultrafiltration is then ultrafiltered against a membrane with a molecular cut off greater than the molecular weight of the protein of interest. The recombinant protein will pass through the membrane into the filtrate. The filtrate can then be chromatographed as described below.

Column chromatography

The T1R proteins or T1R3-comprising receptors can also be separated from other proteins on the basis of its size, net surface charge, hydrophobicity, and affinity for ligands. In addition, antibodies raised against proteins can be conjugated to column matrices and the proteins immunopurified. All of these methods are well known in the art. It will be

apparent to one of skill that chromatographic techniques can be performed at any scale and using equipment from many different manufacturers (e.g., Pharmacia Biotech).

ASSAYS FOR MODULATORS OF T1R PROTEIN

5 A. Assays

Modulation of a T1R3-comprising sweet taste receptor, and corresponding modulation of taste, can be assessed using a variety of *in vitro* and *in vivo* assays. Such assays can be used to test for inhibitors and activators of T1R3-comprising sweet taste receptors, and, consequently, inhibitors and activators of taste. Such modulators of T1R3-
10 comprising sweet taste receptors, which are involved in taste signal transduction. Modulators of T1R3-comprising sweet taste receptors are tested using either recombinant or naturally occurring T1R3-comprising sweet taste receptors, preferably human receptors.

Preferably, the T1R3-comprising sweet taste receptor will have a sequence as encoded by a sequence provided herein or a conservatively modified variant thereof.
15 Alternatively, the T1R3-comprising sweet taste receptor of the assay will be derived from a eukaryote and include an amino acid subsequence having substantial amino acid sequence identity to the sequences provided herein or is encoded by a nucleotide sequence that hybridizes under stringent conditions (moderate or high) to a nucleotide sequence as described herein. Generally, the amino acid sequence identity will be at least 60%,
20 preferably at least 65%, 70%, 75%, 80%, 85%, or 90%, most preferably at least 95%.

Measurement of sweet taste signal transduction or loss-of-sweet taste signal transduction phenotype on T1R3-comprising sweet taste receptor or cell expressing the T1R3-comprising sweet taste receptor, either recombinant or naturally occurring, can be performed using a variety of assays, *in vitro*, *in vivo*, and *ex vivo*, as described herein. A
25 suitable physical, chemical or phenotypic change that affects activity or binding can be used to assess the influence of a test compound on the polypeptide of this invention. When the functional effects are determined using intact cells or animals, one can also measure a variety of effects such as, in the case of signal transduction, e.g., ligand binding, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., northern
30 blots), changes in cell metabolism such as pH changes, and changes in intracellular second messengers such as Ca^{2+} , IP3, cGMP, or cAMP.

In vitro assays

Assays to identify compounds with T1R3-comprising sweet taste receptor modulating activity can be performed *in vitro*. Such assays can use a full length T1R3-comprising sweet taste receptor or a variant thereof, or a fragment of a T1R3-comprising sweet taste receptor, such as an extracellular domain, fused to a heterologous protein to form a chimera. Purified recombinant or naturally occurring T1R3-comprising sweet taste receptor can be used in the *in vitro* methods of the invention. In addition to purified T1R3-comprising sweet taste receptor, the recombinant or naturally occurring T1R3-comprising sweet taste receptor can be part of a cellular lysate or a cell membrane. As described below, the binding assay can be either solid state or soluble. Preferably, the protein or membrane is bound to a solid support, either covalently or non-covalently. Often, the *in vitro* assays of the invention are ligand binding or ligand affinity assays, either non-competitive or competitive (with known extracellular ligands as described herein, or with a known intracellular ligand GTP). Other *in vitro* assays include measuring changes in spectroscopic (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein.

In one embodiment, a high throughput binding assay is performed in which the T1R3-comprising sweet taste receptor or chimera comprising a fragment thereof is contacted with a potential modulator and incubated for a suitable amount of time. In one embodiment, the potential modulator is bound to a solid support, and the T1R3-comprising sweet taste receptor is added. In another embodiment, the T1R3-comprising sweet taste receptor is bound to a solid support. A wide variety of modulators can be used, as described below, including small organic molecules, peptides, antibodies, and T1R3-comprising sweet taste receptor ligand analogs. A wide variety of assays can be used to identify T1R3-comprising sweet taste receptor-modulator binding, including labeled protein-protein binding assays, electrophoretic mobility shifts, immunoassays, enzymatic assays such as phosphorylation assays, and the like. In some cases, the binding of the candidate modulator is determined through the use of competitive binding assays, where interference with binding of a known ligand is measured in the presence of a potential modulator. Ligands for T1R3-comprising sweet taste receptors are provided herein. Either the modulator or the known ligand is bound first, and then the competitor is added. After the T1R3-comprising sweet taste receptor is washed, interference with binding, either of the potential modulator or of the known ligand, is determined. Often, either the potential modulator or the known ligand is labeled.

Cell-based *in vivo* assays

In another embodiment, a T1R3-comprising sweet taste receptor is expressed in a cell (e.g., by co-expression two heterologous members of the T1R family such as T1R1 and T1R3 or T1R2 and T1R3), and functional, e.g., physical and chemical or phenotypic, changes are assayed to identify T1R3-comprising sweet taste receptor taste modulators. Cells expressing T1R3-comprising sweet taste receptor can also be used in binding assays. Any suitable functional effect can be measured, as described herein. For example, ligand binding, G-protein binding, and GPCR signal transduction, e.g., changes in intracellular Ca^{2+} levels, are all suitable assays to identify potential modulators using a cell based system. Suitable cells for such cell based assays include both primary cells and cell lines, as described herein. The T1R3-comprising sweet taste receptor can be naturally occurring or recombinant. Also, as described above, chimeric T1R3-comprising sweet taste receptors with GPCR activity can be used in cell based assays. For example, the extracellular domain of an T1R protein can be fused to the transmembrane and/or cytoplasmic domain of a heterologous protein, preferably a heterologous GPCR. Such a chimeric GPCR would have GPCR activity and could be used in cell based assays of the invention.

In another embodiment, cellular T1R polypeptide levels are determined by measuring the level of protein or mRNA. The level of T1R protein or proteins related to T1R signal transduction are measured using immunoassays such as western blotting, ELISA and the like with an antibody that selectively binds to the T1R3-comprising sweet taste receptor or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNase protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.

Alternatively, T1R3-comprising receptor expression can be measured using a reporter gene system. Such a system can be devised using an T1R protein promoter operably linked to a reporter gene such as chloramphenicol acetyltransferase, firefly luciferase, bacterial luciferase, β -galactosidase and alkaline phosphatase. Furthermore, the protein of interest can be used as an indirect reporter via attachment to a second reporter such as red or green fluorescent protein (see, e.g., Mistili & Spector, *Nature Biotechnology* 15:961-964 (1997)). The reporter construct is typically transfected into a cell. After treatment with a

potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art.

In another embodiment, a functional effect related to GPCR signal transduction can be measured. An activated or inhibited T1R3-comprising G-coupled protein receptor will alter the properties of target enzymes, second messengers, channels, and other effector proteins. The examples include the activation of cGMP phosphodiesterase, adenylyate cyclase, phospholipase C, IP3, and modulation of diverse channels by G proteins. Downstream consequences can also be examined such as generation of diacyl glycerol and IP3 by phospholipase C, and in turn, for calcium mobilization by IP3. Activated GPCR receptors become substrates for kinases that phosphorylate the C-terminal tail of the receptor (and possibly other sites as well). Thus, activators will promote the transfer of ^{32}P from gamma-labeled GTP to the receptor, which can be assayed with a scintillation counter. The phosphorylation of the C-terminal tail will promote the binding of arrestin-like proteins and will interfere with the binding of G-proteins. For a general review of GPCR signal transduction and methods of assaying signal transduction, see, e.g., *Methods in Enzymology*, vols. 237 and 238 (1994) and volume 96 (1983); Bourne *et al.*, *Nature* 10:349:117-27 (1991); Bourne *et al.*, *Nature* 348:125-32 (1990); Pitcher *et al.*, *Annu. Rev. Biochem.* 67:653-92 (1998).

As described above, activation of some G-protein coupled receptors stimulates the formation of inositol triphosphate (IP3) through phospholipase C-mediated hydrolysis of phosphatidylinositol (Berridge & Irvine, *Nature* 312:315-21 (1984)). IP3 in turn stimulates the release of intracellular calcium ion stores. Thus, a change in cytoplasmic calcium ion levels, or a change in second messenger levels such as IP3 can be used to assess G-protein coupled receptor function. Cells expressing such G-protein coupled receptors may exhibit increased cytoplasmic calcium levels as a result of contribution from both intracellular stores and via activation of ion channels, in which case it may be desirable although not necessary to conduct such assays in calcium-free buffer, optionally supplemented with a chelating agent such as EGTA, to distinguish fluorescence response resulting from calcium release from internal stores.

In one example, T1R3-comprising sweet taste receptor GPCR activity is measured by expressing a T1R3-comprising sweet taste receptor in a heterologous cell with a promiscuous G-protein that links the receptor to a phospholipase C signal transduction pathway (see Offermanns & Simon, *J. Biol. Chem.* 270:15175-15180 (1995)). Modulation of signal transduction is assayed by measuring changes in intracellular Ca^{2+} levels, which

change in response to modulation of the GPCR signal transduction pathway via administration of a molecule that associates with an T1R3-comprising sweet taste receptor. Changes in Ca^{2+} levels are optionally measured using fluorescent Ca^{2+} indicator dyes and fluorometric imaging.

5 In another example, phosphatidyl inositol (PI) hydrolysis can be analyzed according to U.S. Patent 5,436,128, herein incorporated by reference. Briefly, the assay involves labeling of cells with ^3H -myoinositol for 48 or more hrs. The labeled cells are treated with a test compound for one hour. The treated cells are lysed and extracted in chloroform-methanol-water after which the inositol phosphates were separated by ion
10 exchange chromatography and quantified by scintillation counting. Fold stimulation is determined by calculating the ratio of cpm in the presence of agonist to cpm in the presence of buffer control. Likewise, fold inhibition is determined by calculating the ratio of cpm in the presence of antagonist to cpm in the presence of buffer control (which may or may not contain an agonist).

15 Other assays can involve determining the activity of receptors which, when activated, result in a change in the level of intracellular cyclic nucleotides, e.g., cAMP or cGMP, by activating or inhibiting enzymes such as adenylate cyclase. In cases where activation of the receptor results in a decrease in cyclic nucleotide levels, it may be preferable to expose the cells to agents that increase intracellular cyclic nucleotide levels, e.g., forskolin,
20 prior to adding a receptor-activating compound to the cells in the assay.

 In one example, the changes in intracellular cAMP or cGMP can be measured using immunoassays. The method described in Offermanns & Simon, *J. Biol. Chem.* 270:15175-15180 (1995) may be used to determine the level of cAMP. Also, the method described in Felley-Bosco *et al.*, *Am. J. Resp. Cell and Mol. Biol.* 11:159-164 (1994) may be
25 used to determine the level of cGMP. Further, an assay kit for measuring cAMP and/or cGMP is described in U.S. Patent 4,115,538, herein incorporated by reference.

 In one example, assays for G-protein coupled receptor activity include cells that are loaded with ion or voltage sensitive dyes to report receptor activity. Assays for determining activity of such receptors can also use known agonists and antagonists for other
30 G-protein coupled receptors as negative or positive controls to assess activity of tested compounds. In assays for identifying modulatory compounds (e.g., agonists, antagonists), changes in the level of ions in the cytoplasm or membrane voltage will be monitored using an ion sensitive or membrane voltage fluorescent indicator, respectively. Among the ion-sensitive indicators and voltage probes that may be employed are those disclosed in the

Molecular Probes 1997 Catalog. For G-protein coupled receptors, promiscuous G-proteins such as G α 15 and G α 16 can be used in the assay of choice (Wilkie *et al.*, *Proc. Nat'l Acad. Sci. USA* 88:10049-10053 (1991)). Such promiscuous G-proteins allow coupling of a wide range of receptors.

5

Animal models

Animal models of taste also find use in screening for modulators of taste, such as the Sac taster and non-taster mouse strains as described herein. Similarly, transgenic animal technology including gene knockout technology, for example as a result of homologous recombination with an appropriate gene targeting vector, or gene overexpression, will result in the absence or increased expression of the T1R3-comprising receptor or components thereof. When desired, tissue-specific expression or knockout of the T1R3-comprising receptors or components thereof may be necessary. Transgenic animals generated by such methods find use as animal models of taste modulation and are additionally useful in screening for modulators of taste modulation.

10
15

B. Modulators

The compounds tested as modulators of T1R3-comprising sweet taste receptors can be any small organic molecule, or a biological entity, such as a protein, e.g., an antibody or peptide, a sugar, a nucleic acid, e.g., an antisense oligonucleotide or a ribozyme, or a lipid. Alternatively, modulators can be genetically altered versions of a T1R3-comprising sweet taste receptor. Typically, test compounds will be small organic molecules, peptides, lipids, and lipid analogs.

20

Essentially any chemical compound can be used as a potential modulator or ligand in the assays of the invention, although most often compounds can be dissolved in aqueous or organic (especially DMSO-based) solutions are used. The assays are designed to screen large chemical libraries by automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays). It will be appreciated that there are many suppliers of chemical compounds, including Sigma (St. Louis, MO), Aldrich (St. Louis, MO), Sigma-Aldrich (St. Louis, MO), Fluka Chemika-Biochemica Analytika (Buchs Switzerland) and the like.

25
30

In one preferred embodiment, high throughput screening methods involve providing a combinatorial small organic molecule or peptide library containing a large number of potential therapeutic compounds (potential modulator or ligand compounds). Such "combinatorial chemical libraries" or "ligand libraries" are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (*see, e.g.*, U.S. Patent 5,010,175, Furka, *Int. J. Pept. Prot. Res.* 37:487-493 (1991) and Houghton *et al.*, *Nature* 354:84-88 (1991)). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (e.g., PCT Publication No. WO 91/19735), encoded peptides (e.g., PCT Publication No. WO 93/20242), random bio-oligomers (e.g., PCT Publication No. WO 92/00091), benzodiazepines (e.g., U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs *et al.*, *Proc. Nat. Acad. Sci. USA* 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara *et al.*, *J. Amer. Chem. Soc.* 114:6568 (1992)), nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann *et al.*, *J. Amer. Chem. Soc.* 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen *et al.*, *J. Amer. Chem. Soc.* 116:2661 (1994)), oligocarbamates (Cho *et al.*, *Science* 261:1303 (1993)), and/or peptidyl phosphonates (Campbell *et al.*, *J. Org. Chem.* 59:658 (1994)), nucleic acid libraries (*see* Ausubel, Berger and Sambrook, *all supra*), peptide nucleic acid libraries (*see, e.g.*, U.S. Patent 5,539,083), antibody libraries (*see, e.g.*, Vaughn *et al.*, *Nature Biotechnology*, 14(3):309-314 (1996) and PCT/US96/10287), carbohydrate libraries (*see, e.g.*, Liang *et al.*, *Science*, 274:1520-1522 (1996) and U.S. Patent 5,593,853), small organic molecule libraries (*see, e.g.*, benzodiazepines, Baum C&EN, Jan 18, page 33 (1993);

isoprenoids, U.S. Patent 5,569,588; thiazolidinones and metathiazanones, U.S. Patent 5,549,974; pyrrolidines, U.S. Patents 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent 5,506,337; benzodiazepines, 5,288,514, and the like).

Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY; Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA). In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

C. Solid state and soluble high throughput assays

In one embodiment the invention provides soluble assays using a T1R3-comprising sweet taste receptor, or a cell or tissue expressing a T1R3-comprising sweet taste receptor, either naturally occurring or recombinant. In another embodiment, the invention provides solid phase based *in vitro* assays in a high throughput format, where the T1R3-comprising sweet taste receptor is attached to a solid phase substrate. Any one of the assays described herein can be adapted for high throughput screening, e.g., ligand binding, cellular proliferation, cell surface marker flux, e.g., screening, radiolabeled GTP binding, second messenger flux, e.g., Ca^{2+} , IP3, cGMP, or cAMP, cytokine production, etc.

In the high throughput assays of the invention, either soluble or solid state, it is possible to screen up to several thousand different modulators or ligands in a single day. This methodology can be used for T1R3-comprising sweet taste receptors *in vitro*, or for cell-based or membrane-based assays comprising T1R3-comprising sweet taste receptors. In particular, each well of a microtiter plate can be used to run a separate assay against a selected potential modulator, or, if concentration or incubation time effects are to be observed, every 5-10 wells can test a single modulator. Thus, a single standard microtiter plate can assay about 100 (e.g., 96) modulators. If 1536 well plates are used, then a single plate can easily assay from about 100- about 1500 different compounds. It is possible to assay many plates per day; assay screens for up to about 6,000, 20,000, 50,000, or more than 100,000 different compounds are possible using the integrated systems of the invention.

For a solid state reaction, the protein of interest or a fragment thereof, e.g., an extracellular domain, or a cell or membrane comprising the protein of interest or a fragment thereof as part of a fusion protein can be bound to the solid state component, directly or

indirectly, via covalent or non covalent linkage e.g., via a tag. The tag can be any of a variety of components. In general, a molecule which binds the tag (a tag binder) is fixed to a solid support, and the tagged molecule of interest is attached to the solid support by interaction of the tag and the tag binder.

5 A number of tags and tag binders can be used, based upon known molecular interactions well described in the literature. For example, where a tag has a natural binder, for example, biotin, protein A, or protein G, it can be used in conjunction with appropriate tag binders (avidin, streptavidin, neutravidin, the Fc region of an immunoglobulin, etc.) Antibodies to molecules with natural binders such as biotin are also widely available and
10 appropriate tag binders; *see*, SIGMA Immunochemicals 1998 catalogue SIGMA, St. Louis MO).

 Similarly, any haptenic or antigenic compound can be used in combination with an appropriate antibody to form a tag/tag binder pair. Thousands of specific antibodies are commercially available and many additional antibodies are described in the literature.
15 For example, in one common configuration, the tag is a first antibody and the tag binder is a second antibody which recognizes the first antibody. In addition to antibody-antigen interactions, receptor-ligand interactions are also appropriate as tag and tag-binder pairs. For example, agonists and antagonists of cell membrane receptors (e.g., cell receptor-ligand interactions such as transferrin, c-kit, viral receptor ligands, cytokine receptors, chemokine
20 receptors, interleukin receptors, immunoglobulin receptors and antibodies, the cadherein family, the integrin family, the selectin family, and the like; *see, e.g.*, Pigott & Power, *The Adhesion Molecule Facts Book I* (1993). Similarly, toxins and venoms, viral epitopes, hormones (e.g., opiates, steroids, etc.), intracellular receptors (e.g. which mediate the effects of various small ligands, including steroids, thyroid hormone, retinoids and vitamin D;
25 peptides), drugs, lectins, sugars, nucleic acids (both linear and cyclic polymer configurations), oligosaccharides, proteins, phospholipids and antibodies can all interact with various cell receptors.

 Synthetic polymers, such as polyurethanes, polyesters, polycarbonates, polyureas, polyamides, polyethyleneimines, polyarylene sulfides, polysiloxanes, polyimides,
30 and polyacetates can also form an appropriate tag or tag binder. Many other tag/tag binder pairs are also useful in assay systems described herein, as would be apparent to one of skill upon review of this disclosure.

 Common linkers such as peptides, polyethers, and the like can also serve as tags, and include polypeptide sequences, such as poly gly sequences of between about 5 and

200 amino acids. Such flexible linkers are known to persons of skill in the art. For example, poly(ethylene glycol) linkers are available from Shearwater Polymers, Inc. Huntsville, Alabama. These linkers optionally have amide linkages, sulfhydryl linkages, or heterofunctional linkages.

5 Tag binders are fixed to solid substrates using any of a variety of methods currently available. Solid substrates are commonly derivatized or functionalized by exposing all or a portion of the substrate to a chemical reagent which fixes a chemical group to the surface which is reactive with a portion of the tag binder. For example, groups which are suitable for attachment to a longer chain portion would include amines, hydroxyl, thiol, and
10 carboxyl groups. Aminoalkylsilanes and hydroxyalkylsilanes can be used to functionalize a variety of surfaces, such as glass surfaces. The construction of such solid phase biopolymer arrays is well described in the literature. *See, e.g., Merrifield, J. Am. Chem. Soc.* 85:2149-2154 (1963) (describing solid phase synthesis of, e.g., peptides); Geysen *et al., J. Immun. Meth.* 102:259-274 (1987) (describing synthesis of solid phase components on pins); Frank &
15 Doring, *Tetrahedron* 44:60316040 (1988) (describing synthesis of various peptide sequences on cellulose disks); Fodor *et al., Science*, 251:767-777 (1991); Sheldon *et al., Clinical Chemistry* 39(4):718-719 (1993); and Kozal *et al., Nature Medicine* 2(7):753759 (1996) (all describing arrays of biopolymers fixed to solid substrates). Non-chemical approaches for fixing tag binders to substrates include other common methods, such as heat, cross-linking by
20 UV radiation, and the like.

IMMUNOLOGICAL DETECTION OF T1R3-COMPRISING RECEPTORS

In addition to the detection of T1R genes and gene expression using nucleic acid hybridization technology, one can also use immunoassays to detect T1R3-comprising
25 sweet taste receptors of the invention. Such assays are useful for screening for modulators of T1R3-comprising sweet taste receptors, as well as for therapeutic and diagnostic applications. Immunoassays can be used to qualitatively or quantitatively analyze T1R3-comprising sweet taste receptors. A general overview of the applicable technology can be found in Harlow & Lane, *Antibodies: A Laboratory Manual* (1988).

30

A. Production of antibodies

Methods of producing polyclonal and monoclonal antibodies that react specifically with the T1R proteins and T1R3-comprising sweet taste receptors are known to those of skill in the art (*see, e.g., Coligan, Current Protocols in Immunology* (1991); Harlow

& Lane, *supra*; Goding, *Monoclonal Antibodies: Principles and Practice* (2d ed. 1986); and Kohler & Milstein, *Nature* 256:495-497 (1975). Such techniques include antibody preparation by selection of antibodies from libraries of recombinant antibodies in phage or similar vectors, as well as preparation of polyclonal and monoclonal antibodies by immunizing rabbits or mice (*see, e.g., Huse et al., Science* 246:1275-1281 (1989); Ward *et al., Nature* 341:544-546 (1989)).

A number of immunogens comprising portions of T1R protein or T1R3-comprising sweet taste receptor may be used to produce antibodies specifically reactive with T1R protein. For example, recombinant T1R protein or an antigenic fragment thereof, can be isolated as described herein. Recombinant protein can be expressed in eukaryotic or prokaryotic cells as described above, and purified as generally described above. Recombinant protein is the preferred immunogen for the production of monoclonal or polyclonal antibodies. Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated to a carrier protein can be used as an immunogen. Naturally occurring protein may also be used either in pure or impure form. The product is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies may be generated, for subsequent use in immunoassays to measure the protein.

Methods of production of polyclonal antibodies are known to those of skill in the art. An inbred strain of mice (e.g., BALB/C mice) or rabbits is immunized with the protein using a standard adjuvant, such as Freund's adjuvant, and a standard immunization protocol. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to the beta subunits. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be done if desired (*see, Harlow & Lane, supra*).

Monoclonal antibodies may be obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (*see, Kohler & Milstein, Eur. J. Immunol.* 6:511-519 (1976)). Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, one may

isolate DNA sequences which encode a monoclonal antibody or a binding fragment thereof by screening a DNA library from human B cells according to the general protocol outlined by Huse, *et al.*, *Science* 246:1275-1281 (1989).

Monoclonal antibodies and polyclonal sera are collected and titered against the immunogen protein in an immunoassay, for example, a solid phase immunoassay with the immunogen immobilized on a solid support. Typically, polyclonal antisera with a titer of 10^4 or greater are selected and tested for their cross reactivity against non-T1R or T1R3-comprising sweet taste receptor proteins, using a competitive binding immunoassay. Specific polyclonal antisera and monoclonal antibodies will usually bind with a K_d of at least about 0.1 mM, more usually at least about 1 μ M, preferably at least about 0.1 μ M or better, and most preferably, 0.01 μ M or better. Antibodies specific only for a particular T1R3-comprising sweet taste receptor ortholog, such as human T1R3-comprising sweet taste receptor, can also be made, by subtracting out other cross-reacting orthologs from a species such as a non-human mammal. In addition, individual T1R proteins can be used to subtract out antibodies that bind both to the receptor and the individual T1R proteins. In this manner, antibodies that bind only to a heterodimeric receptor may be obtained.

Once the specific antibodies against T1R3-comprising sweet taste receptors are available, the protein can be detected by a variety of immunoassay methods. In addition, the antibody can be used therapeutically as a T1R3-comprising sweet taste receptor modulators. For a review of immunological and immunoassay procedures, see *Basic and Clinical Immunology* (Stites & Terr eds., 7th ed. 1991). Moreover, the immunoassays of the present invention can be performed in any of several configurations, which are reviewed extensively in *Enzyme Immunoassay* (Maggio, ed., 1980); and Harlow & Lane, *supra*.

B. Immunological binding assays

T1R3-comprising sweet taste receptors can be detected and/or quantified using any of a number of well recognized immunological binding assays (*see, e.g.*, U.S. Patents 4,366,241; 4,376,110; 4,517,288; and 4,837,168). For a review of the general immunoassays, see also *Methods in Cell Biology: Antibodies in Cell Biology*, volume 37 (Asai, ed. 1993); *Basic and Clinical Immunology* (Stites & Terr, eds., 7th ed. 1991). Immunological binding assays (or immunoassays) typically use an antibody that specifically binds to a protein or antigen of choice (in this case the T1R3-comprising sweet taste receptor or antigenic subsequence thereof). The antibody (*e.g.*, anti-T1R3-comprising sweet taste receptor) may

be produced by any of a number of means well known to those of skill in the art and as described above.

Immunoassays also often use a labeling agent to specifically bind to and label the complex formed by the antibody and antigen. The labeling agent may itself be one of the moieties comprising the antibody/antigen complex. Thus, the labeling agent may be a labeled T1R3-comprising sweet taste receptor or a labeled anti-T1R3-comprising sweet taste receptor antibody. Alternatively, the labeling agent may be a third moiety, such a secondary antibody, that specifically binds to the antibody/ T1R3-comprising sweet taste receptor complex (a secondary antibody is typically specific to antibodies of the species from which the first antibody is derived). Other proteins capable of specifically binding immunoglobulin constant regions, such as protein A or protein G may also be used as the label agent. These proteins exhibit a strong non-immunogenic reactivity with immunoglobulin constant regions from a variety of species (*see, e.g., Kronval et al., J. Immunol.* 111:1401-1406 (1973); *Akerstrom et al., J. Immunol.* 135:2589-2542 (1985)). The labeling agent can be modified with a detectable moiety, such as biotin, to which another molecule can specifically bind, such as streptavidin. A variety of detectable moieties are well known to those skilled in the art.

Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, optionally from about 5 minutes to about 24 hours. However, the incubation time will depend upon the assay format, antigen, volume of solution, concentrations, and the like. Usually, the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10°C to 40°C.

Non-competitive assay formats

Immunoassays for detecting T1R3-comprising sweet taste receptors in samples may be either competitive or noncompetitive. Noncompetitive immunoassays are assays in which the amount of antigen is directly measured. In one preferred “sandwich” assay, for example, the anti-T1R3-comprising sweet taste receptor antibodies can be bound directly to a solid substrate on which they are immobilized. These immobilized antibodies then capture T1R3-comprising sweet taste receptors present in the test sample. T1R3-comprising sweet taste receptors thus immobilized are then bound by a labeling agent, such as a second T1R3-comprising sweet taste receptor antibody bearing a label. Alternatively,

the second antibody may lack a label, but it may, in turn, be bound by a labeled third antibody specific to antibodies of the species from which the second antibody is derived. The second or third antibody is typically modified with a detectable moiety, such as biotin, to which another molecule specifically binds, e.g., streptavidin, to provide a detectable moiety.

5

Competitive assay formats

In competitive assays, the amount of T1R3-comprising sweet taste receptor present in the sample is measured indirectly by measuring the amount of a known, added (exogenous) T1R3-comprising sweet taste receptor displaced (competed away) from an anti-
10 T1R3-comprising sweet taste receptor antibody by the unknown T1R3-comprising sweet taste receptor present in a sample. In one competitive assay, a known amount of T1R3-comprising sweet taste receptor is added to a sample and the sample is then contacted with an antibody that specifically binds to a T1R3-comprising sweet taste receptor. The amount of exogenous T1R3-comprising sweet taste receptor bound to the antibody is inversely
15 proportional to the concentration of T1R3-comprising sweet taste receptor present in the sample. In a particularly preferred embodiment, the antibody is immobilized on a solid substrate. The amount of T1R3-comprising sweet taste receptor bound to the antibody may be determined either by measuring the amount of T1R3-comprising sweet taste receptor present in a T1R3-comprising sweet taste receptor/antibody complex, or alternatively by
20 measuring the amount of remaining uncomplexed protein. The amount of T1R3-comprising sweet taste receptor may be detected by providing a labeled T1R3-comprising sweet taste receptor molecule.

A hapten inhibition assay is another preferred competitive assay. In this assay the known T1R3-comprising sweet taste receptor is immobilized on a solid substrate. A
25 known amount of anti-T1R3-comprising sweet taste receptor antibody is added to the sample, and the sample is then contacted with the immobilized T1R3-comprising sweet taste receptor. The amount of anti-T1R3-comprising sweet taste receptor antibody bound to the known immobilized T1R3-comprising sweet taste receptor is inversely proportional to the amount of T1R3-comprising sweet taste receptor present in the sample. Again, the amount of
30 immobilized antibody may be detected by detecting either the immobilized fraction of antibody or the fraction of the antibody that remains in solution. Detection may be direct where the antibody is labeled or indirect by the subsequent addition of a labeled moiety that specifically binds to the antibody as described above.

Cross-reactivity determinations

Immunoassays in the competitive binding format can also be used for crossreactivity determinations. For example, a T1R3-comprising sweet taste receptor can be immobilized to a solid support. Proteins (e.g., T1R3-comprising sweet taste receptors and homologs) are added to the assay that compete for binding of the antisera to the immobilized antigen. The ability of the added proteins to compete for binding of the antisera to the immobilized protein is compared to the ability of the T1R3-comprising sweet taste receptor to compete with itself. The percent crossreactivity for the above proteins is calculated, using standard calculations. Those antisera with less than 10% crossreactivity with each of the added proteins listed above are selected and pooled. The cross-reacting antibodies are optionally removed from the pooled antisera by immunoabsorption with the added considered proteins, e.g., distantly related homologs.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described above to compare a second protein, thought to be perhaps an allele or polymorphic variant of a T1R3-comprising sweet taste receptor, to the immunogen protein. In order to make this comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required to inhibit 50% of binding is less than 10 times the amount of the T1R3-comprising sweet taste receptor that is required to inhibit 50% of binding, then the second protein is said to specifically bind to the polyclonal antibodies generated to a T1R3-comprising sweet taste receptor immunogen.

Other assay formats

Western blot (immunoblot) analysis is used to detect and quantify the presence of T1R3-comprising sweet taste receptors in the sample. The technique generally comprises separating sample proteins by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with the antibodies that specifically bind T1R3-comprising sweet taste receptors. The anti-T1R3-comprising sweet taste receptor antibodies specifically bind to the T1R3-comprising sweet taste receptor on the solid support. These antibodies may be directly labeled or alternatively may be subsequently detected using labeled antibodies (e.g., labeled sheep anti-mouse antibodies) that specifically bind to the anti-T1R3-comprising sweet taste receptor antibodies.

Other assay formats include liposome immunoassays (LIA), which use liposomes designed to bind specific molecules (e.g., antibodies) and release encapsulated reagents or markers. The released chemicals are then detected according to standard techniques (see Monroe *et al.*, *Amer. Clin. Prod. Rev.* 5:34-41 (1986)).

5

Reduction of non-specific binding

One of skill in the art will appreciate that it is often desirable to minimize non-specific binding in immunoassays. Particularly, where the assay involves an antigen or antibody immobilized on a solid substrate it is desirable to minimize the amount of non-specific binding to the substrate. Means of reducing such non-specific binding are well known to those of skill in the art. Typically, this technique involves coating the substrate with a proteinaceous composition. In particular, protein compositions such as bovine serum albumin (BSA), nonfat powdered milk, and gelatin are widely used with powdered milk being most preferred.

15

Labels

The particular label or detectable group used in the assay is not a critical aspect of the invention, as long as it does not significantly interfere with the specific binding of the antibody used in the assay. The detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of immunoassays and, in general, most any label useful in such methods can be applied to the present invention. Thus, a label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include magnetic beads (e.g., DYNABEADSTM), fluorescent dyes (e.g., fluorescein isothiocyanate, Texas red, rhodamine, and the like), radiolabels (e.g., ³H, ¹²⁵I, ³⁵S, ¹⁴C, or ³²P), enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic beads (e.g., polystyrene, polypropylene, latex, etc.).

25
30

The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. As indicated above, a wide variety of labels may be used, with the choice of label depending on sensitivity required, ease of conjugation with the compound, stability requirements, available instrumentation, and disposal provisions.

Non-radioactive labels are often attached by indirect means. Generally, a ligand molecule (e.g., biotin) is covalently bound to the molecule. The ligand then binds to another molecules (e.g., streptavidin) molecule, which is either inherently detectable or covalently bound to a signal system, such as a detectable enzyme, a fluorescent compound, or a chemiluminescent compound. The ligands and their targets can be used in any suitable combination with antibodies that recognize T1R3-comprising sweet taste receptors, or secondary antibodies that recognize anti-T1R3-comprising sweet taste receptor.

The molecules can also be conjugated directly to signal generating compounds, e.g., by conjugation with an enzyme or fluorophore. Enzymes of interest as labels will primarily be hydrolases, particularly phosphatases, esterases and glycosidases, or oxidotases, particularly peroxidases. Fluorescent compounds include fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc. Chemiluminescent compounds include luciferin, and 2,3-dihydrophthalazinediones, e.g., luminol. For a review of various labeling or signal producing systems that may be used, see U.S. Patent No. 4,391,904.

Means of detecting labels are well known to those of skill in the art. Thus, for example, where the label is a radioactive label, means for detection include a scintillation counter or photographic film as in autoradiography. Where the label is a fluorescent label, it may be detected by exciting the fluorochrome with the appropriate wavelength of light and detecting the resulting fluorescence. The fluorescence may be detected visually, by means of photographic film, by the use of electronic detectors such as charge coupled devices (CCDs) or photomultipliers and the like. Similarly, enzymatic labels may be detected by providing the appropriate substrates for the enzyme and detecting the resulting reaction product. Finally simple colorimetric labels may be detected simply by observing the color associated with the label. Thus, in various dipstick assays, conjugated gold often appears pink, while various conjugated beads appear the color of the bead.

Some assay formats do not require the use of labeled components. For instance, agglutination assays can be used to detect the presence of the target antibodies. In this case, antigen-coated particles are agglutinated by samples comprising the target antibodies. In this format, none of the components need be labeled and the presence of the target antibody is detected by simple visual inspection.

PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION

Pharmaceutically acceptable carriers are determined in part by the particular composition being administered (e.g., nucleic acid, oligonucleotide, protein, peptide, small organic molecule, lipid, carbohydrate, particle, or transduced cell), as well as by the particular method used to administer the composition. Accordingly, there are a wide variety of suitable formulations of pharmaceutical compositions of the present invention (*see, e.g., Remington's Pharmaceutical Sciences*, 17th ed., 1989). Administration can be in any convenient manner, e.g., by injection, oral administration, inhalation, transdermal application, or rectal administration.

Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the packaged nucleic acid suspended in diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers. Lozenge forms can comprise the active ingredient in a flavor, e.g., sucrose, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.

The compound of choice, alone or in combination with other suitable components, can be made into aerosol formulations (i.e., they can be "nebulized") to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

Formulations suitable for parenteral administration, such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or

intrathecally. Parenteral administration and intravenous administration are the preferred methods of administration. The formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials.

Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. Cells transduced by nucleic acids for *ex vivo* therapy can also be administered intravenously or parenterally as described above.

The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial therapeutic response in the patient over time. The dose will be determined by the efficacy of the particular vector employed and the condition of the patient, as well as the body weight or surface area of the patient to be treated. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular vector, or transduced cell type in a particular patient.

In determining the effective amount of the vector to be administered in the treatment or prophylaxis of conditions owing to diminished or aberrant expression of a T1R3-comprising sweet taste receptor, the physician evaluates circulating plasma levels of the vector, vector toxicities, progression of the disease, and the production of anti-vector antibodies. In general, the dose equivalent of a naked nucleic acid from a vector is from about 1 µg to 100 µg for a typical 70 kilogram patient, and doses of vectors which include a retroviral particle are calculated to yield an equivalent amount of therapeutic nucleic acid.

For administration, compounds and transduced cells of the present invention can be administered at a rate determined by the LD-50 of the inhibitor, vector, or transduced cell type, and the side-effects of the inhibitor, vector or cell type at various concentrations, as applied to the mass and overall health of the patient. Administration can be accomplished via single or divided doses.

CELLULAR TRANSFECTION AND GENE THERAPY

The present invention provides the nucleic acids of T1R3-comprising sweet taste receptors for the transfection of cells *in vitro* and *in vivo*. These nucleic acids can be inserted into any of a number of well-known vectors for the transfection of target cells and organisms as described below. The nucleic acids are transfected into cells, *ex vivo* or *in vivo*, through the interaction of the vector and the target cell. The nucleic acid, under the control of a promoter, then expresses a T1R3-comprising sweet taste receptor of the present invention, by co-expressing two members of the T1R family, thereby mitigating the effects of absent,

partial inactivation, or abnormal expression of a T1R3-comprising sweet taste receptor. The compositions are administered to a patient in an amount sufficient to elicit a therapeutic response in the patient. An amount adequate to accomplish this is defined as “therapeutically effective dose or amount.”

5 Such gene therapy procedures have been used to correct acquired and inherited genetic defects and other diseases in a number of contexts. The ability to express artificial genes in humans facilitates the prevention and/or cure of many important human diseases, including many diseases which are not amenable to treatment by other therapies (for a review of gene therapy procedures, *see* Anderson, *Science* 256:808-813 (1992); Nabel & Felgner, *TIBTECH* 11:211-217 (1993); Mitani & Caskey, *TIBTECH* 11:162-166 (1993); Mulligan, *Science* 926-932 (1993); Dillon, *TIBTECH* 11:167-175 (1993); Miller, *Nature* 357:455-460 (1992); Van Brunt, *Biotechnology* 6(10):1149-1154 (1998); Vigne, *Restorative Neurology and Neuroscience* 8:35-36 (1995); Kremer & Perricaudet, *British Medical Bulletin* 51(1):31-44 (1995); Haddada *et al.*, in *Current Topics in Microbiology and Immunology* 15 (Doerfler & Böhm eds., 1995); and Yu *et al.*, *Gene Therapy* 1:13-26 (1994)).

REFERENCES

- Adler, E., Hoon, M. A., Mueller, K. L., Chandrashekar, J., Ryba, N. J. P., and Zuker, C. S. (2000). A novel family of mammalian taste receptors. *Cell* 100, 693-702.
- 20 Bachmanov, A. A., Reed, D. R., Ninomiya, Y., Inoue, M., Tordoff, M. G., Price, R. A., and Beauchamp, G. K. (1997). Sucrose consumption in mice: major influence of two genetic loci affecting peripheral sensory responses. *Mamm. Genome* 8, 545-548.
- 25 Baker, E. K., Colley, N. J., and Zuker, C. S. (1994). The cyclophilin homolog NinaA functions as a chaperone, forming a stable complex *in vivo* with its protein target rhodopsin. *EMBO J.* 13, 4886-4895.
- 30 Boughter Jr., J. D., Pumplin, D. W., Yu, C., Christy, R. C., and Smith, D. V. (1997). Differential expression of alpha-gustducin in taste bud populations of the rat and hamster. *J. Neurosci.* 17, 2852-2858.

Brown, E. M., Gamba, G., Riccardi, D., Lombardi, M., Butters, R., Kifor, O., Sun, A., Hediger, M. A., Lytton, J., and Hebert, S. C. (1993). Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. *Nature* 366, 575-580.

5 Capeless, C. G., and Whitney, G. (1995). The genetic basis of preference for sweet substances among inbred strains of mice: preference ratio phenotypes and the alleles of the Sac and DNA loci. *Chem. Senses* 20, 291-298.

 Chandrashekar, J., Mueller, K. L., Hoon, M. A., Adler, E., Feng, L., Guo, W.,
10 Zuker, C. S., and Ryba, N. J. P. (2000). T2Rs function as bitter taste receptors. *Cell* 100, 703-11.

 Danilova, V., Hellekant, G., Tinti, J.-M., and Nofre, C. (1998). Gustatory Responses of the Hamster *Mesocricetus auratus* to Various Compounds Considered Sweet by
15 Humans. *J. Neurophysiol.* 80, 2102-2112.

 Dwyer, N. D., Troemel, E. R., Sengupta, P., and Bargmann, C. I. (1998). Odorant receptor localization to olfactory cilia is mediated by ODR-4, a novel membrane-associated protein. *Cell* 93, 455-466.

20 Fuller, J. L. (1974). Single-locus control of saccharin preference in mice. *J. Hered.* 65, 33-36.

 Herrada, G., and Dulac, C. (1997). A novel family of putative pheromone
25 receptors in mammals with a topographically organized and sexually dimorphic distribution. *Cell* 90, 763-773.

 Hoon, M. A., Adler, E., Lindemeier, J., Battey, J. F., Ryba, N. J. P., and
Zuker, C. S. (1999). Putative mammalian taste receptors: a class of taste-specific GPCRs with
30 distinct topographic selectivity. *Cell* 96, 541-551.

 Kaupmann, K., Huggel, K., Heid, J., Flor, P. J., Bischoff, S., Mickel, S. J., McMaster, G., Angst, C., Bittiger, H., Froestl, W., and Bettler, B. (1997). Expression cloning

of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. *Nature* 386, 239-246.

Kitagawa, M., Kusakabe, Y., Miura, H., Ninomiya, Y., and Hino, A. (2001).

- 5 Molecular genetic identification of a candidate receptor gene for sweet taste. *Biochem. Biophys. Res. Commun.* 283, 236-242.

Krautwurst, D., Yau, K. W., and Reed, R. R. (1998). Identification of ligands for olfactory receptors by functional expression of a receptor library. *Cell* 95, 917-926.

10

Lefkowitz, R. J., Inglese, J., Koch, W. J., Pitcher, J., Attramadal, H., and Caron, M. G. (1992). G-protein-coupled receptors: regulatory role of receptor kinases and arrestin proteins. *Cold Spring Harb. Symp. Quant. Biol.* 57, 127-133.

15

Li, X., Inoue, M., Reed, D. R., Huque, T., Puchalski, R. B., Tordoff, M. G., Ninomiya, Y., Beauchamp, G. K., and Bachmanov, A. A. (2001). High-resolution genetic mapping of the saccharin preference locus (Sac) and the putative sweet taste receptor (T1R1) gene (Gpr70) to mouse distal Chromosome 4. *Mamm. Genome* 12, 13-16.

20

Lindemann, B. (1996). Taste reception. *Physiol. Rev.* 76, 718-766.

Lush, I. E. (1989). The genetics of tasting in mice. VI. Saccharin, acesulfame, dulcin and sucrose. *Genet. Res.* 53, 95-99.

25

Matsunami, H., and Buck, L. B. (1997). A multigene family encoding a diverse array of putative pheromone receptors in mammals. *Cell* 90, 775-784.

Matsunami, H., Montmayeur, J. P., and Buck, L. B. (2000). A family of candidate taste receptors in human and mouse. *Nature* 404, 601-604.

30

Max, M., Shanker, Y. G., Huang, L., Rong, M., Liu, Z., Campagne, F., Weinstein, H., Damak, S., and Margolskee, R. F. (2001). Tas1r3, encoding a new candidate taste receptor, is allelic to the sweet responsiveness locus Sac. *Nat. Genet.* 28, 58-63.

McBurney, D. H., and Gent, J. F. (1979). On the nature of taste qualities. *Psychol. Bull.* 86, 151-167.

Mistretta, C. M., and Hill, D. L. (1995). Development of the taste system. Basic neurobiology. In *Handbook of olfaction and gustation*, R. L. Doty, ed. (New York: Marcel Dekker), pp. 635-668.

Mody, S. M., Ho, M. K., Joshi, S. A., and Wong, Y. H. (2000). Incorporation of Galpha(z)-specific sequence at the carboxyl terminus increases the promiscuity of galpha(16) toward G(i)-coupled receptors. *Mol. Pharmacol.* 57, 13-23.

Montmayeur, J. P., Liberles, S. D., Matsunami, H., and Buck, L. B. (2001). A candidate taste receptor gene near a sweet taste locus. *Nat. Neurosci.* 4, 492-498.

Nagarajan, S., Kellogg, M. S., DuBois, G. E., and Hellekant, G. (1996). Understanding the mechanism of sweet taste: synthesis of ultrapotent guanidinoacetic acid photoaffinity labeling reagents. *J. Med. Chem.* 39, 4167-4172.

Nakanishi, S. (1992). Molecular diversity of glutamate receptors and implications for brain function. *Science* 258, 597-603.

Ninomiya, Y., Inoue, M., Imoto, T., and Nakashima, K. (1997). Lack of gurmarin sensitivity of sweet taste receptors innervated by the glossopharyngeal nerve in C57BL mice. *Am. J. Physiol.* 272, R1002-R1006.

Ninomiya, Y., Mizukoshi, T., Higashi, T., Katsukawa, H., and Funakoshi, M. (1984). Gustatory neural responses in three different strains of mice. *Brain Res.* 302, 305-314.

Offermanns, S., and Simon, M. I. (1995). G alpha 15 and G alpha 16 couple a wide variety of receptors to phospholipase C. *J. Biol. Chem.* 270, 15175-80.

Ryba, N. J. P., and Tirindelli, R. (1997). A new multigene family of putative pheromone receptors. *Neuron* 19, 371-379.

Sainz, E., Korley, J. N., Battey, J. F., and Sullivan, S. L. (2001). Identification of a novel member of the T1R family of putative taste receptors. *J. Neurochem.* 77, 896-903.

5 Salahpour, A., Angers, S., and Bouvier, M. (2000). Functional significance of oligomerization of G-protein-coupled receptors. *Trends Endocrinol. Metab.* 11, 163-168.

Schiffman, S. S., Cahn, H., and Lindley, M. G. (1981). Multiple receptor sites mediate sweetness: evidence from cross adaptation. *Pharmacol. Biochem. Behav.* 15, 377-
10 388.

Scott, K., Brady, R., Jr., Cravchik, A., Morozov, P., Rzhetsky, A., Zuker, C., and Axel, R. (2001). A chemosensory gene family encoding candidate gustatory and olfactory receptors in *Drosophila*. *Cell* 104, 661-673.

15 Smith, D. V., and Frank, M. E. (1993). Sensory coding by peripheral taste fibers. In *Mechanisms of Taste Transduction*, S. A. Simon and S. D. Roper, eds. (Boca Raton: CRC Press), pp. 295-338.

20 Troemel, E. R., Chou, J. H., Dwyer, N. D., Colbert, H. A., and Bargmann, C. I. (1995). Divergent seven transmembrane receptors are candidate chemosensory receptors in *C. elegans*. *Cell* 83, 207-218.

25 Tsien, R. Y., Rink, T. J., and Poenie, M. (1985). Measurement of cytosolic free Ca²⁺ in individual small cells using fluorescence microscopy with dual excitation wavelengths. *Cell Calcium* 6, 145-157.

EXAMPLES

30 The following examples are offered to illustrate, but not to limit the claimed invention.

RESULTS

T1R3 is encoded by the *Sac* locus

In previous studies, we identified two novel G protein-coupled receptors of the T1R family, T1R1 and T1R2, that are selectively expressed in subsets of taste receptor cells of the tongue and palate epithelium (Hoon *et al.*, 1999; Genbank Accession numbers: AY032620-AY032623). We also previously identified functional bitter taste receptor genes, the T2R family (Adler *et al.*, 2000; Chandrashekar *et al.*, 2000). Both *T1R1* and *T1R2* were initially mapped to the distal end of chromosome 4, in the proximity of *Sac* (Hoon *et al.*, 1999). However, radiation hybrid analysis and high-resolution genetic mapping separated these receptors from the *Sac* genetic interval (Li *et al.*, 2001), thus eliminating them as candidate *Sac* genes (figure 1). Recently, six independent groups reported that a related receptor gene, *T1R3*, is tightly linked to the *Sac* locus (Kitagawa *et al.*, 2001; Max *et al.*, 2001; Montmayeur *et al.*, 2001; Sainz *et al.*, 2001 and press releases from Senomyx, La Jolla, CA and Li *et al.*, 2001 Achems XXIII, Sarasota FL), and that polymorphic variants of *T1R3* co-segregate with *Sac* taster and non-taster alleles. This genetic linkage was used to hypothesize that *T1R3* corresponds to the *Sac* gene. We also isolated and characterized T1R3, and reasoned that if *Sac* in fact encodes T1R3, then introduction of a taster allele of this candidate receptor should rescue the taste deficit of *Sac* non-taster mice.

A 15 kb genomic clone containing the *T1R3* sequence from a *Sac* taster strain (C57 BL/6) was used to engineer a transgenic rescue construct (figure 2a). In order to follow the presence and expression of the transgene versus the endogenous *T1R3* allele, we replaced its 3'-UTR and poly-adenylation signal with that of bovine growth hormone. Our strategy was to produce progeny that were homozygous for the *T1R3* non-taster allele, but carried the taster-derived transgene. We obtained 4 founder mice, and two independent lines were examined for appropriate expression of the transgene and assayed for behavioral rescue of sucrose and saccharin tasting (Fuller, 1974). Age- and sex-matched siblings that lacked the transgene were used as controls in all experiments. Figure 2b illustrates that all the cells expressing the endogenous T1R3 receptor, and only these cells, also express the transgene (identical results were obtained in taster and non-taster genetic backgrounds; data not shown).

If the *T1R3* taster allele rescues the taste deficiency of *Sac* non-tasters, their saccharin and sucrose dose-responses should be shifted to recapitulate the sensitivity seen in *Sac* taster animals (Fuller, 1974; Bachmanov *et al.*, 1997). Figure 2 demonstrates that the T1R3 transgene fully rescues the taste defect of *Sac* non-tasters. Animals without a transgene are indistinguishable from non-taster 129/Sv control mice (figure 2c and d, open black

circles). In contrast, siblings with the same *Sac* non-taster background but expressing the transgene are now equivalent to taster C57BL/6 control mice (Figure 2c and d, red traces). The presence of the transgene did not influence other taste modalities (Figure 2e-h), nor did it alter the sweet sensitivity of taster strains (data not shown). Equivalent results were obtained with the two independent transgenic lines. These results validate *T1R3* as the *Sac* locus, and suggest that T1R3 may function as a sweet taste receptor.

Expression of T1Rs

Recently, T1R3 was shown to be expressed in subsets of taste receptor cells in various taste papillae (Kitagawa *et al.*, 2001; Max *et al.*, 2001; Montmayeur *et al.*, 2001; Sainz *et al.*, 2001). However, there were significant discrepancies between the reported patterns of expression, with results ranging from little if any expression at the front of the tongue (fungiform papillae; Sainz *et al.*, 2001) to significant expression in all taste buds (Kitagawa *et al.*, 2001). We examined the expression of T1R3 in circumvallate, foliate, fungiform and palate taste buds and find that T1R3 is expressed in ~ 30% of cells from all types of taste buds (Figure 3; see also Montmayeur *et al.*, 2001). This topographic pattern of expression closely approximates the aggregate of T1R1 and T1R2 expression (figure 3, Hoon *et al.*, 1999), and suggests possible co-expression of T1R1 with T1R3 and T1R2 with T1R3. The co-expression of T1R2 and T1R3 in circumvallate (Max *et al.*, 2001; Montmayeur *et al.*, 2001) and foliate papillae (Montmayeur *et al.*, 2001) was recently examined by RT-PCR and by *in situ* hybridization, but a comprehensive study of all three T1Rs in the different classes of taste buds was lacking. Thus, we performed double labeling experiments using two-color fluorescent *in situ* hybridization. Our results demonstrated that T1R3 is co-expressed with T1R2 in all circumvallate, foliate and palate taste buds, with every T1R2-positive cell also expressing T1R3 (figure 4). Similarly, T1R1 is co-expressed with T1R3 in fungiform and palate taste receptor cells. However, there is also a fraction of cells with non-overlapping expression of T1R3 in fungiform and palate taste buds. Therefore, we can define three major classes of cell types based on their T1R expression profiles: T1R1 and T1R3 (T1R1+3), T1R2 and T1R3 (T1R2+3) and T1R3.

T1Rs encode functional sweet taste receptors

Demonstration that T1Rs encode sweet receptors requires functional validation. To monitor translocation of receptors to the plasma membrane we raised antibodies against T1R1, T1R2 and T1R3, and tested expression of native and epitope-tagged

mouse, human and rat receptors in various tissue culture cell lines. We observed that rat T1Rs were expressed efficiently; we therefore used the rat genes in all heterologous expression studies. To assay function, we expressed T1Rs with a G α 16-Gz chimera and G α 15, two G-protein α -subunits that together efficiently couple Gs, Gi, Gq and gustducin-linked receptors to phospholipase C β (Offermanns and Simon, 1995; Krautwurst *et al.*, 1998; Chandrashekar *et al.*, 2000; Mody *et al.*, 2000). In this system, receptor activation leads to increases in intracellular calcium [Ca²⁺]_i, which can be monitored at the single cell level using the FURA-2 calcium-indicator dye (Tsien *et al.*, 1985).

Because of the apparent co-expression of T1R1 or T1R2 with T1R3, we transfected various rat T1Rs singly and in combinations (for co-expression) into HEK-293 cells expressing the promiscuous G α 15 and G α 16-Gz proteins. After loading the cells with FURA-2, we assayed for responses to a wide range of sweet tastants, including sugars, amino acids, and artificial sweeteners; we also tested several bitter tastants (see Experimental Procedures). Cells expressing rat T1R2 and T1R3 (T1R2+3) robustly responded to a subset of sweet compounds including sucrose, fructose, saccharin (but not to N-methyl-saccharin, a non-sweet saccharin derivative), acesulfame-K, dulcin, and two novel intensely sweet compounds (Nagarajan *et al.*, 1996, guanidinoacetic acid 1 and 2, referred to as GA-1 and GA-2; figures 5 and 6a). The responses were receptor- and G α -dependent because cells lacking either of these components did not trigger [Ca²⁺]_i changes, even at vastly higher concentrations of tastants (figure 5). Notably, the activation of T1R2+3 is extremely selective. On the one hand, this receptor combination did not respond to a large number of mono- and disaccharides and artificial sweeteners, including glucose, galactose, maltose and aspartame (figure 6a). On the other hand, the response was dependent on the presence of both T1R2 and T1R3; either receptor alone did not respond to any of the compounds assayed in these studies, even at concentrations that far exceeded their biologically relevant range of action (data not shown). These results demonstrate that T1R2 and T1R3, when co-expressed in the same cell, function as a sweet taste receptor.

Evidence that association of the polypeptides, or heteromerization, is required for the formation of a functional T1R receptor was obtained by co-expression of a dominant negative T1R. Co-transfection of wild type T1R2 and T1R3 with a T1R2 receptor harboring a C-terminal truncation (Salahpour *et al.*, 2000) nearly abolished the T1R2+3 responses (>85% reduction, data not shown).

If the responses of T1R2+3 reflect the function of the native sweet receptor, we reasoned that the sensitivity thresholds seen in the cell-based assays should parallel the behavioral thresholds for detection of these sweet tastants *in vivo*. Indeed, figure 6b shows dose-responses for GA-2 (*in vivo* threshold ~2 μ M), saccharin (*in vivo* threshold ~ 0.5 mM),
5 acesulfame-K (*in vivo* threshold ~0.5 mM) and sucrose (*in vivo* threshold ~20 mM), demonstrating a good match between the cell-based responses and their biological threshold. No responses were detected against a panel of bitter tastants, or umami stimuli.

To examine the sweet taste responses in detail, cells transfected with T1R2+3 were placed on a microperfusion chamber and superfused with test solutions under various
10 conditions. Figure 6c shows that responses to the sweet tastants closely follow application of the stimulus (latency <1 s). As expected, when the tastant was removed, $[Ca^{2+}]_i$ returned to baseline. A prolonged exposure to the sweet compound (>10 s) resulted in adaptation: a fast increase of $[Ca^{2+}]_i$ followed by a rapid, but incomplete decline to the resting level. Similarly, successive applications of the tastant led to significantly reduced responses, indicative of
15 desensitization (Lefkowitz *et al.*, 1992), while a prolonged period of rest (>5 min) was required for full response recovery. As would be expected if T1R2+3 mediate the responses to the various sweet compounds (i.e., GA-2, sucrose and acesulfame-K), successive application of different tastants from this panel led to full cross-desensitization (figure 6c), while sweet tastants that did not activate this receptor complex (e.g. glucose and cyclamate)
20 had no effect on the kinetics, amplitude or time course of the responses. Taken together, these results validate T1R2+3 as a sweet taste receptor.

We propose that all T1Rs encode sweet receptors: First, they are all members of the same receptor family. Second, T1R1, T1R2 and T1R3 are tightly co-expressed in distinct subsets of cells. Third, data is presented herein demonstrating that two of the three
25 T1Rs combine to function as a validated sweet receptor.

Spatial map of T1R and T2R expression

Studying the expression of T1Rs in the context of other taste modalities may provide a view of the representation of sweet taste coding at the periphery. Recently, we
30 showed that members of the T2R family of bitter taste receptors are rarely expressed in fungiform taste buds, but are present in 15-20% of the cells of all circumvallate, foliate and palate taste buds. Given that T1Rs are also expressed in the same taste buds, we examined whether there is overlap between T1R- and T2R-expressing cells. Double-labeling

experiments using mixes of T1Rs and T2R probes demonstrated that T2Rs are not co-expressed with any of the T1R family members (figure 7, see also Adler *et al.*, 2000). This was seen in all taste buds, and with mixes that included as many as 20 T2Rs. The strong segregation in the expression profile of these two receptor families makes an important prediction about the logic of taste coding and discrimination at the taste bud level: sweet and bitter are encoded by the activation of different cell types.

A prediction of this study is that taste buds in all taste papillae contain sweet receptor cells and that the anatomical representation of sweet sensitivity in the oral cavity should match the topographic distribution of T1R receptor expression. For instance, the back of the tongue and palate contain all of the T1R2+3 expressing cells, and so they would display high sensitivity for ligands of this receptor combination. Conversely, the front of the tongue would respond to the T1R1+3 combination, but poorly to the repertoire specific for T1R2+3. Moreover, since the front and back of the tongue are innervated by nerves originating in different ganglia (Mistretta and Hill, 1995), we conclude that T1R2+3 sweet cells must exhibit connectivity pathways that differ from those of T1R1+3 cells. Interestingly, the rat is known to be more sensitive to sucrose applied to the back of the tongue and palate, than to stimulation of the front of the tongue (Smith and Frank, 1993). Our expression and functional studies now provide a molecular explanation to these findings.

EXPERIMENTAL PROCEDURES

Molecular Cloning of T1R3

Human T1R3 was identified in the draft sequence of BAC clone RP5-890O3 by homology to T1R1. A fragment of rat T1R3 was amplified from genomic DNA using degenerate PCR primers designed on the basis of the human sequence. The PCR derived probe was used to identify full-length rat T1R3 from a circumvallate cDNA library (Hoon *et al.*, 1999) and to probe mouse BAC filter arrays (Incyte Genomics and Research Genetics). The sequences of T1R3 in Sac-taster and non-taster mouse strains (C57BL/6 and 129/Sv) were determined from the genomic clones. The sequence of the entire coding region of the gene of other mouse strains that are sweet sensitive: SWR, ST, C57L, FVB/N and sweet insensitive: DBA/1Lac, DBA/2, C3H, AKR, BALB/c was determined from amplified genomic DNA (Jackson Laboratory). For SWR mice, T1R3 was also sequenced from amplified taste-tissue cDNA. Amongst the 11 inbred strains, we found two taster alleles (taster 1: C57BL/6, C57L and taster 2: SWR, ST, FVB/N) and a single non-taster allele (DBA/1Lac, DBA/2, C3H, AKR, BALB/c, 129/Sv). Taster 1 and taster 2 alleles differ from

each other in six amino acid positions (P61L, C261R, R371Q, S692L, I706T, G855E; one of this G855E, was missed by (Kitagawa *et al.*, 2001; Max *et al.*, 2001) likely due to its inclusion in the primers used in their amplifications reactions). Non-tasters differ from taster 1 allele in six residues (A55T, T60I, L61P, Q371R, T706I, E855G), and from taster 2 in 4 amino acid positions (A55T, T60I, R261C, L692S).

Mouse T1Rs were mapped using a mouse/hamster radiation hybrid panel (Research Genetics). Physical mapping of T1R3 involved PCR based typing of T1R3 positive BAC clones for the presence of STS-markers.

In situ hybridization

Tissue was obtained from adult mice. No sex-specific differences of expression patterns were observed. Therefore male and female animals were used interchangeably. For foliate sections, no differences in expression pattern were observed between the papillae. Fresh frozen sections (16 µm/section) were attached to silanized slides and prepared for *in situ* hybridization as described previously (Hoon *et al.*, 1999). All *in situ* hybridizations were carried out at high stringency (hybridization, 5 X SSC, 50% formamide, 65 - 72°C; washing, 0.2 X SSC, 72°C). For single-label detection, signals were developed using alkaline-phosphatase conjugated antibodies to digoxigenin and standard chromogenic substrates (Boehringer Mannheim). Control hybridizations with sense probes produced no specific signals in any of the taste papillae. Cells were counted based on the position of their nucleus as previously described (Boughter *et al.*, 1997). For double-label fluorescent detection, probes were labeled either with fluorescein or with digoxigenin. At least 50 taste buds from at least 3 different animals were analyzed with any combination of probes. An alkaline-phosphatase conjugated anti-fluorescein antibody (Amersham) and a horseradish-peroxidase conjugated anti-digoxigenin antibody were used in combination with fast-red and tyramide fluorogenic substrates (Boehringer Mannheim and New England Nuclear). Confocal images were obtained with a Leica TSC confocal microscope using an argon-krypton laser; 1-2 µm optical sections were recorded to ensure that any overlapping signal originated from single cells.

Generation of T1R3 transgenic mice and behavioral assays

An approximately 15 kb EcoRI fragment including the 6 coding exons of T1R3 and about 12 kb upstream of the starting ATG was isolated from a C57BL/6 BAC

clone. This fragment contains the stop codon of the *T1R3* coding sequence but lacks much of the 3'-UTR. The sequence of the entire 15 kb clone was determined from a taster and a non-taster strains. This fragment also contains the full sequence for a glycolipid transferase-like gene ~3 kb upstream of *T1R3*, but there are neither expression nor amino acid sequence differences in this gene between Sac taster (SWR) or non-taster (129/Sv) strains. In the transgenic construct, the bovine growth hormone polyadenylation (BGH) signal from pCDNA3.0 (Invitrogen) was ligated to the 3'-end of the *T1R3* gene. This modification allowed PCR based genotyping of mice and permitted direct comparison of the expression of *T1R3* from the transgene with that from the normal gene. Transgenic mice were generated by pronuclear injection of FVB/N oocytes. Since we determined that FVB/N mice are sensitive to sweet tastants, and carry a *T1R3* taster allele, transgenic founders were crossed to 129/SvJ. F1-mice carrying the transgene were then back-crossed to 129/SvJ. F2 mice were typed for the presence of the transgene using the BGH tag, and for homozygosity of the endogenous non-taster *T1R3* allele using a Bsp120I restriction polymorphism between FVB/N and 129/SvJ (see figure 2a). All four genetic groups were tested behaviorally. Mice were weaned at 3 weeks and trained for 7-10 days to drinking from two bottles of water prior to initiating testing.

For behavioral assays, 2 or 3 mice were housed per cage; mice derived from different transgenic founders (and males and females) were kept separate to allow comparison of the raw-data. The group sizes used for assays consisted of 4 or more cages, each with a minimum of 2 animals. Mice were always assayed at the low concentrations first (Fuller, 1974). In all cases, animals were given at least 2 days of water between concentration series. Each test consisted of a two-bottle choice assay over a 48 hr period; the positions of the bottles were switched after 24 hr. Preference ratios were calculated by dividing the consumption of the test solution by total intake. Data from each cage were individually analyzed to prevent systematic bias. The same assay was used to analyze the taste preferences of 129/Sv, C57BL/6 and FVB/N control mice.

Heterologous expression of T1Rs

All receptors were cloned into a pEAK10 mammalian expression vector (Edge Biosystems, MD). Modified HEK-293 cells (PEAK^{rapid} cells; Edge BioSystems, MD) were grown and maintained at 37°C in UltraCulture medium (Bio Whittaker) supplemented with 5% fetal bovine serum, 100 µg/ml gentamycin sulphate (Fisher), 1 µg/ml amphotericin B and

2 mM GlutaMax I (Lifetechnologies). For transfection, cells were seeded onto matrigel coated 6-well culture plates, 24-well culture plates, or 35 mm recording chambers. After 24 h at 37 °C, cells were washed in OptiMEM medium (Lifetechnologies) and transfected using LipofectAMINE reagent (Lifetechnologies). Transfection efficiencies were estimated by co-transfection of a GFP reporter plasmid, and were typically >70%. Activity assays were performed 36-48 h after transfection for cells transfected in 24-well culture plates and 35 mm recording chambers; cells transfected in 6-well culture plates were grown overnight, trypsinized, transferred to 96-well culture plates, and assayed 36-48 hours following re-seeding.

Calcium Imaging

Transfected cells were washed once in Hank's balanced salt solution containing 1 mM sodium pyruvate and 10 mM HEPES, pH 7.4 (assay buffer), and loaded with 2 μ M FURA-2 AM (Molecular Probes) for 1 h at room temperature. The loading solution was removed and cells in 24-well plates were incubated with 250 μ l of assay buffer (cells in 96-well plates were incubated with 50 μ l) for 1 h to allow the cleavage of the AM ester. Cells expressing T1Rs and G proteins (Offermanns and Simon, 1995; Chandrashekar *et al.*, 2000; Mody *et al.*, 2000) in 24-well tissue culture plates were stimulated with 250 μ l of a 2x tastant solution (cells in 96-well plates were stimulated with 50 μ l of a 2x tastant solution). As a control for G α 15 and G α 16-Gz signaling a set of plates was co-transfected with mGluR1 and the μ -opioid receptor and assayed for responses to ACPD and DAMGO.

One of two imaging stations were used to measure $[Ca^{2+}]_i$ changes. One system comprises of a Nikon Diaphot 200 microscope equipped with a 10x/0.5 fluor objective, the TILL imaging system (T.I.L.L Photonics GmbH), and a cooled CCD camera. Acquisition and analysis of these fluorescence images used TILL-Vision software. Also, an Olympus IX-70/FLA microscope equipped with a 10x/0.5 fluor objective, a variable filter wheel (Sutter Instruments), and an intensified CCD camera (Sutter Instruments) was utilized. VideoProbe software (Instrutech) was used for acquisition and analysis of these fluorescence images. Generally, individual responses were measured for 60s. The F_{340}/F_{380} ratio was analyzed to measure $[Ca^{2+}]_i$.

Kinetics of activation and deactivation were measured using a bath perfusion system. Cells were seeded onto a 150 μ l microperfusion chamber, and test solutions were pressure-ejected with a picospritzer apparatus (General Valve, Inc.). Flow-rate was adjusted

to ensure complete exchange of the bath solution within 4s. Responses were measured from 80 individual responding cells.

List of Tastants

5 The following tastants were tested, with the following typical maximal concentrations: sucrose (250 mM), sodium saccharin (25 mM), N-methyl saccharin (5 mM), dulcin (2 mM), aspartame (2 mM), palatinose (250 mM), sodium cyclamate (15 mM), guanidinoacetic acid-1 (1 mM), guanidinoacetic acid-2 (1 mM), guanidinoacetic acid-3 (1 mM), acesulfame-K (10 mM), glucose (250 mM), maltose (250 mM), lactose (250 mM),
10 fructose (250 mM), galactose (250 mM), xylitol (250 mM), raffinose (250 mM), sorbitol (250 mM), trehalose (250 mM), thaumatin (0.1%), monellin (0.1%), alanine (20 mM), glycine (20 mM), arginine (20 mM), monosodium glutamate (20 mM), cycloheximide (5 μ M), denatonium (10 mM), phenyl-thiocarbamide (2.5 mM).

15 It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all
20 purposes.

SEQUENCE LISTING

T1R1 SEQUENCES

5 Rat T1R1 amino acid sequence--SEQ ID NO:1

MLFWAAHLLLSLQLVYCWAFCQRTSSPGFSLPGDFLLAGLFSLHGDCLQVRHRPLVTSCD
RPDSFNHGYHLFQAMRFTVEEINNSSALLPNITLGYELYDVCSANVYATLRVLALQGPR
HIEIQKDLRNHSSKVVAFIGPDNTDHAVTTAALLGPFLMPLVSYEASSVLSAKRKFPSPFLR
10 TVPSDRHQVEVMVQLLQSFQWVWISLIGSYGDYQGLGVQALEELAVPRGICVAFKDIVPFS
VTGIQIGIGTVLGVAVQQRQVPGLKEFEESYVRAVTAAPSACPEGSWCSTNQLCRECHTFTTR
NMPTLGAFSMSAAYRVYEAHYAVAHGLHQLLGCTSEICSRGPVYPWQLLQIYKVNFLLEN
TVAFDDNGDTLGYDYDIIAWDWNPEWTFEIIIGSASLSPVHLDINKTKIQWHGKNNQVPVSV
15 TTDCLAGHHRVVGSHHCCFECVPCEAGTFLNMSELHICQPCGTEEWAPKESTTCFPRTVEF
LAWHEPISLVLIAANTLLLLLLVGTAGLFAWHFHTPVVRSAGGRLCFLMLGSLVAGSCSFYS
FFGEPTVPACLLRQPLFSLGFAIFLSCLTIRSFQLVIIIFKFSTKVPTFYRTWAQNHGAGLFV
IVSSTVHLLICTLWLMWTPRPTREYQRFPHLVILECTEVNSVGFLAFTHNILLSISTFVC
SYLGKELPENYNEAKCVTFSLLLNFVSWIAFFTMAIYQGSYLPVNVLAGLTTLSGGFSGY
FLPKCYVILCRPELNTEHFQASIQDYTRRCGTT

20

Mouse T1R1 amino acid sequence--SEQ ID NO:2

MLFWAAHLLLSLQLAVAYCWAFCQRTSSPGFSLPGDFLLAGLFSLHADCLQVRHRPLVTS
CDRSDSFNHYGYHLFQAMRFTVEEINSTALLPNITLGYELYDVCSSESNVYATLRVPAQQG
TGHLEMQRDLRNHSSKVVALIGPDNTDHAVTTAALLSPFLMPLVSYEASSVILSGKRKFPSF
25 LRTIPSDKYQVEVIVRLQLQSFQWVWISLVGSYGDYQGLGVQALEELATPRGICVAFKDVVPL
SAQAGDPRMQRMMLRLARARTTVVVVFSNRHLAVFFRSVVLANTLGKVIASEDWAI STYI
TNVPGIIGIGTVLGVAIQQRQVPGLKEFEESYVQAVMGAPRTCPEGSWCSTNQLCRECHTFT
TWNMPELGAFSMSAAYNVYEAHYAVAHGLHQLLGCTSGTCARGPVYPWQLLQIYKVNFLH
KKTVAFDKGDPLGYDYDIIAWDWNPEWTFEIVIGSASLSPVHLDINKTKIQWHGKNNQVPVS
30 VCTRDCLEGHRLVMGSHHCCFECMPCEAGTFLNTSELHTCQPCGTEEWAPEGSSACFSRTV
EFLGWHEPISLVLLAANTLLLLLLIGTAGLFAWRLHTPVVRSAGGRLCFLMLGSLVAGSCSL
YSFFGKPTVPACLLRQPLFSLGFAIFLSCLTIRSFQLVIIIFKFSTKVPTFYHTWAQNHGAGI
FVIVSSTVHLFLCLTWLAWMTPRPTREYQRFPHLVILECTEVNSVGFLVAFAHNILLSISTF
VCSYLGKELPENYNEAKCVTFSLLLHFVSWIAFFTMSIYQGSYLPVNVLAGLATLSGGFS
35 GYFLPKCYVILCRPELNTEHFQASIQDYTRRCGTT

Human T1R1 amino acid sequence--SEQ ID NO:3

RSCSFNEHGYHLFQAMRLGVVEINSTALLPNITLGYQLYDVCSDSANVYATLRVLSLPGQH
HIELQGDLLHYSPTVLAVIGPDSTNRAATTAALLSPFLVHISYAASSETLSVKRQYPSFLRT
40 IPNDKYQVETMVLLLQKFGWTWISLVGSSDDYQGLGVQALENQALVRGICIAFKDIMPFSQ
VGDERMQCLMRHLAQAGATVVVVFSRQLARVFFESVVLTNLTGKVVVASEAWALSRHITGV
PGIQRIGMVLGVAIQKRAVPGLKAFEEAYARADKEAPRPCHKGSWCSSNQLCRECQAFMAHT
MPKLKAFSMSSAYNAYRAVYAVAHGLHQLLGCASELCSRGRVYPWQLLEQIHKVHFLHKT
VAFNDNRDPLSSYNI IAWDWNPKWTFVTLGSSTWSPVQLNINETKIQWHGKNHQPVSVC
45 SDCLEGHQRVVTGFHCCFECVPCGAGTFLNKSELYRCQPCGTEEWAPEGSQTCFPRTVVFL
ALREHTSWVLLAANTLLLLLLLG TAGLFAWHLDTPVVRSAGGRLCFLMLGSLAAGSGSLYGF
FGEPTRPACLLRQALFALGFTIFLSCLTVRSFQLIIIFKFSTKVPTFYHAWVQNHGAGLFV
ISSAAQLLICLTWLVVWTPLPAREYQRFPHLVMLECTETNSLGFILAFLYNGLLSISAFACS
YLGKDLPENYNEAKCVTFSLLFNFVSWIAFFTASVYDGKYLPAANMMAGLSSSLSSGFGGYF
50 LPKCYVILCRPDLNSTEHFQASIQDYTRRCGST

Rat T1R1 nucleotide sequence--SEQ ID NO:4

ATTACATCAGAGCTGTGCTCAGCCATGCTGGGCAGAGGGACGACGGCTGGCCAGCATGCTC
TTCTGGGCTGCTCACCTGCTGCTCAGCCTGCAGTTGGTCTACTGCTGGGCTTTTCAGCTGCCA
5 AAGGACAGAGTCTCTCCAGGCTTCAGCCTTCCTGGGGACTTCCTCCTTGACAGGTCTGTTCT
CCCTCCATGGTGACTGTCTGCAGGTGAGACACAGACCTCTGGTGACAAGTTGTGACAGGCC
GACAGCTTCAACGGCCATGGCTACCACCTCTTCCAAGCCATGCGGTTCACTGTTGAGGAGAT
AAACAACCTCCTCGGCCCTGCTTCCCAACATCACCTGGGGTATGAGCTGTACGACGTGTGCT
CAGAATCTGCCAATGTGTATGCCACCCTGAGGGTGCTTGCCCTGCAAGGGCCCCGCCACATA
10 GAGATACAGAAAGACCTTCGCAACCCTCCTCCAAGGTGGTGGCCTTCATCGGGCCTGACAA
CACTGACCACGCTGTCACTACCGCTGCCTTGCTGGGTCTTTCCTGATGCCCTGGTCAGCT
ATGAGGCAAGCAGCGTGGTACTCAGTGCCAAGCGCAAGTTCCCGTCTTTCCTTCGTACCGTC
CCCAGTGACCGGCACCAGGTGGAGGTCACTGGTGCAGCTGCTGCAGAGTTTGGGTGGGTGTG
GATCTCGCTCATTTGGCAGCTACGGTGATTACGGGCAGCTGGGTGTGACGGCGCTGGAGGAGC
15 TGGCCGTGCCCCGGGGCATCTGCGTCGCCTTCAAGGACATCGTGCCTTTCTCTGCCCGGGTG
GGTGACCCGAGGATGCAGAGCATGATGCAGCATCTGGCTCAGGCCAGGACCACCGTGGTTGT
GGTCTTCTCTAACCGGCACCTGGCTAGAGTGTTCTTCAGGTCCGTGGTGCTGGCCAACCTGA
CTGGCAAAGTGTGGGTGCGCTCAGAAGACTGGGCCATCTCCACGTACATCACCAGCGTGACT
GGGATCCAAGGCATTGGGACGGTGCTCGGTGTGGCCGTCCAGCAGAGACAAGTCCCTGGGCT
20 GAAGGAGTTTGAGGAGTCTTATGTCAGGGCTGTAACAGCTGCTCCCAGCGCTTGCCCCGAGG
GGTCTGTGTCAGCACTAACCAGCTGTGCCGGGAGTGCCACACGTTACGACTCGTAACATG
CCCACGCTTGAGGCCTTCTCCATGAGTGCCGCCTACAGAGTGTATGAGGCTGTGTACGCTGT
GGCCACGGCCTCCACCAGCTCCTGGGATGTACTTCTGAGATCTGTTCCAGAGGCCAGTCT
ACCCCTGGCAGCTTCTTCAGCAGATCTACAAGGTGAATTTTCTTCTACATGAGAATACTGTG
25 GCATTTGATGACAACGGGGACACTCTAGGTACTACGACATCATCGCCTGGGACTGGAATGG
ACCTGAATGGACCTTTGAGATCATTGGCTCTGCCTCACTGTCTCCAGTTTCATCTGGACATAA
ATAAGACAAAAATCCAGTGGCACGGGAAGAACAATCAGGTGCCTGTGTGTCAGTGTGTACCACG
GACTGTCTGGCAGGGCACCACAGGGTGGTTGTGGGTTCACCACACTGCTGCTTTGAGTGTGT
GCCCTGCGAAGCTGGGACCTTTCTCAACATGAGTGAGCTTCACATCTGCCAGCCTTGTGGAA
30 CAGAAGAATGGGCACCCAAGGAGAGCACTACTTGCTTCCCACGCACGGTGGAGTTCTTGGCT
TGGCATGAACCATCTCTTTGGTGCTAATAGCAGCTAACACGCTATTGCTGCTGCTGCTGGT
TGGGACTGCTGGCCTGTTTGCCTGGCATTTTCACACACCTGTAGTGAGGTCAGCTGGGGTA
GGCTGTGCTTCTCATGCTGGGTTCCTGGTGGCCGGAAGTTGCAGCTTCTATAGCTTCTTC
GGGGAGCCCACGGTGCCCGCTGCTTGCTGCGTCAGCCCCCTCTTTTCTCTCGGGTTTGCCAT
35 CTTCTCTCCTGCCTGACAATCCGCTCCTTCCAAGTGGTCATCATCTTCAAGTTTCTACCA
AGGTGCCACATTCTACCGTACCTGGGCCCAAACCATGGTGCAGGTCTATTCTGTATTGTC
AGCTCCACGGTCCATTGCTCATCTGTCTCACATGGCTTGTAATGTGGACCCACGACCCAC
CAGGGAATACCAGCGCTTCCCCCATCTGGTGATTCTCGAGTGACAGAGGTCAACTCTGTAG
GCTTCTGTGCTTTACCCACAACATTCTCCTCTCCATCAGTACCTTCGTCTGCAGCTAC
40 CTGGGTAAGGAACTGCCAGAGAACTATAATGAAGCCAAATGTGTACCTTCAGCCTGCTCCT
CAACTTCGTATCCTGGATCGCCTTCTTACCATGGCCAGCATTACAGGGCAGCTACCTGC
CTGCGGTCAATGTGCTGGCAGGGCTGACCACACTGAGCGGCGGCTTCAGCGGTTACTTCCTC
CCCAAGTGCTATGTGATTCTCTGCCGTCCAGAACTCAACAATACAGAACACTTTCAGGCCTC
CATCCAGGACTACACGAGGCGCTGCGGCACTACCTGATCCACTGGAAAGGTGCAGACGGGAA
45 GGAAGCCTCTCTTCTTGTGCTGAAGGTGGCGGGTCCAGTGGGGCCGAGAGCTTGAGGTGTCT
GGGAGAGCTCCGGCACAGCTTACGATGTATAAGCACGCGGAAGAATCCAGTGCAATAAAGAC
GGGAAGTGTGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

Mouse T1R1 nucleotide sequence--SEQ ID NO:5

50 TTTGGCCAGCATGCTTTTCTGGGCAGCTCACCTGCTGCTCAGCCTGCAGCTGGCCGTTGCTT
ACTGCTGGGCTTTCAGCTGCCAAAGGACAGAATCCTCTCAGGTTTCAGCCTCCCTGGGGAC

TTCCTCCTGGCAGGCCTGTTCTCCCTCCATGCTGACTGTCTGCAGGTGAGACACAGACCTCT
 GGTGACAAGTTGTGACAGGTCTGACAGCTTCAACGGCCATGGCTATCACCTCTTCCAAGCCA
 TGCGGTTACCGTTGAGGAGATAAACTCCACAGCTCTGCTTCCCAACATCACCTTGGGG
 TATGAACTGTATGACGTGTGCTCAGAGTCTTCCAATGTCTATGCCACCCTGAGGGTGGCCGC
 5 CCAGCAAGGGACAGGCCACCTAGAGATGCAGAGAGATCTTCGCAACCACTCCTCCAAGGTGG
 TGGCACTCATTGGGCCTGATAACACTGACCACGCTGTCAACCACTGCTGCCCTGCTGAGCCCT
 TTTCTGATGCCCTGGTCAGCTATGAGGCGAGCAGCGTGATCCTCAGTGGGAAGCGCAAGTT
 CCCGTCTTCTTGCGCACCATCCCCAGCGATAAGTACCAGGTGGAAGTCATAGTGCGGCTGC
 TGCAGAGCTTCGGCTGGGTCTGGATCTCGCTCGTTGGCAGCTATGGTGACTACGGGCAGCTG
 10 GCGTACAGGCGCTGGAGGAGCTGGCCACTCCACGGGGCATCTGCGTCGCCCTTCAAGGACGT
 GGTGCCTCTCTCCGCCCAGGCGGGTGACCCAAGGATGCAGCGCATGATGCTGCGTCTGGCTC
 GAGCCAGGACCACCGTGGTCTGTGGTCTTCTCTAACCGGCACCTGGCTGGAGTGTTCTTCAGG
 TCTGTGGTCTGGCCAACCTGACTGGCAAAGTGTGGATCGCCTCCGAAGACTGGGCCATCTC
 CACGTACATACCAATGTGCCCGGGATCCAGGGCATTGGGACGGTCTGGGGGTGGCCATCC
 15 AGCAGAGACAAGTCCCTGGCCTGAAGGAGTTTGAAGAGTCCTATGTCCAGGCAGTGATGGGT
 GCTCCCAGAACTTGCCAGAGGGGTCTGGTGGCGCACTAACCAGCTGTGCAGGGAGTGTC
 CGCTTTCACGACATGGAACATGCCCGAGCTTGGAGCCTTCTCCATGAGCGCTGCCTACAATG
 TGTATGAGGCTGTGTATGCTGTGGCCACGGCCTCCACCAGCTCCTGGGATGTACCTCTGGG
 ACCTGTGCCAGAGGCCAGTCTACCCCTGGCAGCTTCTTCAGCAGATCTACAAGGTGAATTT
 20 CTTTCTACATAAGAAGACTGTAGCATTTCGATGACAAGGGGGACCCTCTAGGTTATTATGACA
 TCATCGCCTGGGACTGGAATGGACCTGAATGGACCTTTGAGGTCAATTGGTCTGCCTCACTG
 TCTCCAGTTCATCTAGACATAAATAAGACAAAAATCCAGTGGCACGGGAAGAACATCAGGT
 GCCTGTGTCAGTGTGTACCAGGGACTGTCTCGAAGGGCACCACAGGTTGGTCAATGGGTCCC
 ACCACTGCTGCTTCGAGTGCATGCCCTGTGAAGCTGGGACATTTCTCAACACGAGTGAGCTT
 25 CACACCTGCCAGCCTTGTGGAACAGAAGAATGGGGCCCTGAGGGGAGCTCAGCCTGCTTCTC
 ACGCACCGTGGAGTTCTTGGGGTGGCATGAACCCATCTCTTTGGTGCTATTAGCAGCTAACA
 CGCTATTGCTGCTGCTGCTGATTGGGACTGCTGGCCTGTTTGCCTGGCGTCTTCACACGCCT
 GTTGTGAGGTCAGCTGGGGGTAGGCTGTGCTTCTCATGCTGGGTTCTTGGTAGCTGGGAG
 TTGCAGCCTCTACAGCTTCTTCGGGAAGCCACGGTGCCCGCGTGCTTGCTGCGTCAGCCCC
 30 TCTTTTCTCTCGGGTTTGCCATTTTCTCTCTCTGTCTGACAATCCGCTCCTTCCAAGTGGT
 ATCATCTTCAAGTTTTCTACCAAGGTACCCACATTCTACCACACTTGGGCCCCAAACCATGG
 TGCCGGAATATTGCTCATTGTGAGCTCCACGGTCCATTTGTTCTCTGTCTCACGTGGCTTG
 CAATGTGGACCCACGGCCACACAGGGAGTACCAGCGCTTCCCCCATCTGGTGATTCTTGAG
 TGCACAGAGGTCAACTCTGTGGGCTTCTGGTGGCTTTCGCACACAACATCCTCCTCTCCAT
 35 CAGCACCTTTGTCTGCAGCTACCTGGGTAAGGAACTGCCGGAAGTATAACGAAGCCAAAT
 GTGTACCTTCAGCCTGCTCCTCCACTTCGTATCCTGGATCGCTTTCTTACCATGTCCAGC
 ATTTACCAGGGCAGCTACCTACCCGCGGTCAATGTGCTGGCAGGGCTGGCCACTCTGAGTGG
 CGGCTTCAGCGGCTATTTCTCCTAAATGCTACGTGATTCTCTGCCGTCCAGAACTCAACA
 ACACAGAACACTTTCAGGCCTCCATCCAGGACTACACGAGGCGCTGCGGCACTACCTGAGGC
 40 GCTGCGGCACTACCTGAGGCGCTGCGGCACTACCTGA

Human T1R1 nucleotide sequence--SEQ ID NO:6

AGGTCTTGTAGCTTCAATGAGCATGGCTACCACCTCTTCCAGGCTATGCGGCTTGGGGTTGA
 GGAGATAAACTCCACGGCCCTGCTGCCCAACATCACCTTGGGGTACCAGCTGTATGATG
 45 TGTGTTCTGACTCTGCCAATGTGTATGCCACGCTGAGAGTGCTCTCCCTGCCAGGGCAACAC
 CACATAGAGCTCCAAGGAGACCTTCTCCACTATTCCCCTACGGTGCTGGCAGTGATTGGGCC
 TGACAGCACCAACCGTGCTGCCACCACAGCCGCCCTGCTGAGCCCTTCTGGTGCATATTA
 GCTATGCGGCCAGCAGCGAGACGCTCAGCGTGAAGCGGCAGTATCCCTCTTCTGCGCACC
 ATCCCCAATGACAAGTACCAGGTGGAGACCATGGTGCTGCTGCTGCAGAAGTTCGGGTGGAC
 50 CTGGATCTCTCTGGTTGGCAGCAGTGACGACTATGGGCAGCTAGGGGTGCAGGCACTGGAGA
 ACCAGGCCCTGGTCAGGGGCATCTGCATTGCTTTCAAGGACATCATGCCCTTCTTGCCCAG

GTGGGCGATGAGAGGATGCAGTGCCTCATGCGCCACCTGGCCCAGGCCGGGGCCACCGTCGT
 GGTTGTTTTTCCAGCCGGCAGTTGGCCAGGGTGTTCGAGTCCGTGGTGCTGACCAACC
 TGACTGGCAAGGTGTGGGTGCGCTCAGAAGCCTGGGCCCTCTCCAGGCACATCACTGGGGTG
 5 CCCGGGATCCAGCGCATTGGGATGGTGCTGGGCGTGGCCATCCAGAAGAGGGCTGTCCCTGG
 CCTGAAGGCGTTTGAAGAAGCCTATGCCCGGGCAGACAAGGAGGCCCTAGGCCTTGACAA
 GGGCTCCTGGTGACGAGCAATCAGCTCTGCAGAGAATGCCAAGCTTTCATGGCACACACGA
 TGCCCAAGCTCAAAGCCTTCTCCATGAGTTCTGCCTACAACGCATACCGGGCTGTGTATGCG
 GTGGCCCATGGCCTCCACCAGCTCCTGGGCTGTGCCTCTGAGCTCTGTTCCAGGGGCCGAGT
 CTACCCCTGGCAGCTTTTGGAGCAGATCCACAAGGTGCATTTCTTCTACACAAGGACACTG
 10 TGGCGTTTAATGACAACAGAGATCCCCTCAGTAGCTATAACATAATTGCCTGGGACTGGAAT
 GGACCCAAGTGGACCTTCACGGTCCTCGGTTCTCCACATGGTCTCCAGTTCAGCTAAACAT
 AAATGAGACCAAAAATCCAGTGGCAGCGAAAGAACCACAGGTGCCTAAGTCTGTGTGTTCCA
 GCGACTGTCTTGAAGGGCACCAGCGAGTGGTTACGGGTTTCCATCACTGCTGCTTTGAGTGT
 GTGCCCTGTGGGGCTGGGACCTTCTCAACAAGAGCGAGCTCTACAGATGCCAGCCTTGTTGG
 15 AACAGAAGAGTGGGCACCTGAGGGAAGCCAGACCTGCTTCCCGCGCACTGTGGTGTGTTTGG
 CTTTGGCTGAGCACACCTCTTGGGTGCTGCTGGCAGCTAACACGCTGCTGCTGCTGCTGCTG
 CTTGGGACTGCTGGCCTGTTTGCCTGGCACCTAGACACCCCTGTGGTGAGGTCAGCAGGGGG
 CCGCTGTGCTTCTTATGCTGGGCTCCCTGGCAGCAGGTAGTGGCAGCCTCTATGGCTTCT
 TTGGGGAACCCACAAGGCTGCGTGCTTGCTACGCCAGGCCCTCTTGGCCTTGGTTTCACC
 20 ATCTTCTGTCTGCTGACAGTTCGCTCATTCCAATAATCATCATCTTCAAGTTTTCCAC
 CAAGGTACCTACATTCTACCACGCTGGGTCCAAAACACGGTGTGGCCTGTTTGTGATGA
 TCAGCTCAGCGGCCAGCTGCTTATCTGTCTAACTTGGCTGGTGGTGTGGACCCCACTGCCT
 GCTAGGGAATACCAGCGCTTCCCCCATCTGGTGATGCTTGAGTGCACAGAGACCAACTCCCT
 GGGCTTCATACTGGCCTTCTCTACAATGGCCTCCTCTCCATCAGTGCCTTTGCCTGCAGCT
 25 ACCTGGGTAAAGACTTGCCAGAGAACTACAACGAGGCCAAATGTGTACCTTCAGCCTGCTC
 TTCAACTTCGTGTCCTGGATCGCCTTCTTACCACGGCCAGCGTCTACGACGGCAAGTACCT
 GCCTGCGGCCAACATGATGGCTGGGCTGAGCAGCCTGAGCAGCGGCTTCGGTGGGTATTTTC
 TGCCTAAGTGCTACGTGATCCTCTGCCGCCAGACCTCAACAGCACAGAGCACTTCCAGGCC
 TCCATTACAGGACTACACGAGGCGCTGCGGCTCCACCTGA

30

T1R2 SEQUENCES

Rat T1R2 amino acid sequence--SEQ ID NO:7

MGPQARTLCLLSLLLHVLPKPGKLVENSDFHLAGDYLLGGLFTLHANVKSISHLSYLQVPKC
 35 NEFTMKVLGYNLMQAMRFAVEEINNCSLLPGVLLGYEMVDVCYLSNNIHPGLYFLAQDDDL
 LPILKDYSQYMPHVAVIGPDNSESATVSNILSHFLIPQITYSAISDKLRDKRHFPMSMLRT
 VPSATHHIEAMVQLMVHFQWNWIVVLVSDDDYGRENSHLLSQRLTKTSDICIAFQEVLPPIPE
 SSQVMRSEEQRQLDNILDKLRRTSARVVVVSPELSLYSFFHEVLRWNFTGFVWIASESWAI
 DPVLHNLTELRLHTGTFLGVTIQRVSI PGFSQFRVRRDKPGYPVPNTTNLRTTCNQDCDACLN
 40 TTKSFNNILILSGERVVYSVYSAVYAVAHALHRLGCGNRVRCCTKQKVYPWQLLREIWHVNFT
 LLGNRLFFDQQGDMPMLLDIIQWQWDLSONPFQSIASYSPTSRLTYINNVSWYTPNNTVPV
 SMCSSKSCQPGQMKSVGLHPCCFECLDCMPGTYLNRSADEFNCLSCPGSMWSYKNDITCFQR
 RPTFLEWHEVPTIVVAILAALGFFSTLAILFIFWRHFQTPMVRSAAGGPMCFMLVPLLLAFG
 MYPVYVGPPTVFSCFCRQAFFTVCFSICLSCITVRSFQIVCVFKMARRLPSAYSFWMYHGP
 45 YVFVAFITAIKVALVVGNMALATTINPIGRTPDDPNIMILSCHPNYRNGLLFNSTMDLLLSV
 LGFSFAYMGKELPTNYNEAKFITLSMTFSFTSSI SLCTFMSVHDGVLVLTIMDLLVTVLNFLA
 IGLGYFGPKCYMILFYPERNTSAYFNSMIQGYTMRKS

Mouse T1R2 amino acid sequence--SEQ ID NO:8

MGPQARTLHLLFLLHALPKPVMLVGNPDFLAGDYLLGGLFTLHANVKSVSLSYLVQVPKC
NEYNMKVLGYNLMQAMRFAVEEINNCSLLPGVLLGYEMVDVCYLSNNIQPGLYFLSQIDDF
LPILKDYSQYRPQVAVIGPDNSESATVSNILSYFLVPQVTYSAITDKLQDKRRFPAMLRT
5 VPSATHHIEAMVQLMVHFQWNWIVVLVSDDDYGRENSHLLSQRLTNTGDI CIAFQEVLPVPE
PNQAVRPEEQDQLDNILDKLRRTSARVVVIFSPELSLHNFFREVLRWNFTGFVWIASESWAI
DPVLHNLTEL RHTGTFLGVTIQRVSI PGFSQFRVRHDKPGYRMPNETSLRTTCNQDCDACMN
ITESFNNVLM LSGERVVYSVYSAVYAVAHTLHRL LHCNQVRCTKQIVYPWQLLREIWHVNFT
10 LLGNQLFFDEQGDMPMLLDI IQWQWGLSQNP FQSIASYSPTETRLTYISNVSWYTPNNTVPI
SMCSKSCQPGQM KKP IGLHPCCFECVDCPPDTYLNRSVDEFNCLSCPGSMWSYKNNIACFKR
RLAFLEWHEVPTIVVTILAALGFISTLAILLIFWRHFQTPMVR SAGGPMCFLMLVPLLLAFG
MVPVYVGPPTVFSCFCRQAFFTVCF SVCLSCITVRSFQIVCVFKMARRLP SAYGFWMYHGP
YVFVAFITAVKVALVAGNMLATTINPIGRTPDDPNII ILSCHPNYRNGLLFNTSMDLLLSV
15 LGFSFAYVGKELPTNYNEAKFITLSMTFSFTSSISLCTFMSVHDGVLVTIMDLLVTVLNFLA
IGLGYFGPKCYMILFYPERNTSAYFNSMIQGYTMRKS

Human T1R2 amino acid sequence--SEQ ID NO:9

MGPRAKTICSLFFLLWVLAEP AENSDFYLP GDYLLGGLFSLHANMKGI VHLNFLQVPMCKEY
EVKVIGYNLMQAMRFAVEEINNDSLLPGVLLGYEIVDVCYISNNVQPVLYFLAHEDNLLPI
20 QEDYSNYISR VAVIGPDNSESVM TVANFLSLFLLPQITYSAISDEL RDKVRFPALLRTPS
ADHHVEAMVQLMLHFRWNWIVLVSSDTYGRDNGQLLGERVARRDICIAFQETLPTLQPNQN
MTSEERQRLVTIVDKLQQSTARVVVVFSPDLTLYHFFNEVLRQNFTGAVWIASESWAIDPVL
HNLTELGLHGTFLGITI QSVPIPGFSEFREWGPQAGPPPLSRTS QSYTCNQECDNCLNATLS
25 FNTILRLSGERVVYSVYSAVYAVAHALHSL LGCDKSTCTKR VVYPWQLLEEIWKVNFTLLDH
QIFFDPQGDVALHLEIVQWQWDRSQNP FQSVASYPLQRQLKNIQDISWHTVNNTIPMSMCS
KRCQSGQKKKPVGIHVCCFECIDCLPGTFLNHTEDEYECQACPNNEWSYQSETSCFKRQLVF
LEWHEAPTIAVALLAALGFLSTLA ILVIFWRHFQTPIVRSAGGPMCFLMLTLLLVAYMVVPV
YVGPPKVSTCLCRQALFPLCFTICISCI AVR SFQIVCAFKMASRFP RAYSYWVRYQGPYVSM
AFITVLKMVIVVIGMLARPQSHPRTPDDPKITIVSCNPNYRNSL LFN TSLDLLLSVVGFSF
30 AYMKGELPTNYNEAKFITLSMTFYFTSSVSLCTFMSAYS GVLVTIVDLLVTVLNLLAISLG
YFGPKCYMILFYPERNTPAYFNSMIQGYTMRD

Rat T1R2 nucleotide sequence--SEQ ID NO:10

CACCTTGCTGT CATGGGTCCCCAGGCAAGGACACTCTGCTTGCTGTCTCTCCTGCTGCATGT
35 TCTGCCTAAGCCAGGCAAGCTGGTAGAGAACTCTGACTTCCACCTGGCCGGGGACTACCTCC
TGGGTGGCCTCTTTACCCCTCCATGCCAACGTGAAGAGCATCTCCACCTCAGCTACCTGCAG
GTGCCCAAGTGCAATGAGTTCACCATGAAGGTGTTGGGCTACAACCTCATGCAGGCCATGCG
TTTCGCTGTGGAGGAGATCAACA ACTGTAGCTCCCTGCTACCCGGCGTGCTGCTCGGCTACG
AGATGGTGGATGTCTGTTACCTCTCCAACAATATCCACCCTGGGCTCTACTTCTGTCACAG
40 GACGACGACCTCCTGCCCATCCTCAAAGACTACAGCCAGTACATGCCCCACGTGGTGGCTGT
CATTGGCCCCGACA ACTCTGAGTCCGCCATTACCGTGTCCAACATTCTCTCTCATTTCCTCA
TCCCACAGATCACATACAGCGCCATCTCCGACAAGCTGCGGGACAAGCGGCACTTCCCTAGC
ATGCTACGCACAGTGCCCGAGCGCCACCCACCACATCGAGGCCATGGTGCAGCTGATGGTTCA
CTTCCAATGGA ACTGGATTGTGGTGTGGTGAGCGACGACGATTACGGCCGCGAGAACAGCC
45 ACCTGTTGAGCCAGCGTCTGACCAAAACGAGCGACATCTGCATTGCCTTCCAGGAGGTTCTG
CCCATACCTGAGTCCAGCCAGGTCATGAGGTCCGAGGAGCAGAGACA ACTGGACAACATCCT
GGACAAGCTGCGGCGGACCTCGGCGCGCGTCGTGGTGGTGTCTCGCCCGAGCTGAGCCTGT
ATAGCTTCTTTACGAGGTGCTCCGCTGGA ACTTCACGGGTTTTGTGTGGATCGCCTCTGAG
TCCTGGGCTATCGACCCAGTTCTGCATAACCTCACGGAGCTGCGCCACACGGGTACTTTTCT
50 GGGCGTCACCATCCAGAGGGTGTCCATCCCTGGCTTCAGTCAGTTCCGAGTGCGCCGTGACA
AGCCAGGGTATCCCGTGCTAACACGACCAACCTGCGGACGACCTGCAACCAGGACTGTGAC

GCCTGCTTGAACACCACCAAGTCCTTCAACAACATCCTTATACTTTTCGGGGGAGCGCGTGGT
 CTACAGCGTGTACTCGGCAGTTTACGCGGTGGCCCATGCCCTCCACAGACTCCTCGGCTGTA
 ACCGGGTCCGCTGCACCAAGCAAAAGGTCTACCCGTGGCAGCTACTCAGGGAGATCTGGCAC
 GTCAACTTCACGCTCCTGGGTAACCGGCTCTTCTTTGACCAACAAGGGGACATGCCGATGCT
 5 CTTGGACATCATCCAGTGGCAGTGGGACCTGAGCCAGAATCCCTTCCAAAGCATCGCCTCCT
 ATTCTCCCACCAGCAAGAGGCTAACCTACATTAACAATGTGTCTGGTACACCCCCAACAAC
 ACGGTCCCTGTCTCCATGTGTTCCAAGAGCTGCCAGCCAGGGCAAATGAAAAAGTCTGTGGG
 CCTCCACCCTTGTTGCTTCGAGTGCTTGGATTGTATGCCAGGCACCTACCTCAACCGCTCAG
 CAGATGAGTTTAACTGTCTGTCTGCTGCCCGGGTTCCATGTGGTCTTACAAGAACGACATCACT
 10 TGCTTCCAGCGGCGGCCTACCTTCCTGGAGTGGCACGAAGTGCCCAACCATCGTGGTGGCCAT
 ACTGGCTGCCCTGGGCTTCTTCAGTACACTGGCCATTCTTTTCATCTTCTGGAGACATTTCC
 AGACACCCATGGTGCCTCGGCCGGTGGCCCCATGTGCTTCCTGATGCTCGTGCCCTGCTG
 CTGGCGTTTGGGATGGTGGCCGTGTATGTGGGGCCCCCACGGTCTTCTCATGCTTCTGCCG
 ACAGGCTTTCTTCACCGTCTGCTTCTCCATCTGCCTATCCTGCATCACCGTGCGCTCCTTCC
 15 AGATCGTGTGTGTCTTCAAGATGGCCAGACGCCTGCCAAGTGCCCTACAGTTTTTGGATGCGT
 TACCACGGGCCCCATATGTCTTCGTGGCCTTCATCACGGCCATCAAGGTGGCCCTGGTGGTGGG
 CAACATGCTGGCCACCACCATCAACCCATTGGCCGGACCGACCCGGATGACCCCAACATCA
 TGATCCTCTCGTGCCACCCTAACTACCGCAACGGGCTACTGTTCAACACCAGCATGGACTTG
 CTGCTGTCTGTGCTGGGTTTCAGCTTCGCTTACATGGGCAAGGAGCTGCCACCAACTACAA
 20 CGAAGCCAAGTTCATCACTCTCAGCATGACCTTCTCCTTCACCTCCTCCATCTCCCTCTGCA
 CCTTCATGTCTGTGCACGACGGCGTGCTGGTACCATCATGGACCTCCTGGTCACTGTGCTC
 AACTTCCTGGCCATCGGCTTGGGATACTTTGGCCCCAAGTGTTACATGATCCTTTTCTACCC
 GGAGCGCAACACCTCAGCCTATTTCAATAGCATGATCCAGGGCTACACCATGAGGAAGAGCT
 AGCTCCGCCCCACGGCCTCAGCAGCAGAGCCCCCGGCCACGTTAATGGTGTTCCTCTGCCAT
 25 TCTCTGCAGCGTAGCTATTTTTTACCCACATAGCGCTTAAATACCCATGATGCACTCTCCCC
 CGACCCCCAAGCCATTTCACTGGCCAGGACCTACCACCCACTTATAGATGAAACCACCAAGG
 CGCCCTATGGGGCTCCAAGGATGGCCTACCACTGCCATCTGGTGGTCAAGTGAAGCACATGC
 GGGCCGTGGCCCATGGCTCCCAGCCAGCTGGTGGCTAGTGGCTGTGAGGCCAGATGTCTGTG
 TATCTGAGTTTCTGGGAAGCAGAGACTGGGGCTCCTGTGTTCTAATGGTCAAGTGGGCATCA
 30 TGGGCCCTTCATTATTGCTTACGAATAAACTTCCCTCCGGTGAAAAAAAAAAAAAAAAAAAA
 AAAAAAAAAAAAAAAAAA

Mouse T1R2 nucleotide sequence--SEQ ID NO:11

ATGGGACCCAGGCGAGGACACTCCATTTGCTGTTTCTCCTGCTGCATGCTCTGCCTAAGCC
 35 AGTCATGCTGGTAGGGAACCTCCGACTTTCACCTGGCTGGGGACTACCTCCTGGGTGGCCTCT
 TTACCCCTCCATGCCAACGTGAAGAGTGTCTCTCACCTCAGCTACCTGCAGGTGCCCAAGTGC
 AATGAGTACAACATGAAGGTGTTGGGCTACAACCTCATGCAGGCCATGCGATTGCGCGTGGA
 GGAAATCAACAACCTGTAGCTCTTTGCTGCCCGCGTGCTGCTCGGCTACGAGATGGTGGATG
 TCTGCTACCTCTCCAACAATATCCAGCCTGGGCTCTACTTCCTGTACAGATAGATGACTTC
 40 CTGCCCATCCTCAAAGACTACAGCCAGTACAGGCCCAAGTGGTGGCTGTTATTGGCCCAGA
 CAACTCTGAGTCTGCCATCACCGTGTCCAACATTCTCTCCTACTTCCTCGTGCCACAGGTCA
 CATATAGCGCCATCACCGACAAGCTGCAAGACAAGCGGCGCTTCCTGCCATGCTGCGCACT
 GTGCCCAGCGCCACCCACCACATCGAGGCCATGGTGCACCTGATGGTTCACTTCCAGTGGAA
 CTGGATCGTGGTGTGGTGAGCGATGACGATTATGGCCGAGAGAACAGCCACCTGCTGAGCC
 45 AGCGTCTGACCAACACTGGCGACATCTGCATTGCCTTCCAGGAGGTTCTGCCCCGTACCAGAA
 CCAACCAGGCTGTGAGGCCTGAGGAGCAGGACCAACTGGACAACATCCTGGACAAGCTGCG
 GCGGACTTCGGCGCGTGTGGTGGTGATATTCTCGCCGGAGCTGAGCCTGCACAACCTTCTTCC
 GTGAGGTGCTGCGCTGGAACCTTCACGGGCTTTGTGTGGATTGCCTCTGAGTCTGGGCCATC
 GACCCTGTTCTACACAACCTCACAGAGCTGCGCCACACGGGCACCTTCTGCGGTGTCAACAT
 50 CCAGAGGGTGTCCATCCCTGGCTTCAGCCAGTTCGAGTGCGCCATGACAAGCCAGGGTATC
 GCATGCCTAACGAGACCAGCCTGCGGACTACCTGTAACCAGGACTGCGACGCCTGCATGAAC

ATCACTGAGTCCTTCAACAACGTTCTCATGCTTTCGGGGGAGCGTGTGGTCTACAGCGTGTA
 CTCGGCCGTCTACGCGGTGGCCACACCTCCACAGACTCCTCCACTGCAATCAGGTCCGCT
 GCACCAAGCAAATCGTCTATCCATGGCAGCTACTCAGGGAGATCTGGCATGTCAACTTCACG
 CTCCTGGGCAACCAGCTCTTCTTCGACGAACAAGGGGACATGCCGATGCTCCTGGACATCAT
 5 CCAGTGGCAGTGGGGCCTGAGCCAGAACCCCTTCCAAAGCATCGCCTCCTACTCCCCACCG
 AGACGAGGCTGACCTACATTAGCAATGTGTCTTGGTACACCCCCAACACACGGTCCCCATA
 TCCATGTGTTCTAAGAGTTGCCAGCCTGGGCAAATGAAAAAACCCATAGGCCTCCACCCATG
 CTGCTTCGAGTGTGTGGACTGTCCGCCGGACACCTACCTCAACCGATCAGTAGATGAGTTTA
 ACTGTCTGTCTGCCCCGGTTCCATGTGGTCTTACAAGAACACATCGCTTGCTTCAAGCGG
 10 CGGCTGGCCTTCCTGGAGTGGCACGAAGTGGCCACTATCGTGGTGACCATCCTGGCCGCCCT
 GGGCTTCATCAGTACGCTGGCCATTCTGCTCATCTTCTGGAGACATTTCCAGACGCCCATGG
 TGCGCTCGGCGGGCGGCCCATGTGCTTCCTGATGCTGGTGCCCCCTGCTGCTGGCGTTTCGGG
 ATGGTCCCCGTGTATGTGGGCCCCCCCCACGGTCTTCTCCTGTTTCTGCCGCCAGGCTTTCTT
 CACCGTTTGGCTTCTCCGTCTGCCTCTCCTGCATCACGGTGCCTCCTTCCAGATTGTGTGCG
 15 TCTTCAAGATGGCCAGACGCCTGCCAAGCGCCTACGGTTTCTGGATGCGTTACCACGGGCCC
 TACGTCTTCGTGGCCTTCATCACGGCCGTCAAGGTGGCCCTGGTGGCGGGCAACATGCTGGC
 CACCACCATCAACCCCATTTGGCCGGACCGACCCCGATGACCCCAATATCATAATCCTCTCCT
 GCCACCCTAACTACCGCAACGGGCTACTCTTCAACACCAGCATGGACTTGCTGCTGTCCGTG
 CTGGGTTTTCAGCTTCGCGTACGTGGGCAAGGAAGTGGCCACCAACTACAACGAAGCCAAGTT
 20 CATCACCTCAGCATGACCTTCTCCTTCACTCCTCCATCTCCTCTGCACGTTTATGTCTG
 TCCACGATGGCGTGCTGGTCACCATCATGGATCTCCTGGTCACTGTGCTCAACTTTCTGGCC
 ATCGGCTTGGGGTACTTTGGCCCCAAATGTTACATGATCCTTTTCTACCCGGAGCGCAACAC
 TTCAGCTTATTTCAATAGCATGATTACAGGGCTACACGATGAGGAAGAGCTAG

 25 Human T1R2 nucleotide sequence--SEQ ID NO:12
 ATCACCTACAGCGCCATCAGCGATGAGCTGCGAGACAAGGTGCGCTTCCCGGCTTTGCTGCG
 TACCACACCCAGCGCCGACCACCACGTCGAGGCCATGGTGCAGCTGATGCTGCACTTCCGCT
 GGAAGTGGATCATTGTGCTGGTGGAGCAGCAGACCTATGGCCGCGACAATGGCCAGCTGCTT
 30 GCGAGCGCGTGGCCCGGCGGACATCTGCATCGCCTTCCAGGAGACGCTGCCACACTGCA
 GCCCAACCAGAACATGACGTCAGAGGAGCGCCAGCGCCTGGTGGCATTGTGGACAAGCTGC
 AGCAGAGCACAGCGCGCGTCTGTGGTCTGTTCTCGCCCGACCTGACCCTGTACCACTTCTTC
 AATGAGGTGCTGCGCCAGAACTTACGGGCGCCGTGTGGATCGCCTCCGAGTCTGGGCCAT
 CGACCCGGTCTTGCACAACCTCACGGAGCTGGGCCACTTGGGCACCTTCTGGGCATCACCA
 35 TCCAGAGCGTGCCCATCCCGGGCTTCAGTGAGTTCCGCGAGTGGGGCCCACAGGCTGGGCCG
 CCACCCCTCAGCAGGACCAGCCAGAGCTATACCTGCAACCAGGAGTGGGACAACCTGCCTGAA
 CGCCACCTTGTCTTCAACACCATCTCAGGCTCTCTGGGGAGCGTGTGCTCTACAGCGTGT
 ACTCTGCGGTCTATGCTGTGGCCCATGCCCTGCACAGCCTCCTCGGCTGTGACAAAAGCACC
 TGCACCAAGAGGGTGGTCTACCCCTGGCAGCTGCTTGAGGAGATCTGGAAGGTCAACTTCAC
 40 TCTCCTGGACCACCAAATCTTCTTCGACCCGCAAGGGGACGTGGCTCTGCACTTGGAGATTG
 TCCAGTGGCAATGGGACCGGAGCCAGAATCCCTTCCAGAGCGTCGCCTCCTACTACCCCTG
 CAGCGACAGCTGAAGAACATCAAGACATCTCTGCACACCGTCAACAACACGATCCCTATGTC
 CATGTGTTCCAAGAGGTGCCAGTCAGGGCAAAGAAGAAGCCTGTGGGCATCCACGTCTGCT
 GCTTCGAGTGCATCGACTGCCTTCCCGGCACCTTCTCAACCACACTGAATGCCCGAATAAC
 GAGTGGTCTTACCAGAGTGAGACCTCCTGCTTCAAGCGGACAGCTGGTCTTCTGGAATGGCA
 45 TGAGGCACCCACCATCGCTGTGGCCCTGCTGGCCGCCCTGGGCTTCTCAGCACCTTGGCCA
 TCCTGGTGATATTCTGGAGGCACTTCCAGACACCCATAGTTTCGCTCGGCTGGGGGCCCATG
 TGCTTCTGATGCTGACACTGCTGCTGGTGGCATAATGGTGGTCCCGGTGTACGTGGGGCC
 GCCCAAGGTCTCCACCTGCCTCTGCCGCCAGGCCCTCTTTCCCTCTGCTTCACAATTTGCA
 TCTCCTGTATCGCCGTGCGTTCTTTCCAGATCGTCTGCGCCTTCAAGATGGCCAGCCGCTTC
 50 CCACGCGCTACAGCTACTGGGTCCGCTACCAGGGGCCCTACGTCTCTATGGCATTATCAC
 GGTACTCAAAATGGTCATTGTGGTAATTGGCATGCTGGCACGGCCTCAGTCCCACCCCCGTA

CTGACCCCGATGACCCCAAGATCACAATTGTCTCCTGTAACCCCAACTACCGCAACAGCCTG
 CTGTTCAACACCAGCCTGGACCTGCTGCTCTCAGTGGTGGGTTTCAGCTTCGCCTACATGGG
 CAAAGAGCTGCCACCAACTACAACGAGGCCAAGTTCATCACCCCTCAGCATGACCTTCTATT
 TCACCTCATCCGTCTCCCTCTGCACCTTCATGTCTGCCTACAGCGGGGTGCTGGTCACCATC
 5 GTGGACCTCTTGGTCACTGTGCTCAACCTCCTGGCCATCAGCCTGGGCTACTTCGGCCCCAA
 GTGCTACATGATCCTCTTCTACCCGGAGCGCAACACGCCCGCCTACTTCAACAGCATGATCC
 AGGGCTACACCATGAGGAGGGACTAG

TIR3 SEQUENCES

10

Human T1R3 genomic nucleotide sequence--SEQ ID NO:13

GCTCACTCCATGTGAGGCCCCAGTCGGGGCAGCCACCTGCCGTGCCTGTTGGAAGTTGCCTC
 TGCCATGCTGGGCCCTGCTGTCTGGGCCTCAGCCTCTGGGCTCTCCTGCACCCTGGGACGG
 GGGCCCCATTGTGCCTGTACAGCAACTTAGGATGAAGGGGGACTACGTGCTGGGGGGGCTG
 15 TTCCCCCTGGGCGAGGCCGAGGAGGCTGGCCTCCGCAGCCGGACACGGCCCAGCAGCCCTGT
 GTGCACCAGGTACAGAGGTGGGACGGCCTGGGTGGGGGTGAGGGTGACCAGGTCTGGGGTGC
 TCCTGAGCTGGGGCCGAGGTGGCCATCTGCGGTTCTGTGTGGCCCCAGGTTCTCCTCAAACG
 GCCTGCTCTGGGCACTGGCCATGAAAATGGCCGTGGAGGAGATCAACAACAAGTCGGATCTG
 CTGCCCCGGGCTGCGCCTGGGCTACGACCTCTTTGATACGTGCTCGGAGCCTGTGGTGGCCAT
 20 GAAGCCAGCCTCATGTTCTGGCCAAGGCAGGCAGCCGCGACATCGCCGCCTACTGCAACT
 ACACGCAGTACCAGCCCCGTGTGCTGGCTGTATCGGGCCCCACTCGTCAGAGCTCGCCATG
 GTCACCGGCAAGTTCTTCAGCTTCTTCCTCATGCCCCAGGTGGCGCCCCCACCATCACCCA
 CCCCCACCCAGCCCTGCCCGTGGGAGCCCCCTGTGTGAGGAGATGCCTCTTGGCCCTTGCAAG
 TCAGCTACGGTGCTAGCATGGAGCTGCTGAGCGCCCCGGGAGACCTTCCCCTCCTTCTTCCGC
 25 ACCGTGCCAGCGACCGTGTGAGCTGACGGCCGCCGCGGAGCTGCTGCAGGAGTTCGGCTG
 GAACTGGGTGGCCGCCCTGGGCAGCGACGACGAGTACGGCCGGCAGGGCCTGAGCATCTTCT
 CGGCCCTGGCCGCGGCACGCGGCATCTGCATCGCGCACGAGGGCCTGGTGCCGCTGCCCGT
 GCCGATGACTCGCGCTGGGGAAGGTGCAGGACGTCTGACACAGGTGAACCAGAGCAGCGT
 GCAGGTGGTGTGCTGTTTCGCTCCGTGCACGCCGCCACGCCCTCTTCAACTACAGCATCA
 30 GCAGCAGGCTCTCGCCCAAGGTGTGGGTGGCCAGCGAGGCCTGGCTGACCTCTGACCTGGTC
 ATGGGGCTGCCCGGCATGGCCAGATGGGCACGGTGCTTGGCTTCTCCAGAGGGGTGCCCA
 GCTGCACGAGTTCCTCCAGTACGTGAAGACGCACCTGGCCCTGGCCACCGACCCGGCCTTCT
 GCTCTGCCCTGGGCGAGAGGGAGCAGGGTCTGGAGGAGGACGTGGTGGGCCAGCGCTGCCCG
 CAGTGTGACTGCATCACGCTGCAGAACGTGAGCGCAGGGGCTAAATCACCACCAGACGTTCTC
 35 TGTCTACGCAGCTGTGTATAGCGTGGCCCAGGCCCTGCACAACACTCTTCAGTGCAACGCCT
 CAGGCTGCCCCGCGCAGGACCCCGTGAAGCCCTGGCAGGTGAGCCCCGGGAGATGGGGGTGTG
 CTGTCTCTGTCATGTGCCCAGGCCACCAGGCACGGCCACCACGCCTGAGCTGGAGGTGGCTG
 GCGGCTCAGCCCCGTCCCCCGCCCGCAGCTCCTGGAGAACATGTACAACCTGACCTTCCACG
 TGGGCGGGCTGCCGCTGCGGTTTCGACAGCAGCGGAAACGTGGACATGGAGTACGACCTGAAG
 40 CTGTGGGTGTGGCAGGGCTCAGTGCCAGGCTCCACGACGTGGGCAGGTTCAACGGCAGCCT
 CAGGACAGAGCGCCTGAAGATCCGCTGGCACACGTCTGACAACCAGGTGAGGTGAGGGTGGG
 TGTGCCAGGCGTGCCCGTGGTAGCCCCCGCGGCAGGGCGCAGCCTGGGGGTGGGGGCCGTTT
 CAGTCTCCCGTGGGCATGCCAGCCGAGCAGAGCCAGACCCAGGCCTGTGCGCAGAAGCCC
 GTGTCCCGGTGCTCGCGGCAGTGCCAGGAGGGCCAGGTGCGCCGGGTCAAGGGGTTCCACTC
 45 CTGCTGCTACGACTGTGTGGACTGCGAGGCGGGCAGCTACCGGCAAAACCCAGGTGAGCCGC
 CTTCCCGGCAGGCGGGGGTGGGAACGCAGCAGGGGAGGGTCCTGCCAAGTCCTGACTCTGAG
 ACCAGAGCCACAGGGTACAAGACGAACACCCAGCGCCCTTCTCCTCTCTCACAGACGACAT
 CGCCTGCACCTTTTGTGGCCAGGATGAGTGGTCCCCGGAGCGAAGCACACGCTGCTTCCGCC
 GCAGGTCTCGGTTCTTGGCATGGGGCGAGCCGGCTGTGCTGCTGCTGCTCCTGCTGCTGAGC

CTGGCGCTGGGCCTTGTGCTGGCTGCTTTGGGGCTGTTTCGTTACCATCGGGACAGCCCACT
 GGTTCAGGCCTCGGGGGGGCCCCCTGGCCTGCTTTGGCCTGGTGTGCCTGGGCCTGGTCTGCC
 TCAGCGTCCTCCTGTTCCCTGGCCAGCCAGCCCTGCCCGATGCCTGGCCCAGCAGCCCTTG
 TCCACCTCCCGCTCACGGGCTGCCTGAGCACACTCTTCCTGCAGGCGGCCGAGATCTTCGT
 5 GGAGTCAGAACTGCCTCTGAGCTGGGCAGACCGGCTGAGTGGCTGCCTGCGGGGGCCCTGGG
 CCTGGCTGGTGGTGTCTGCTGGCCATGCTGGTGGAGGTCGCACTGTGCACCTGGTACCTGGTG
 GCCTTCCCGCCGGAGGTGGTGACGGAAGTGGCACATGCTGCCACGAGGCGCTGGTGCCTG
 CCGCACACGCTCCTGGGTGAGCTTCGGCCTAGCGCACGCCACCAATGCCACGCTGGCCTTTC
 TCTGCTTCCTGGGCACTTTCCTGGTGCAGGAGCCAGCCGGGCTGCTACAACCGTGGCCGCTGGC
 10 CTCACCTTTGCCATGCTGGCCTACTTCATCACCTGGGTCTCCTTTGTGCCCTCCTGGCCAA
 TGTGCAGGTGGTCTCAGGCCCGCCGTGCAGATGGGCGCCCTCCTGCTCTGTGTCTGGGCA
 TCCTGGCTGCCTTCCACCTGCCAGGTGTTACCTGCTCATGCGGCAGCCAGGGCTCAACACC
 CCCGAGTTCTTCCTGGGAGGGGGCCCTGGGGATGCCCAAGGCCAGAATGACGGGAACACAGG
 AAATCAGGGGAAACATGAGTGACCCAACCCTGTGATCT

15

Human T1R3 cds nucleotide sequence--SEQ ID NO:14

atgctgggcctgctgtcctgggcctcagcctctgggctctcctgcaccctgggacggggggc
 cccattgtgcctgtcacagcaacttaggatgaaggggactacgtgctgggggggctgttcc
 cctgggcgaggccgaggaggctggcctccgcagccggacacggcccagcagccctgtgtgc
 20 accaggttctcctcaaacggcctgctctgggcaactggccatgaaaatggccgtggaggagat
 caacaacaagtcggatctgctgcccgggctgcgccctgggctacgacctcttgatacgtgct
 cggagcctgtggtggccatgaagcccagcctcatgttcctggccaaggcaggcagccgcgac
 atcgccgcctactgcaactacacgcagtagccagccccgtgtgctggctgtcatcgggcccca
 ctgctcagagctcgccatgggtcacccggaagttcttcagcttcttctcatgccccagGTCA
 25 GCTACGGTGCTAGCATGGAGCTGCTGAGCGCCCCGGGAGACCTTCCCCTCCTTCTTCCGCACC
 GTGCCAGCGACCGTGTGCAGCTGACGGCCGCCGCGGAGCTGCTGCAGGAGTTCGGCTGGAA
 CTGGGTGGCCGCCCTGGGCAGCGACGACGAGTACGGCCGGCAGGGCCTGAGCATCTTCTCGG
 CCCTGGCCGCGGCACGCGGCATCTGCATCGCGCACGAGGGCCTGGTGGCGCTGCCCCGTGCC
 GATGACTCGCGGCTGGGGAAGGTGCAGGACGTCCTGCACCAGGTGAACCAGAGCAGCGTGCA
 30 GGTGGTGTCTGCTGTTTCGCTCCGTGCACGCCGCCACGCCCTCTTCAACTACAGCATCAGCA
 GCAGGCTCTCGCCCAAGGTGTGGGTGGCCAGCGAGGCCTGGCTGACCTCTGACCTGGTCATG
 GGGCTGCCCCGCATGGCCCAGATGGGCACGGTGCTTGGCTTCCTCCAGAGGGGTGCCAGCT
 GCACGAGTTCCCCCAGTACGTGAAGACGCACCTGGCCCTGGCCACCGACCCGGCCTTCTGCT
 CTGCCCTGGGCGAGAGGGAGCAGGGTCTGGAGGAGGACGTGGTGGGCCAGCGCTGCCCGCAG
 35 TGTGACTGCATCACGCTGCAGAACGTGAGCGCAGGGCTAAATCACCACCAGACGTTCTCTGT
 CTACGCAGCTGTGTATAGCGTGGCCCAGGCCCTGCACAACACTCTTCAGTGCAACGCCTCAG
 GCTGCCCCGCGCAGGACCCCGTGAAGCCCTGGCAGCTCCTGGAGAACATGTACAACCTGACC
 TTCCACGTGGGCGGGCTGCCGCTGCGGTTTCGACAGCAGCGGAAACGTGGACATGGAGTACGA
 CCTGAAGCTGTGGGTGTGGCAGGGCTCAGTGCCCAGGCTCCACGACGTGGGCAGGTTCACG
 40 GCAGCCTCAGGACAGAGCGCCTGAAGATCCGCTGGCACACGTCTGACAACCAGAAGCCCGTG
 TCCCGGTGCTCGCGGCAGTGCCAGGAGGGCCAGGTGCGCCGGGTCAAGGGGTTCCTACTCTG
 CTGCTACGACTGTGTGGACTGCGAGGCGGGCAGCTACCGGCAAAACCCAGACGACATCGCCT
 GCACCTTTTGTGGCCAGGATGAGTGGTCCCCGGAGCGAAGCACACGCTGCTTCCGCCGAGG
 TCTCGGTTCTTGGCATGGGGCGAGCCGGCTGTGCTGCTGCTCCTGCTGCTGAGCCTGGC
 45 GCTGGGCCTTGTGCTGGCTGCTTTGGGGCTGTTTCGTTACCATCGGGACAGCCCACTGGTTC
 AGGCCTCGGGGGGGCCCCCTGGCCTGCTTTGGCCTGGTGTGCCTGGGCCTGGTCTGCCTCAGC
 GTCCTCCTGTTCCCTGGCCAGCCCAGCCCTGCCCGATGCCTGGCCCAGCAGCCCTTGTCCCA
 CCTCCCGCTCACGGGCTGCCTGAGCACACTCTTCCTGCAGGCGGCCGAGATCTTCGTGGAGT
 CAGAACTGCCTCTGAGCTGGGCAGACCGGCTGAGTGGCTGCCTGCGGGGGGCCCTGGGCCTGG
 50 CTGGTGGTGTGCTGCTGGCCATGCTGGTGGAGGTCGCACTGTGCACCTGGTACCTGGTGGCCTT
 CCCGCCGAGGTGGTGACGGAAGTGGCACATGCTGCCACGAGGCGCTGGTGCCTGCCGCA

CACGCTCCTGGGTCAGCTTCGGCCTAGCGCACGCCACCAATGCCACGCTGGCCTTTCTCTGC
 TTCCTGGGCACTTTCTCTGGTGCGGAGCCAGCCGGGCTGCTACAACCGTGCCCGTGGCCTCAC
 CTTTGCCATGCTGGCCTACTTCATCACCTGGGTCTCCTTTGTGCCCCCTCCTGGCCAATGTGC
 AGGTGGTCCTCAGGCCCGCCGTGCAGATGGGCGCCCTCCTGCTCTGTGTCTTGGGCATCCTG
 5 GCTGCCTTCCACCTGCCCAGGTGTTACCTGCTCATGCGGCAGCCAGGGCTCAACACCCCCGA
 GTTCTTCTGGGAGGGGCCCTGGGGATGCCCAAGGCCAGAATGACGGGAACACAGGAAATC
 AGGGGAAACATGAGTGA

Human T1R3 amino acid sequence--SEQ ID NO:15

10 MLGPAVLGLSLWALLHPGTGAPLCLSQQLRMKGDYVLGGLFPLGEAEEAGLRSRTRPSSPVC
 TRFSSNGLLWALAMKMAVEEINNKSDDLPLGLRLGYDLFDTCSEPVVAMKPSLMFLAKAGSRD
 IAAYCNYTQYQPRVLAVIGPHSSELAMVTGKFFSFLLMPQVSYGASMELLSARETFPSFFRT
 VPSDRVQLTAAAEELLQEFQWVVAALGSDDEYGRQGLSIFSAALAAARGICIAHEGLVPLPRA
 DDSRLGKVQDVLHQVNQSSVQVLLFASVHAHALFNYSISSRLSPKVVVASEAWLTSDLVM
 15 GLPGMAQMGTVLGFLQGAQLHEFPQYVKTHLALATDPAFCSALGEREQGLEEDVVGQRCPQ
 CDCITLQNVSAAGLNHHQTFSVYAAVYSVAQALHNTLQCNASGCPAQDPVKPWQLLENMYNLT
 FHVGGPLPRFDSSGNVDMEDYDLKLWVWQGSVPRLLHDVGRFNGSLRTERLKIWHWTSNPKPV
 SRCRSQCQEQVRRVKGFHSCCYDCVDCEAGSYRQNPDDIACTFCGQDEWSPERSTRCFRRR
 SRFLAWGEPVLLLLLLLLSLALGLVLAALGLFVHHRDPLVQASGGPLACFGLVCLGLVCLS
 20 VLLFPQGQSPARCLAQQPLSHLPLTGCLSTLFLQAAEI FVESELPLSWADRLSGCLRGPWAW
 LVLLAMLVEVALCTWYLVAFPEVVTDWMLPTEALVHCRTRSWVSFGLAHATNATLAFLC
 FLGTFLVRSQPGCYNRARGLTFAMLAYFITWVSFVPLLANVQVVLRAVQMGALLLCVLGIL
 AAFHLPRCYLLMRQPLNTPEFFLGGGPGDAQGQNDGNTGNQKHE

25

Mouse T1R3 Sac non taster 129 genomic nucleotide sequence--SEQ ID NO:16

ACATCTGTGGCTCCAACCCACACACCCATCTATTGTTAGTGCTGGAGACTTCTACCTACCA
 TGCCAGCTTTGGCTATCATGGGTCTCAGCCTGGCTGCTTTCTCCTGGAGCTTGGGATGGGGGCC
 TCTTTGTGTCTGTACAGCAATTCAAGGCACAAGGGGACTACATACTGGGCGGGCTATTTCC
 30 CCTGGGCTCGACCGAGGAGGCCACTCTCAACCAGAGAGCACAACCCAAACAGCACCTGTGTA
 ACAGGTATGGAGGCTAGTAGCTGGGGTGGGAGTGAACCGAAGCTTGGCAGCTTTGGCTCCGT
 GGTACTACCAATCTGGGGAAGGGGTGGTGATCAGTTTCCATGTGGCCTCAGGTTCTCACCCC
 TCGGTTTGTTCCTGGCCATGGCTATGAAGATGGCTGTGGAGGAGATCAACAATGGATCTGCC
 TTGCTCCCTGGGCTGCGGCTGGGCTATGACCTATTTGACACATGCTCCGAGCCAGTGGTCAC
 35 CATGAAATCCAGTCTCATGTTCTTGGCCAAGGTGGGCAGTCAAAGCATTGCTGCCTACTGCA
 ACTACACACAGTACCAACCCCGTGTGCTGGCTGTGATCGGCCCCCACTCATCAGAGCTTGCC
 CTCATTACAGGCAAGTTCTTCAGCTTCTTCCTCATGCCACAGGTGAGCCCACTTCCTTTGTG
 TTCTCAACCGATTGCACCCATTGAGCTCTCACATCAGAAAGTGCTTCTTGATCACCACAGGT
 CAGCTATAGCGCCAGCATGGATCGGCTAAGTGACCGGGAACGTTTCCATCCTTCTTCCGCA
 40 CAGTGCCCAGTGACCGGGTGCAGCTGCAGGCAGTTGTGACTCTGTTGCAGAACTTCAGCTGG
 AACTGGGTGGCCGCCTTAGGGAGTGATGATGACTATGGCCGGGAAGGTCTGAGCATCTTTTC
 TAGTCTGGCCAATGCACGAGGTATCTGCATCGCACATGAGGGCCTGGTGCCACAACATGACA
 CTAGTGGCCAACAGTTGGGCAAGGTGCTGGATGTGCTACGCCAAGTGAACCAAAGTAAAGTA
 CAAGTGGTGGTGCTGTTTGCCTCTGCCCCGTGCTGTCTACTCCCTTTTGTAGTTACAGCATCCA
 45 TCATGGCCTCTCACCCAAGGTATGGGTGGCCAGTGAGTCTTGGCTGACATCTGACCTGGTCA
 TGACACTTCCCAATATTGCCCCGTGTGGGCAGTGTGCTTGGGTTTTTGCAGCGGGGTGCCCTA
 CTGCCTGAATTTTCCCATTATGTGGAGACTCACCTTGCCCTGGCCGCTGACCCAGCATCTG
 TGCCTCACTGAATGCGGAGTTGGATCTGGAGGAACATGTGATGGGGCAACGCTGTCCACAGT
 GTGACGACATCATGCTGCAGAACCTATCATCTGGGCTGTTGCAGAACCTATCAGCTGGGCAA
 50 TTGCACCACCAATATTTGCAACCTATGCAGCTGTGTACAGTGTGGCTCAAGCCCTTCACAA
 CACCCTACAGTGCAATGTCTCACATTGCCACGTATCAGAACATGTTCTACCCTGGCAGGTAA

GGGTAGGGTTTTTGGCTGGGTTTTGCCTGCTCCTGCAGGAACACTGAACCAGGCAGAGCCAA
 ATCATGTTGTGACTGGAGAGGCCTTACCCTGACTCCACTCCACAGCTCCTGGAGAACATGTA
 CAATATGAGTTTCCATGCTCGAGACTTGACACTACAGTTTGATGCTGAAGGGAATGTAGACA
 TGGAATATGACCTGAAGATGTGGGTGTGGCAGAGCCCTACACCTGTATTACATACTGTGGGC
 5 ACCTTCAACGGCACCCTTCAGCTGCAGCAGTCTAAAATGTACTGGCCAGGCAACCAGGTAAG
 GACAAGACAGGCAAAAAGGATGGTGGGTAGAAGCTTGTGGTCTTGGGCCAGTGCTAGCCAA
 GGGGAGGCCTAACCCAAGGCTCCATGTCCAGGTGCCAGTCTCCCAGTGTTCCCGCCAGTGCA
 AAGATGGCCAGGTTGCGCCGAGTAAAGGGCTTTCATTCTGCTGCTATGACTGCGTGGACTGC
 AAGGCGGGCAGCTACCGGAAGCATCCAGGTGAACCGTCTTCCCTAGACAGTCTGCACAGCCG
 10 GGCTAGGGGGCAGAAGCATTCAAGTCTGGCAAGCGCCCTCCCGCGGGGCTAATGTGGAGACA
 GTTACTGTGGGGGCTGGCTGGGGAGGTGCGGTCTCCCATCAGCAGACCCACATTACTTTTCT
 TCCTTCCATCACTACAGATGACTTCACCTGTACTCCATGTAACCAGGACCAGTGGTCCCCAG
 AGAAAAGCACAGCCTGCTTACCTCGCAGGCCCAAGTTTCTGGCTTGGGGGAGCCAGTTGTG
 CTGTCACTCCTCCTGCTGCTTTGCCTGGTGTGGGTCTAGCACTGGCTGCTCTGGGGCTCTC
 15 TGTCCACCACTGGGACAGCCCTCTTGTCCAGGCCTCAGGCGGCTCACAGTTCTGCTTTGGCC
 TGATCTGCCTAGGCCTCTTCTGCCTCAGTGTCTTCTGTTCCAGGACGGCCAAGCTCTGCC
 AGCTGCCTTGACACAACAACCAATGGCTCACCTCCCTCTCACAGGCTGCCTGAGCACACTCTT
 CCTGCAAGCAGCTGAGACCTTTGTGGAGTCTGAGCTGCCACTGAGCTGGGCAAACCTGGCTAT
 GCAGCTACCTTCGGGGACTCTGGGCCTGGCTAGTGGTACTGTTGGCCACTTTTGTGGAGGCA
 20 GCACTATGTGCCTGGTATTTGACCGCTTTCCACCAGAGGTGGTGACAGACTGGTCAGTGCT
 GCCCACAGAGGTACTGGAGCACTGCCACGTGCGTTCTTGGGTGAGCCTGGGCTTGGTGACA
 TCACCAATGCAATGTTAGCTTTCCTCTGCTTCTGCGCACTTCTGTTACAGAGCCAGCCT
 GGCCGCTACAACCGTGCCCGTGGTCTCACCTTCGCCATGCTAGCTTATTTTCATCACCTGGGT
 CTCTTTTGTGCCCCCTCCTGGCCAATGTGCAGGTGGCCTACCAGCCAGCTGTGCAGATGGGTG
 25 CTATCCTAGTCTGTGCCCTGGGCATCCTGGTCACTTCCACCTGCCCAAGTGCTATGTGCTT
 CTTTGGCTGCCAAAGCTCAACACCCAGGAGTTCTTCTGGGAAGGAATGCCAAGAAAGCAGC
 AGATGAGAACAGTGGCGGTGGTGAGGCAGCTCAGGAACACAATGAATGACCACTGACCCGTG
 ACCTTCCCTTTAGGGA

30 Mouse T1R3 Sac non taster 129 cds nucleotide sequence--SEQ ID NO:17
 ATGCCAGCTTTGGCTATCATGGGTCTCAGCCTGGCTGCTTTCCTGGAGCTTGGGATGGGGGC
 CTCTTTGTGTCTGTACAGCAATTCAAGGCACAAGGGGACTACATACTGGGCGGGCTATTTT
 CCCTGGGCTCGACCGAGGAGGCCACTCTCAACCAGAGAGCACAAACCAACAGCACCCCTGTGT
 AACAGGTTCTCACCCCTCGGTTTGTTCCTGGCCATGGCTATGAAGATGGCTGTGGAGGAGAT
 35 CAACAATGGATCTGCCTTGCTCCCTGGGCTGCGGCTGGGCTATGACCTATTTGACACATGCT
 CCGAGCCAGTGGTCAACATGAAATCCAGTCTCATGTTCTGCGCAAGGTGGGCAGTCAAAGC
 ATTGCTGCCTACTGCAACTACACACAGTACCAACCCCGTGTGCTGGCTGTGCTCATCGCCCCCA
 CTCATCAGAGCTTGCCCTCATTACAGGCAAGTTCTTCAGCTTCTTCTCATGCCACAGGTCA
 GCTATAGCGCCAGCATGGATCGGCTAAGTGACCGGGAACGTTTCCATCCTTCTTCCGCACA
 40 GTGCCCAGTGACCGGGTGACGCTGCAGGCAGTTGTGACTCTGTTGCAGAACTTCAGCTGGAA
 CTGGGTGGCCGCCTTAGGGAGTGATGATGACTATGGCCGGGAAGGTCTGAGCATCTTTTCTA
 GTCTGGCCAATGCACGAGGTATCTGCATCGCACATGAGGGCCTGGTGCCACAACATGACACT
 AGTGGCCAACAGTTGGGCAAGGTGCTGGATGTGCTACGCCAAGTGAACCAAAGTAAAGTACA
 AGTGGTGGTGCTGTTTGCCTCTGCCCCGTGCTGTCTACTCCCTTTTTAGTTACAGCATCCATC
 45 ATGGCCTCTCACCAAGGTATGGGTGGCCAGTGAGTCTTGGCTGACATCTGACCTGGTCATG
 AACTTCCCAATATTGCCCGTGTGGGCACTGTGCTTGGGTTTTTGCAGCGGGGTGCCCTACT
 GCCTGAATTTTCCCATTATGTGGAGACTCACCTTGCCCTGGCCGCTGACCCAGCATTTCTGTG
 CCTACTGAATGCGGAGTTGGATCTGGAGGAACATGTGATGGGGCAACGCTGTCCACAGTGT
 GACGACATCATGCTGCAGAACCTATCATCTGGGCTGTTGCAGAACCTATCAGCTGGGCAATT
 50 GCACCACCAAATATTTGCAACCTATGCAGCTGTGTACAGTGTGGCTCAAGCCCTTACAACA
 CCCTACAGTGCAATGTCTCACATTGCCACGTATCAGAACATGTTCTACCCTGGCAGCTCCTG

AGGCCACTCTCAACCAGAGAACACAACCCAACAGCATCCCCTGCAACAGGTATGGAGGCTAG
 TAGCTGGGGTGGGAGTGAACCGAAGCTTGGCAGCTTTGGCTCCGTGGTACTACCAATCTGGG
 AAGAGGTGGTGATCAGTTTCCATGTGGCCTCAGGTTCTCACCCTTGGTTTGTTCCTGGCCA
 TGGCTATGAAGATGGCTGTGGAGGAGATCAACAATGGATCTGCCTTGCTCCCTGGGCTGCGG
 5 CTGGGCTATGACCTATTTGACACATGCTCCGAGCCAGTGGTCACCATGAAATCCAGTCTCAT
 GTTCCTGGCCAAGGTGGGCAGTCAAAGCATTGCTGCCTACTGCAACTACACACAGTACCAAC
 CCCGTGTGCTGGCTGTTCATCGGCCCCCACTCATCAGAGCTTGCCCTCATTACAGGCAAGTTC
 TTCAGCTTCTTCCTCATGCCACAGGTGAGCCCACTTCCTTTGTGTTCTCAACCGATTGCACC
 CATTGAGCTCTCATATCAGAAAGTGCTTCTTGATCACCACAGGTCAGCTATAGTGCCAGCAT
 10 GGATCGGCTAAGTGACCGGGAAACGTTTCCATCCTTCTTCCGCACAGTGCCCAAGTGACCGGG
 TGCAGCTGCAGGCAGTTGTGACTCTGTTGCAGAACTTCAGCTGGAAGTGGGTGGCCGCTTA
 GGGAGTGATGATGACTATGGCCGGGAAGGTCTGAGCATCTTTTCTAGTCTGGCCAATGCACG
 AGGTATCTGCATCGCACATGAGGGCCTGGTGCCACAACATGACACTAGTGGCCAACAGTTGG
 GCAAGGTGCTGGATGTACTACGCCAAGTGAACCAAAGTAAAGTACAAGTGGTGGTGCTGTTT
 15 GCCTCTGCCCCGTGCTGTCTACTCCCTTTTTAGTTACAGCATCCATCATGGCCTCTCACCCTAA
 GGTATGGGTGGCCAGTGAGTCTTGGCTGACATCTGACCTGGTCATGACACTTCCCAATATTG
 CCCGTGTGGGCACTGTGCTTGGGTTTTTGCAGCGGGGTGCCCTACTGCCTGAATTTTCCCAT
 TATGTGGAGACTCACCTTGCCCTGGCCGCTGACCCAGCATTCTGTGCCTCACTGAATGCGGA
 GTTGGATCTGGAGGAACATGTGATGGGGCAACGCTGTCCACGGTGTGACGACATCATGCTGC
 20 AGAACCTATCATCTGGGCTGTTGCAGAACCTATCAGCTGGGCAATTGCACCACCAATATTT
 GCAACCTATGCAGCTGTGTACAGTGTGGCTCAAGCCCTTCACAACACCCTACAGTGCAATGT
 CTCACATTGCCACGTATCAGAACATGTTCTACCCTGGCAGGTAAGGGTAGGGTTTTTGTCTG
 GGTTTTGCCTGCTCCTGCAGGAACACTGAACCAGGCAGAGCCAAATCTTGTGTGACTGGAG
 AGGCCTTACCCTGACTCCACTCCACAGCTCCTGGAGAACATGTACAATATGAGTTTCCATGC
 25 TCGAGACTTGACACTACAGTTTGATGCTGAAGGGAATGTAGACATGGAATATGACCTGAAGA
 TGTGGGTGTGGCAGAGCCCTACACCTGTATTACATACTGTGGGCACCTTCAACGGCACCTT
 CAGCTGCAGCAGTCTAAATGTACTGGCCAGGCAACCAGGTAAGGACAAGACAGGCAAAAAG
 GATGGTGGGTAGAAGCTTGTCCGTCTTGGGCCAGTGCTAGCCAAGGGGAGGCCTAACCCAAG
 GCTCCATGTACAGGTGCCAGTCTCCAGTGTTCCCGCCAGTGCAAAGATGGCCAGGTTCCGCC
 30 GAGTAAAGGGCTTTTATTCTGCTGCTATGACTGCGTGGAAGTGCAAGGCGGGCAGCTACCGG
 AAGCATCCAGGTGAACCGTCTTCCCTAGACAGTCTGCACAGCCGGGCTAGGGGGCAGAAGCA
 TTCAAGTCTGGCAAGCGCCCTCCCGCGGGGCTAATGTGGAGACAGTTACTGTGGGGGCTGGC
 TGGGGAGGTCCGTCTCCCATCAGCAGACCCACATTACTTTTCTTCTTCCATCACTACAGA
 TGACTTCACCTGTACTCCATGTAACCAGGACCAGTGGTCCCCAGAGAAAAGCACAGCCTGCT
 35 TACCTCGCAGGCCCAAGTTTCTGGCTTGGGGGAGCCAGTTGTGCTGTCACTCCTCCTGCTG
 CTTTGCCTGGTGCTGGGTCTAGCACTGGCTGCTCTGGGGCTCTCTGTCCACCCTGGGACAG
 CCCTCTTGTCCAGGCCTCAGGTGGCTCACAGTTCTGCTTTGGCCTGATCTGCCTAGGCCTCT
 TCTGCCTCAGTGTCTTCTGTTCCAGGGCGGCCAAGCTCTGCCAGCTGCCTTGACACAACAA
 CCAATGGCTCACCTCCCTCTCACAGGCTGCCTGAGCACACTCTTCTGCAAGCAGCTGAGAC
 40 CTTTGTGGAGTCTGAGCTGCCACTGAGCTGGGCAAACTGGCTATGCAGCTACCTTCGGGGAC
 TCTGGGCCTGGCTAGTGGTACTGTTGGCCACTTTTGTGGAGGCAGCACTATGTGCCTGGTAT
 TTGATCGCTTTCCCACCAGAGGTGGTGACAGACTGGTCAGTGCTGCCACAGAGGTACTGGA
 GCACTGCCACGTGCGTTCCTGGGTGAGCCTGGGCTTGGTGACATCACCATGCAATGTTAG
 CTTTCTCTGCTTTCTGGGCACTTTCTGGGTACAGAGCCAGCCTGGCCGCTACAACCGTGCC
 45 CGTGGTCTCACCTTCGCCATGCTAGCTTATTTATCACCTGGGTCTCTTTTGTGCCCTCCT
 GGCCAATGTGCAGGTGGCCTACCAGCCAGCTGTGCAGATGGGTGCTATCCTAGTCTGTGCC
 TGGGCATCCTGGTCACCTTCCACCTGCCCAAGTGCTATGTGCTTCTTTGGCTGCCAAAGCTC
 AACACCCAGGAGTTCTTCTGGGAAGGAATGCCAAGAAAGCAGCAGATGAGAACAGTGGCGG
 TGGTGAGGCAGCTCAGGGACACAATGAATGACCACTGA

Mouse T1R3 Sac taster C57 cds nucleotide sequence-- SEQ ID NO:22

ATGCCAGCTTTGGCTATCATGGGTCTCAGCCTGGCTGCTTTCCTGGAGCTTGGGATGGGGGC
CTCTTTGTGTCTGTCTACAGCAATTC AAGGCACAAGGGGACTACATACTGGGCGGGCTATTTTC
CCCTGGGCTCAACCGAGGAGGCCACTCTCAACCAGAGAACACAACCCAACAGCATCCCGTGC
5 AACAGGTTCTCACCCTTGGTTTGTTCCTGGCCATGGCTATGAAGATGGCTGTGGAGGAGAT
CAACAATGGATCTGCCTTGCTCCCTGGGCTGCGGCTGGGCTATGACCTATTTGACACATGCT
CCGAGCCAGTGGTCACCATGAAATCCAGTCTCATGTTCTCTGGCCAAGGTGGGCAGTCAAAGC
ATTGCTGCCTACTGCAACTACACACAGTACCAACCCCGTGTGCTGGCTGTCATCGGCCCCCA
CTCATCAGAGCTTGCCCTCATTACAGGCAAGTTCTTCAGCTTCTTCCTCATGCCACAGGTCA
10 GCTATAGTGCCAGCATGGATCGGCTAAGTGACCGGGAACGTTTCCATCCTTCTTCCGCACA
GTGCCCAGTGACCGGGTGCAGCTGCAGGCAGTTGTGACTCTGTTGCAGAACTTCAGCTGGAA
CTGGGTGGCCGCTTAGGGAGTGATGATGACTATGGCCGGAAGGTCTGAGCATCTTTTCTA
GTCTGGCCAATGCACGAGGTATCTGCATCGCACATGAGGGCCTGGTGCCACAACATGACACT
AGTGGCCAACAGTTGGGCAAGGTGCTGGATGTACTACGCCAAGTGAACCAAAGTAAAGTACA
15 AGTGGTGGTGCTGTTTGCCTCTGCCCCGTGCTGTCTACTCCCTTTTGTAGTTACAGCATCCATC
ATGGCCTCTCACC AAGGTATGGGTGGCCAGTGAGTCTTGGCTGACATCTGACCTGGTCATG
ACACTTCCCAATATTGCCCGTGTGGGCACTGTGCTTGGGTTTTTCAGCGGGGTGCCCTACT
GCCTGAATTTTCCATTATGTGGAGACTCACCTTGCCCTGGCCGCTGACCCAGCATTTCTGTG
CCTCACTGAATGCGGAGTTGGATCTGGAGGAACATGTGATGGGGCAACGCTGTCCACGGTGT
20 GACGACATCATGCTGCAGAACCTATCATCTGGGCTGTTGCAGAACCTATCAGCTGGGCAATT
GCACCACCAAATATTTGCAACCTATGCAGCTGTGTACAGTGTGGCTCAAGCCCTTCACAACA
CCCTACAGTGCAATGTCTCACATTGCCACGTATCAGAACATGTTCTACCCTGGCAGCTCCTG
GAGAACATGTACAATATGAGTTTCCATGCTCGAGACTTGACACTACAGTTTGATGCTGAAGG
GAATGTAGACATGGAATATGACCTGAAGATGTGGGTGTGGCAGAGCCCTACACCTGTATTAC
25 ATACTGTGGGCACCTTCAACGGCACCCCTTCAGCTGCAGCAGTCTAAAATGTACTGGCCAGGC
AACCAGGTGCCAGTCTCCAGTGTTCCCGCCAGTGCAAAGATGGCCAGGTTCGCCGAGTAAA
GGGCTTTCATTCTCTGCTGCTATGACTGCGTGGACTGCAAGGCGGGCAGCTACCGGAAGCATC
CAGATGACTTCACCTGTACTCCATGTAACCAGGACCAGTGGTCCCCAGAGAAAAGCACAGCC
TGCTTACCTCGCAGGCCCAAGTTTCTGGCTTGGGGGGAGCCAGTTGTGCTGTCACTCCTCCT
30 GCTGCTTTGCCTGGTGCTGGGTCTAGCACTGGCTGCTCTGGGGCTCTCTGTCCACCACTGGG
ACAGCCCTCTTGTCCAGGCCTCAGGTGGCTCACAGTTCTGCTTTGGCCTGATCTGCCTAGGC
CTCTTCTGCCTCAGTGTCTTCTGTTCCAGGGCGGCCAAGCTCTGCCAGCTGCCTTGACACA
ACAACCAATGGCTCACCTCCCTCTCACAGGCTGCCTGAGCACACTCTTCTGCAAGCAGCTG
AGACCTTTGTGGAGTCTGAGCTGCCACTGAGCTGGGCAAACCTGGCTATGCAGCTACCTTCGG
35 GGACTCTGGGCCTGGCTAGTGGTACTGTTGGCCACTTTTGTGGAGGCAGCACTATGTGCCTG
GTATTTGATCGCTTTCCACACAGAGGTGGTGACAGACTGGTCAGTGCTGCCACAGAGGTAC
TGGAGCACTGCCACGTGCGTTCTGGGTGAGCCTGGGCTTGGTGACATCACCAATGCAATG
TTAGCTTTCTCTGCTTTCTGGGCACTTTCTGGTACAGAGCCAGCCTGGCCGCTACAACCG
TGCCCGTGGTCTCACCTTCGCCATGCTAGCTTATTTATCACCTGGGTCTCTTTTGTGCCCC
40 TCCTGGCCAATGTGCAGGTGGCCTACCAGCCAGCTGTGCAGATGGGTGCTATCCTAGTCTGT
GCCCTGGGCATCCTGGTCACCTTCCACCTGCCAAGTGCTATGTGCTTCTTTGGCTGCCAAA
GCTCAACACCCAGGAGTTCTTCTGGGAAGGAATGCCAAGAAAGCAGCAGATGAGAACAGTG
GCGGTGGTGAGGCAGCTCAGGGACACAATGAATGA

Mouse T1R3 Sac taster C57 amino acid sequence--SEQ ID NO:23

MPALAIMGLSLAAFLELGMGASLCLSQQFKAQGDYILGGLFPLGSTEEATLNQRTQPNSIPC
NRFSPGLGLFLAMAMKMAVEEINNGSALLPGLRLGYDLFDTCSEPVVTMKSSLMFLAKVGSQS
IAAYCNYTQYQPRVLAVIGPHSSELALITGKFFSFFLMPQVSYASMDRLSDRETFFSFFRT
VPSDRVQLQAVVTLLQNF SWNWVAALGSDDDYGREGLSIFSSLANARGICIAHEGLVPQHDT
50 SGQQLGKVLDVLRQVNQSKVQVVVLFASARAVYSLSYSIHHGLSPKVWVASESWLTSDLVM
TLPNIARVGTVLGFLQRGALLPEFSHYVETHLALAADPAFCASLNAELDLEEHVMGQRCPRC

DDIMLQNLSSGLLQNL SAGQLHHQIFATYAAVYSVAQALHNTLQCNVSHCHVSEHVL PWQLL
 ENMYNMSFHARDLTLQFDAEGNVDM EYDLKMVWVQSPTPVLHTVGT FNGTLQLQOSKMYWPG
 NQVPVSQCSRQCKDQGVRRVKGFHSCCYDCV DCKAGSYRKHPDDFTCTPCNQDQWSPEKSTA
 CLPRRPKFLAWGEPVVL SLLLLLCLVLGLALAA LGLSVHHWDSPLVQASGGSQFCFGLICLG
 5 LFCLSVLLFPGRPSSASCLAQQPMAHLPLTGCLSTLFLQAAETFVESELPLSWANWLC SYLR
 GLWAWLVVLLATFVEAALCAWYLIAFPPEVVT DWSVLPTEVLEHCHVRSWVSLGLVHITNAM
 LAFLCFLGTLVQSQPGRYNRARGLTFAMLAYFI TWVSFVPLL ANVQVAYQPAVQMGA I LVC
 ALGILVTFHLPKCYVLLWL PKLNTQEFFLGRNAKKAADENSGGGEAAQGHNE

10 Rat TIR3 CDS nucleotide sequence--SEQ ID NO:24

ATGCCGGGTTTGGCTATCTTGGGCCTCAGTCTGGCTGCTTTCCTGGAGCTTGGGATGGGGTC
 CTCTTTGTGTCTGTACAGCAATTCAAGGCACAAGGGGACTATATATTGGGTGGACTATTTC
 CCCTGGGCACAACCTGAGGAGGCCACTCTCAACCAGAGAACACAGCCCAACGGCATCCTATGT
 ACCAGGTTCTCGCCCCTTGGTTTGTTCCTGGCCATGGCTATGAAGATGGCTGTAGAGGAGAT
 15 CAACAATGGATCTGCCTTGCTCCCTGGGCTGCGACTGGGCTATGACCTGTTTGACACATGCT
 CAGAGCCAGTGGTCACCATGAAGCCCAGCCTCATGTTTCATGGCCAAGGTGGGAAGTCAAAGC
 ATTGCTGCCTACTGCAACTACACACAGTACCAACCCCGTGTGCTGGCTGTCAATTGGTCCCCA
 CTCATCAGAGCTTGGCCTCATTACAGGCAAGTCTTCAGCTTCTTCCTCATGCCACAGGTCA
 GCTATAGTGCCAGCATGGATCGGCTAAGTGACCGGGAACATTTCCATCCTTCTTCCGCACA
 20 GTGCCCAGTGACCGGGTGACGCTGCAGGCCGTTGTGACACTGTTGCAGAATTTAGCTGGAA
 CTGGGTGGCTGCCTTAGGTAGTGATGACTATGGCCGGAAGGTCTGAGCATCTTTTCTG
 GTCTGGCCAACCTACGAGGTATCTGCATTGCACACGAGGGCCTGGTGCCACAACATGACACT
 AGTGGCCAACAATTGGGCAAGGTGGTGGATGTGCTACGCCAAGTGAACCAAAGCAAAGTACA
 GGTGGTGGTGCTGTTTGCATCTGCCCCGTGCTGTCTACTCCCTTTTTAGCTACAGCATCCTTC
 25 ATGACCTCTCACCCAAGGTATGGGTGGCCAGTGAGTCCTGGCTGACCTCTGACCTGGTCATG
 ACACTTCCAATATTGCCCGTGTGGGCACTGTTCTTGGGTTTCTGCAGCGCGGTGCCCTACT
 GCCTGAATTTTCCATTATGTGGAGACTCGCCTTGCCCTAGCTGCTGACCCAACATTCTGTG
 CCTCCCTGAAAGCTGAGTTGGATCTGGAGGAGCGCGTGATGGGGCCACGCTGTTCACAATGT
 GACTACATCATGCTACAGAACCTGTCTGCTGGGCTGATGCAGAACCTATCAGCTGGGCAGTT
 30 GCACCACCAAATATTTGCAACCTATGCAGCTGTGTACAGTGTGGCTCAGGCCCTTCACAACA
 CCCTGCAGTGCAATGTCTCACATTGCCACACATCAGAGCCTGTTCAACCCTGGCAGCTCCTG
 GAGAACATGTACAATATGAGTTTCCGTGCTCGAGACTTGACACTGCAGTTTGATGCCAAAGG
 GAGTGTAGACATGGAATATGACCTGAAGATGTGGGTGTGGCAGAGCCCTACACCTGTACTAC
 ATACTGTAGGCACCTTCAACGGCACCCCTTCAGCTGCAGCACTCGAAAATGTATTGGCCAGGC
 35 AACCAGGTGCCAGTCTCCAGTGCTCCCGGCAGTGCAAAGATGGCCAGGTGCGCAGAGTAAA
 GGGCTTTTCATTCTGCTGCTATGACTGTGTGGACTGCAAGGCAGGGAGCTACCGGAAGCATC
 CAGATGACTTCACCTGTACTCCATGTGGCAAGGATCAGTGGTCCCAGAAAAAAGCACAAACC
 TGCTTACCTCGCAGGCCCAAGTTTCTGGCTTGGGGGGAGCCAGCTGTGCTGTCACTTCTCCT
 GCTGCTTTGCCTGGTGCTGGGCCTGACACTGGCTGCCCTGGGGCTCTTTGTCCACTACTGGG
 40 ACAGCCCTCTTGTTTCAGGCCTCAGGTGGGTCACTGTTCTGCTTTGGCCTGATCTGCCTAGGC
 CTCTTCTGCCTCAGTGTCCTTCTGTTCCAGGACGACCACGCTCTGCCAGCTGCCTTGCCCA
 ACAACCAATGGCTCACCTCCCTCTCACAGGCTGCCTGAGCACACTCTTCCTGCAAGCAGCCG
 AGATCTTTGTGGAGTCTGAGCTGCCACTGAGTTGGGCAAACCTGGCTCTGCAGCTACCTTCGG
 GGCCCTTGGGCTTGGCTGGTGGTACTGCTGGCCACTCTTGTGGAGGCTGCACTATGTGCCTG
 45 GTACTTGATGGCTTTCCCTCCAGAGGTGGTGACAGATTGGCAGGTGCTGCCCACGGAGGTAC
 TGAACACTGCCGCATGCGTTCTGGGTGAGCCTGGGCTTGGTGACATCACCAATGCAGTG
 TTAGCTTTCTCTGCTTTCTGGGCACTTTCTGGTACAGAGCCAGCCTGGTCGCTATAACCG
 TGCCCGTGGCCTCACCTTCGCCATGCTAGCTTATTTTCATCATCTGGGTCTCTTTTGTGCCCC
 TCCTGGCTAATGTGCAGGTGGCCTACCAGCCAGCTGTGCAGATGGGTGCTATCTTATTCTGT
 50 GCCCTGGGCATCCTGGCCACCTTCCACCTGCCCAAATGCTATGTACTTCTGTGGCTGCCAGA

GCTCAACACCCAGGAGTTCTTCCTGGGAAGGAGCCCCAAGGAAGCATCAGATGGGAATAGTG
GTAGTAGTGAGGCAACTCGGGGACACAGTGAATGA

Rat T1R3 amino acid sequence--SEQ ID NO:25

5 MPGLAILGLSLAAFLELGMGSSLCLSQQFKAQGDYILGGFLPLGTTEEATLNQRTQPNGILC
TRFSPLGLFLAMAMKMAVEEINNGSALLPGLRLGYDLFDTCSEPVVMTKPSLMFMKVGSSQS
IAAYCNYTQYQPRVLAVIGPHSSELALITGKFFSFFLMPQVSYASMDRLSDRETFFPSFFRT
VPSDRVQLQAVVTLLQNFSWNWVAALGSDDDYGREGLSIFSGLANSRGICIAHEGLVPQHDT
SGQQLGKVVDVLRQVNQSKVQVVVLFASARAVYSLFSYSILHDLSPKVWVASESWLTSDLVM
10 TLPNIARVGTVLGFLQRGALLPEFSHYVETRLALAADPTFCASLKAELDLEERVMGPRCSQC
DYIMLQNLSSGLMQNLSAGQLHHQIFATYAAVYSVAQALHNTLQCNVSHCHTSEPVPWQQLL
ENMYNMSFRARDLTLQFDAKGSVDMEYDLKMWWVQSPTPVLHTVGTFNGLTLQLQHSKMYWPG
NQVPVSQCSRQCKDGQVRRVKGFHSCCYDCVDCKAGSYRKHPDDFTCTPCGKDQWSPEKSTT
CLPRRPKFLAWGEPAVLSLLLLLCLVLGLTLAALGLFVHYWDSPLVQASGGSILFCFLICLG
15 LFCLSVLLFPGRPRSASCLAQQPMAHLPLTGCLSTLFLQAAEIFVESELPLSWANWLCSYLR
GPWAWLVLLATLVEAALCAWYLMAFPPEVVTDWQVLPTEVLEHCRMRSWVSLGLVHITNAV
LAFLCFLGTFLVQSQPGRYNRARGLTFAMLAYFI IWVSFVPLLANVQVAYQPAVQMGAIFC
ALGILATFHLPKCYVLLWLPELNTQEFLGRSPKEASDGNSGSSEATRHSSE